{"PMC7186765": [["A novel coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected over 1,000,000 individuals, claiming more than 56,000 lives in over 200 countries worldwide ever since its mysterious outbreak in Wuhan, China in December 2019.", [["coronavirus disease", "DISEASE", 8, 27], ["acute respiratory syndrome coronavirus", "DISEASE", 57, 95], ["coronavirus", "ORGANISM", 8, 19], ["COVID-19", "ORGANISM", 29, 37], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 50, 97], ["SARS-CoV-2", "ORGANISM", 99, 109], ["severe acute respiratory syndrome coronavirus", "SPECIES", 50, 95], ["SARS-CoV-2", "SPECIES", 99, 109], ["A novel coronavirus disease", "PROBLEM", 0, 27], ["COVID", "TEST", 29, 34], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 50, 95], ["coronavirus disease", "OBSERVATION", 8, 27], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory syndrome", "OBSERVATION", 63, 83]]], ["The largest case series from China had shown that majority of the patients belonged to the age group of 30\u201379 years.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["largest", "OBSERVATION_MODIFIER", 4, 11]]], ["Most of the cases were mild (81%), while 14% cases were severe and only 5% critical.", [["mild", "OBSERVATION_MODIFIER", 23, 27]]], ["The overall case-fatality rate was 2.3% [1].", [["fatality rate", "TEST", 17, 30]]], ["SARS-CoV-2 primarily affects the lungs, resulting in viral pneumonia often complicated by acute respiratory distress syndrome and sepsis.", [["lungs", "ANATOMY", 33, 38], ["respiratory", "ANATOMY", 96, 107], ["SARS", "DISEASE", 0, 4], ["pneumonia", "DISEASE", 59, 68], ["acute respiratory distress syndrome", "DISEASE", 90, 125], ["sepsis", "DISEASE", 130, 136], ["SARS-CoV-2", "ORGANISM", 0, 10], ["lungs", "ORGAN", 33, 38], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["viral pneumonia", "PROBLEM", 53, 68], ["acute respiratory distress syndrome", "PROBLEM", 90, 125], ["sepsis", "PROBLEM", 130, 136], ["lungs", "ANATOMY", 33, 38], ["viral", "OBSERVATION_MODIFIER", 53, 58], ["pneumonia", "OBSERVATION", 59, 68], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory distress syndrome", "OBSERVATION", 96, 125], ["sepsis", "OBSERVATION", 130, 136]]], ["The virus is able to evade the host immune system by avoiding detection of their dsRNA and by inhibiting the host interferon-I pathway [2].", [["immune system", "ANATOMY", 36, 49], ["immune system", "ANATOMICAL_SYSTEM", 36, 49], ["interferon-I", "GENE_OR_GENE_PRODUCT", 114, 126], ["interferon", "PROTEIN", 114, 124], ["The virus", "PROBLEM", 0, 9], ["their dsRNA", "PROBLEM", 75, 86], ["virus", "OBSERVATION", 4, 9]]], ["The pathogen enters the pneumocyte using the host angiotensin-converting enzyme 2 (ACE2) as a receptor.", [["pneumocyte", "ANATOMY", 24, 34], ["angiotensin", "CHEMICAL", 50, 61], ["pneumocyte", "CANCER", 24, 34], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 50, 81], ["ACE2", "GENE_OR_GENE_PRODUCT", 83, 87], ["host angiotensin-converting enzyme 2", "PROTEIN", 45, 81], ["ACE2", "PROTEIN", 83, 87], ["the host angiotensin", "TREATMENT", 41, 61], ["pathogen", "OBSERVATION", 4, 12], ["pneumocyte", "OBSERVATION", 24, 34]]], ["In addition, the enzyme is expressed on the arterial and venous endothelial cells of many organs including the adrenal glands.", [["arterial", "ANATOMY", 44, 52], ["venous endothelial cells", "ANATOMY", 57, 81], ["organs", "ANATOMY", 90, 96], ["adrenal glands", "ANATOMY", 111, 125], ["arterial", "CELL", 44, 52], ["venous endothelial cells", "CELL", 57, 81], ["organs", "ORGAN", 90, 96], ["adrenal glands", "ORGAN", 111, 125], ["arterial and venous endothelial cells", "CELL_TYPE", 44, 81], ["the enzyme", "TEST", 13, 23], ["arterial", "ANATOMY_MODIFIER", 44, 52], ["venous endothelial cells", "OBSERVATION", 57, 81], ["adrenal glands", "ANATOMY", 111, 125]]], ["Autopsy studies on patients who died from SARS (the original outbreak in 2003) had shown degeneration and necrosis of the adrenal cortical cells.", [["adrenal cortical cells", "ANATOMY", 122, 144], ["SARS", "DISEASE", 42, 46], ["necrosis", "DISEASE", 106, 114], ["patients", "ORGANISM", 19, 27], ["adrenal cortical cells", "CELL", 122, 144], ["adrenal cortical cells", "CELL_TYPE", 122, 144], ["patients", "SPECIES", 19, 27], ["Autopsy studies", "TEST", 0, 15], ["SARS", "PROBLEM", 42, 46], ["degeneration", "PROBLEM", 89, 101], ["necrosis of the adrenal cortical cells", "PROBLEM", 106, 144], ["degeneration", "OBSERVATION", 89, 101], ["necrosis", "OBSERVATION", 106, 114], ["adrenal", "ANATOMY", 122, 129], ["cortical cells", "OBSERVATION", 130, 144]]], ["The SARS-CoV (the \u2018cousin\u2019 of SARS-CoV-2) was in fact identified in the adrenal glands, hinting towards a direct cytopathic effect of the virus.", [["adrenal glands", "ANATOMY", 72, 86], ["SARS", "DISEASE", 4, 8], ["SARS", "DISEASE", 30, 34], ["SARS-CoV", "ORGANISM", 4, 12], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 30, 40], ["adrenal glands", "ORGAN", 72, 86], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["SARS", "PROBLEM", 30, 34], ["a direct cytopathic effect of the virus", "PROBLEM", 104, 143], ["adrenal glands", "ANATOMY", 72, 86], ["virus", "OBSERVATION", 138, 143]]], ["Hence it is likely that cortisol dynamics may be altered in patients with SARS (and COVID-19).", [["cortisol", "CHEMICAL", 24, 32], ["SARS", "DISEASE", 74, 78], ["cortisol", "CHEMICAL", 24, 32], ["cortisol", "SIMPLE_CHEMICAL", 24, 32], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["cortisol dynamics", "PROBLEM", 24, 41], ["SARS", "PROBLEM", 74, 78], ["COVID", "TEST", 84, 89], ["is likely", "UNCERTAINTY", 9, 18]]], ["However, the literature is scarce is this regard.", [["scarce", "OBSERVATION", 27, 33]]]], "3e8f1cce602f86dd1f7227dbfe0c21ac995ff470": [["Capacity to receive, verify, analyze, assess, and investigate public health events is essential for epidemic intelligence.", [["epidemic intelligence", "PROBLEM", 100, 121]]], ["Public health Emergency Operations Centers (PHEOCs) can be epidemic intelligence hubs by 1) having the capacity to receive, analyze, and visualize multiple data streams, including surveillance and 2) maintaining a trained workforce that can analyze and interpret data from real-time emerging events.", [["the capacity", "PROBLEM", 99, 111], ["surveillance", "TEST", 180, 192]]], ["Such PHEOCs could be physically located within a ministry of health epidemiology, surveillance, or equivalent department rather than exist as a stand-alone space and serve as operational hubs during nonoutbreak times but in emergencies can scale up according to the traditional Incident Command System structure.", [["a stand-alone space", "TREATMENT", 142, 161]]], ["Emergency Operations Centers (EOCs) are increasingly viewed as necessary components of emergency preparedness and are used for multiagency coordination and response to a variety of hazards, including natural disasters, chemical spills, radionuclear incidents, humanitarian emergencies, and disease outbreaks.", [["emergency preparedness", "TREATMENT", 87, 109], ["multiagency coordination", "PROBLEM", 127, 151], ["disease outbreaks", "PROBLEM", 290, 307]]], ["Public health EOCs (PHEOCs) are physical spaces with the ability to monitor events using various sources of data, improve communication between public health and emergency management personnel, facilitate coordination with multiple response partners, and provide space for members of the incident command team to gather and work (1) (2) (3) (4) (5) (6) (7) .", [["3) (4) (5) (6", "SIMPLE_CHEMICAL", 338, 351], ["emergency management personnel", "TREATMENT", 162, 192]]]], "PMC7212257": [], "027c67dc708d0b074288d169df4266fc022f2aa2": [["To the editor, 1 Coronavirus disease 2019 (COVID-19) was first reported in Wuhan, China in 2 December 2019, has caused an international outbreak.", [["Coronavirus disease", "DISEASE", 17, 36], ["COVID-19", "CHEMICAL", 43, 51], ["1 Coronavirus disease", "PROBLEM", 15, 36], ["COVID", "TEST", 43, 48], ["an international outbreak", "PROBLEM", 119, 144]]], ["A newly isolated severe acute 3 respiratory syndrome coronavirus 2 (SARS-CoV-2) was found to be the etiological 4 agent of COVID-19 [1] .", [["acute 3 respiratory syndrome coronavirus", "DISEASE", 24, 64], ["COVID-19", "CHEMICAL", 123, 131], ["SARS-CoV-2", "ORGANISM", 68, 78], ["severe acute 3 respiratory syndrome coronavirus", "SPECIES", 17, 64], ["SARS-CoV-2", "SPECIES", 68, 78], ["A newly isolated severe acute 3 respiratory syndrome coronavirus", "PROBLEM", 0, 64], ["SARS-CoV", "TEST", 68, 76], ["COVID", "TEST", 123, 128], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["3", "OBSERVATION", 30, 31], ["respiratory syndrome coronavirus", "OBSERVATION", 32, 64]]], ["Thus far, there is no specific antiviral treatment reported that antibodies disappeared within 3 months after the onset of the symptoms. of the highest dilution of the serum that CPE was not observed.", [["serum", "ANATOMY", 168, 173], ["serum", "ORGANISM_SUBSTANCE", 168, 173], ["antibodies", "PROTEIN", 65, 75], ["specific antiviral treatment", "TREATMENT", 22, 50], ["the symptoms", "PROBLEM", 123, 135], ["CPE", "PROBLEM", 179, 182], ["no", "UNCERTAINTY", 19, 21], ["antiviral treatment", "OBSERVATION", 31, 50], ["highest", "OBSERVATION_MODIFIER", 144, 151], ["not observed", "UNCERTAINTY", 187, 199]]], ["We found that 9 neutralizing activity was negative (neutralizing antibodies titers <20).", [["neutralizing antibodies", "PROTEIN", 52, 75], ["9 neutralizing activity", "TEST", 14, 37], ["neutralizing antibodies titers", "TEST", 52, 82]]], ["To assess this, 10 peripheral blood monocytic cells (PBMCs) were isolated from the whole blood and", [["peripheral blood monocytic cells", "ANATOMY", 19, 51], ["PBMCs", "ANATOMY", 53, 58], ["whole blood", "ANATOMY", 83, 94], ["peripheral blood monocytic cells", "CELL", 19, 51], ["PBMCs", "CELL", 53, 58], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["peripheral blood monocytic cells", "CELL_TYPE", 19, 51], ["PBMCs", "CELL_TYPE", 53, 58], ["peripheral blood monocytic cells", "TEST", 19, 51], ["PBMCs", "TEST", 53, 58], ["the whole blood", "TEST", 79, 94], ["peripheral", "ANATOMY_MODIFIER", 19, 29], ["blood", "ANATOMY", 30, 35], ["monocytic cells", "OBSERVATION", 36, 51]]]], "1ee191cacc6d1a57595b53dca3f178fe34050079": [["The Hajj is the fifth pillar of Islam and is mandatory for all adult Muslims who are physically and financially capable at least once in their lifetime.", [["fifth pillar", "OBSERVATION_MODIFIER", 16, 28]]], ["The rituals of the Umrah can be undertaken at any time of the year and include the circumambulation of the Kaaba (Tawaf ) in very crowded conditions (Fig. 1 ) and seven trips (Sa'i) between two small mountains (Al-Safa and Al-Marwah) inside the Grand Mosque (Al-Masjid al Haram).", [["the Umrah", "TREATMENT", 15, 24], ["Al-Safa and Al-Marwah)", "TREATMENT", 211, 233]]], ["As part of the Hajj rituals, pilgrims travel to different sacred places located around the city of Mecca, including Mina, where they camp during the 5-day period of the Hajj in tents (Fig. 2 ) in close contact with others; the plain of Arafat for the culminating experience of the Hajj; and Muzdalifah.", [["Arafat", "TREATMENT", 236, 242], ["Muzdalifah", "TREATMENT", 291, 301]]], ["While not required as part of the Hajj, most pilgrims leave Mecca after a final circumambulation of the Kaaba (Tawaf al-Wada), traveling to the city of Medina to visit Islam's second holiest site, the Mosque of the Prophet, which contains Muhammad's tomb.IntroductionThe presence of a large number of pilgrims from many parts of the world in congested and crowded areas, especially when performing the circumambulation of the Kaaba inside the Grand Mosque in Mecca and when using the pedestrian tunnels leading to the Jamarat bridge in Mina, where each pilgrim performs the ritual of \"Jamarat\" (stoning the columns symbolizing the Devil), greatly increases the risk of spreading infectious diseases [1] , particularly respiratory diseases [2] .", [["respiratory", "ANATOMY", 718, 729], ["infectious diseases", "DISEASE", 679, 698], ["respiratory diseases", "DISEASE", 718, 738], ["congested and crowded areas", "PROBLEM", 342, 369], ["the pedestrian tunnels", "TREATMENT", 480, 502], ["the Jamarat bridge", "TREATMENT", 514, 532], ["spreading infectious diseases", "PROBLEM", 669, 698], ["particularly respiratory diseases", "PROBLEM", 705, 738], ["large", "OBSERVATION_MODIFIER", 285, 290], ["number", "OBSERVATION_MODIFIER", 291, 297], ["pilgrims", "OBSERVATION", 301, 309], ["congested", "OBSERVATION", 342, 351], ["crowded", "OBSERVATION_MODIFIER", 356, 363], ["areas", "OBSERVATION_MODIFIER", 364, 369], ["respiratory diseases", "OBSERVATION", 718, 738]]], ["It was reported that the prevalence of respiratory symptoms among a cohort of French pilgrims during the 2012 Hajj was 90%, with cough (83%) and sore throat (78%) as the most commonly reported symptoms [3] .", [["respiratory", "ANATOMY", 39, 50], ["respiratory symptoms", "DISEASE", 39, 59], ["cough", "DISEASE", 129, 134], ["sore throat", "DISEASE", 145, 156], ["throat", "ORGANISM_SUBDIVISION", 150, 156], ["respiratory symptoms", "PROBLEM", 39, 59], ["cough", "PROBLEM", 129, 134], ["sore throat", "PROBLEM", 145, 156], ["symptoms", "PROBLEM", 193, 201]]], ["Similarly high prevalences of respiratory symptoms were observed in both Iranian and Malaysian cohorts of pilgrims [4, 5] .", [["respiratory", "ANATOMY", 30, 41], ["respiratory symptoms", "DISEASE", 30, 50], ["respiratory symptoms", "PROBLEM", 30, 50], ["high", "OBSERVATION_MODIFIER", 10, 14], ["respiratory symptoms", "OBSERVATION", 30, 50]]], ["Respiratory diseases are by far the main reason for consultation among pilgrims attending primary health care centers during the Hajj [6] .", [["Respiratory diseases", "DISEASE", 0, 20], ["Respiratory diseases", "PROBLEM", 0, 20], ["diseases", "OBSERVATION", 12, 20]]], ["In addition, respiratory diseases are major causes of hospital admission during the Hajj [7] , with pneumonia being a leading cause of hospitalization in intensive care units [8] .", [["respiratory", "ANATOMY", 13, 24], ["respiratory diseases", "DISEASE", 13, 33], ["pneumonia", "DISEASE", 100, 109], ["respiratory diseases", "PROBLEM", 13, 33], ["pneumonia", "PROBLEM", 100, 109], ["respiratory diseases", "OBSERVATION", 13, 33], ["pneumonia", "OBSERVATION", 100, 109]]], ["In a recent study of Indonesian pilgrims, respiratory diseases were found to be the second most common cause of death, immediately after cardiovascular diseases [9] .", [["respiratory", "ANATOMY", 42, 53], ["cardiovascular", "ANATOMY", 137, 151], ["respiratory diseases", "DISEASE", 42, 62], ["death", "DISEASE", 112, 117], ["cardiovascular diseases", "DISEASE", 137, 160], ["a recent study", "TEST", 3, 17], ["respiratory diseases", "PROBLEM", 42, 62], ["death", "PROBLEM", 112, 117], ["cardiovascular diseases", "PROBLEM", 137, 160], ["respiratory diseases", "OBSERVATION", 42, 62]]], ["Respiratory viruses, especially influenza virus, are the main cause of acute respiratory infection (ARI) during the Hajj [10e13].", [["respiratory", "ANATOMY", 77, 88], ["Respiratory viruses", "DISEASE", 0, 19], ["influenza virus", "DISEASE", 32, 47], ["acute respiratory infection", "DISEASE", 71, 98], ["ARI", "DISEASE", 100, 103], ["Respiratory viruses", "ORGANISM", 0, 19], ["influenza virus", "ORGANISM", 32, 47], ["influenza virus", "SPECIES", 32, 47], ["Respiratory viruses", "SPECIES", 0, 19], ["influenza virus", "SPECIES", 32, 47], ["Respiratory viruses", "PROBLEM", 0, 19], ["influenza virus", "PROBLEM", 32, 47], ["acute respiratory infection", "PROBLEM", 71, 98], ["viruses", "OBSERVATION", 12, 19], ["influenza virus", "OBSERVATION", 32, 47], ["main cause of", "UNCERTAINTY", 57, 70], ["acute", "OBSERVATION_MODIFIER", 71, 76], ["respiratory", "ANATOMY", 77, 88], ["infection", "OBSERVATION", 89, 98]]], ["High prevalences of rhinovirus [3] and Streptococcus pneumoniae [14] were found in pilgrims returning from the Hajj, highlighting the potential of pilgrims to spread these infections to their household contacts upon return to their countries of origin.", [["Streptococcus pneumoniae", "DISEASE", 39, 63], ["infections", "DISEASE", 172, 182], ["rhinovirus", "ORGANISM", 20, 30], ["Streptococcus pneumoniae", "ORGANISM", 39, 63], ["Streptococcus pneumoniae", "SPECIES", 39, 63], ["Streptococcus pneumoniae", "SPECIES", 39, 63], ["rhinovirus", "PROBLEM", 20, 30], ["Streptococcus pneumoniae", "PROBLEM", 39, 63], ["rhinovirus", "OBSERVATION", 20, 30]]], ["However, although international outbreaks of Neisseria meningitides serogroup W135 occurred in 2001 and 2002 [15, 16] , no respiratory epidemics linked to the Hajj have been reported to date.IntroductionThe transmission routes of the most common respiratory viral pathogens are diverse [17] , including direct contact between an infected person and healthy individuals, indirect contact with contaminated surfaces, and droplet and airborne transmission at short range.", [["Neisseria meningitides", "DISEASE", 45, 67], ["respiratory epidemics", "DISEASE", 123, 144], ["respiratory viral pathogens", "DISEASE", 246, 273], ["Neisseria meningitides serogroup W135", "ORGANISM", 45, 82], ["Hajj", "DNA", 159, 163], ["Neisseria meningitides serogroup", "SPECIES", 45, 77], ["person", "SPECIES", 338, 344], ["Neisseria meningitides", "SPECIES", 45, 67], ["Neisseria meningitides serogroup", "PROBLEM", 45, 77], ["respiratory epidemics", "PROBLEM", 123, 144], ["droplet", "TREATMENT", 419, 426], ["infected", "OBSERVATION", 329, 337]]], ["Current evidence indicates that simple physical interventions would be useful for reducing the spread of respiratory viruses [18] .", [["respiratory viruses", "DISEASE", 105, 124], ["simple physical interventions", "TREATMENT", 32, 61], ["respiratory viruses", "PROBLEM", 105, 124], ["respiratory viruses", "OBSERVATION", 105, 124]]], ["Consequently, in addition to vaccination, non-pharmaceutical interventions are recommended by various national and international public health agencies, including the Saudi Ministry of Health (MoH), the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), to prevent the spread of infections during the pilgrimage or in the pilgrims' home countries upon their return [19e21] .", [["infections", "DISEASE", 318, 328], ["vaccination", "TREATMENT", 29, 40], ["non-pharmaceutical interventions", "TREATMENT", 42, 74], ["Disease Control", "TREATMENT", 255, 270], ["infections", "PROBLEM", 318, 328], ["infections", "OBSERVATION", 318, 328]]], ["These measures include maintaining hand hygiene, particularly hand washing with soap and water and the use of hand sanitizer; using disposable tissues when coughing or sneezing and disposing of these tissues in a [34] (continued on next page) waste basket; attempting as much as possible to avoid hand contact with the eyes, nose and mouth; avoiding direct contact with ill individuals; wearing masks, especially when in crowded places; and maintaining good personal hygiene, with the aim of interrupting or reducing the spread of infections from person to person.", [["hand", "ANATOMY", 35, 39], ["hand", "ANATOMY", 62, 66], ["hand", "ANATOMY", 110, 114], ["tissues", "ANATOMY", 143, 150], ["tissues", "ANATOMY", 200, 207], ["hand", "ANATOMY", 297, 301], ["eyes", "ANATOMY", 319, 323], ["nose", "ANATOMY", 325, 329], ["mouth", "ANATOMY", 334, 339], ["infections", "DISEASE", 531, 541], ["hand", "ORGANISM_SUBDIVISION", 35, 39], ["hand", "ORGANISM_SUBDIVISION", 62, 66], ["hand", "ORGANISM_SUBDIVISION", 110, 114], ["tissues", "TISSUE", 143, 150], ["tissues", "TISSUE", 200, 207], ["eyes", "ORGAN", 319, 323], ["nose", "ORGANISM_SUBDIVISION", 325, 329], ["mouth", "ORGANISM_SUBDIVISION", 334, 339], ["person", "SPECIES", 547, 553], ["person", "SPECIES", 557, 563], ["hand hygiene", "TREATMENT", 35, 47], ["soap and water", "TREATMENT", 80, 94], ["hand sanitizer", "TREATMENT", 110, 124], ["coughing", "PROBLEM", 156, 164], ["sneezing", "PROBLEM", 168, 176], ["masks", "TREATMENT", 395, 400], ["eyes", "ANATOMY", 319, 323], ["nose", "ANATOMY", 325, 329], ["mouth", "ANATOMY", 334, 339]]], ["The objective of this review is to summarize the evidence related to the effectiveness of non-pharmaceutical interventions in preventing the spread of respiratory infectious diseases during the Hajj.Search strategyOn 1 January 2014, we searched the MEDLINE database (www.ncbi.nlm.nih.gov/pubmed) for articles published in English using the following search strategy: #1: \"hadj\" OR \"hajj\" OR \"mass gathering\" OR \"pilgrimage\"; #2: \"respiratory\" OR \"infection\" OR \"infections\" OR \"infectious diseases\"; #3: #1 AND #2.Search strategyThe search results were surveyed for methodological articles, and their titles and abstracts were then scanned.", [["respiratory infectious diseases", "DISEASE", 151, 182], ["infection", "DISEASE", 447, 456], ["infections", "DISEASE", 462, 472], ["infectious diseases", "DISEASE", 478, 497], ["non-pharmaceutical interventions", "TREATMENT", 90, 122], ["respiratory infectious diseases", "PROBLEM", 151, 182], ["respiratory", "ANATOMY", 151, 162], ["infectious", "OBSERVATION", 163, 173], ["mass", "OBSERVATION", 392, 396], ["infection", "OBSERVATION", 447, 456]]], ["To be included, studies had to provide information on the actual use of nonpharmaceutical preventive measures by pilgrims during the Hajj or present data about the evaluation of the protective effect of these non-pharmaceutical preventive measures.", [["nonpharmaceutical preventive measures", "TREATMENT", 72, 109], ["the evaluation", "TEST", 160, 174], ["these non-pharmaceutical preventive measures", "TREATMENT", 203, 247]]], ["Table 1 summarizes the relevant 17 papers included in this review.Use of face masksMajor studies addressing the knowledge and practice of pilgrims concerning Hajj-related health problems have been conducted in the past by the Saudi Arabia Field Epidemiology Training program [22, 23] .", [["face masks", "TREATMENT", 73, 83], ["Major studies", "TEST", 83, 96]]], ["Large multinational samples of pilgrims were recruited while staying in Mina and interviewed using a self-administered questionnaire.", [["pilgrims", "ORGANISM", 31, 39], ["multinational", "OBSERVATION_MODIFIER", 6, 19]]], ["As part of these studies, face mask use was reported by only 17.8% of the respondents during the 1998 Hajj season [22] compared to 24% and 33.2% in 1999 and 2002, respectively [22, 23] .", [["these studies", "TEST", 11, 24], ["face mask", "TREATMENT", 26, 35]]], ["In a large cohort study of pilgrims recruited during the pre-travel consultation, 53.6% of those who were followed up by telephone after the 2003 Hajj reported using face masks during the pilgrimage [24, 25] .", [["face masks", "TREATMENT", 166, 176], ["large", "OBSERVATION_MODIFIER", 5, 10]]], ["A survey of knowledge, attitude and practice was conducted in the city of Marseille among French pilgrims intending to perform the 2008 Hajj who attended a pre-Hajj meningococcal vaccination campaign [26] .", [["a pre-Hajj meningococcal vaccination campaign", "TREATMENT", 154, 199]]], ["Of the respondents in this study, prior to travel, only 41.3% were aware that face masks could protect them from ARI, and 24.6% were aware that face masks could be used for community protection [26] .", [["ARI", "DISEASE", 113, 116], ["this study", "TEST", 22, 32], ["face masks", "TREATMENT", 78, 88], ["ARI", "PROBLEM", 113, 116], ["face masks", "TREATMENT", 144, 154]]], ["However, the willingness of pilgrims to wear face masks during the Hajj was high (91.7%) after the importance of their use was explained [26] .", [["face masks", "TREATMENT", 45, 55], ["the Hajj", "TEST", 63, 71]]], ["The effect of a health promotion intervention and the distribution of free face masks were evaluated in a study in 2004, showing a significant increase in face mask use among pilgrims who received both health promotion and free face masks (81.3%) compared to controls who did not receive health education or face masks (33.6%) [27] .", [["a health promotion intervention", "TREATMENT", 14, 45], ["free face masks", "TREATMENT", 70, 85], ["a study", "TEST", 104, 111], ["face mask", "TREATMENT", 155, 164], ["free face masks", "TREATMENT", 223, 238], ["face masks", "TREATMENT", 308, 318], ["significant", "OBSERVATION_MODIFIER", 131, 142], ["increase", "OBSERVATION_MODIFIER", 143, 151], ["face mask", "OBSERVATION", 155, 164]]], ["In another study of patients attending Mina hospitals in 2007, pilgrims who received health education were also significantly more likely to wear face masks during the Hajj than those who did not [28] .", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["health education", "TREATMENT", 85, 101], ["face masks", "TREATMENT", 146, 156]]], ["However, the overall compliance with face mask use of pilgrims in this study was low (12.1%) [28] .", [["face mask", "TREATMENT", 37, 46], ["this study", "TEST", 66, 76]]], ["These interventions have improved pilgrim compliance with face mask use during the Hajj; however, it was not stated in these studies whether pilgrims used their masks frequently or intermittently.", [["These interventions", "TREATMENT", 0, 19], ["face mask", "TREATMENT", 58, 67]]], ["The compliance with face mask use of French pilgrims who were recruited during their pre-travel consultation was investigated by telephone questionnaire as the pilgrims returned to France after the 2009 Hajj [29] .", [["face mask", "TREATMENT", 20, 29]]], ["In this study, the percentage of pilgrims who self-reported using face masks during the pilgrimage was 79.6% [29] .", [["this study", "TEST", 3, 13], ["face masks", "TREATMENT", 66, 76], ["the pilgrimage", "TEST", 84, 98]]], ["In a large cross-sectional survey conducted before the 2009 Hajj, 35.1% of pilgrims arriving at the King Abdulaziz international airport in Jeddah reported wearing a face mask, and only 44.7% were aware of this measure as a way to prevent H1N1 infection [30] .", [["infection", "DISEASE", 244, 253], ["a face mask", "TREATMENT", 164, 175], ["H1N1 infection", "PROBLEM", 239, 253], ["large", "OBSERVATION_MODIFIER", 5, 10], ["infection", "OBSERVATION", 244, 253]]], ["A cohort study was conducted among pilgrims traveling from Riyadh with the intention to perform the Hajj in 2010.", [["A cohort study", "TEST", 0, 14]]], ["Pilgrims were recruited as they sought their required pre-Hajj meningococcal vaccination and followed up by telephone upon their return from the Hajj.", [["Pilgrims", "TREATMENT", 0, 8], ["pre-Hajj meningococcal vaccination", "TREATMENT", 54, 88]]], ["In this study, 56.5% of pilgrims reported using face masks during the pilgrimage [31] .", [["pilgrims", "ORGANISM", 24, 32], ["this study", "TEST", 3, 13], ["face masks", "TREATMENT", 48, 58]]], ["This result is comparable to that reported in another study conducted among French pilgrims during the 2012 Hajj by a medical doctor traveling with the pilgrims, in which 55.1% of pilgrims actually used face masks during the pilgrimage [3] .", [["pilgrims", "ORGANISM", 180, 188], ["another study", "TEST", 46, 59], ["face masks", "TREATMENT", 203, 213]]], ["Other studies conducted among pilgrims from various countries [5, 32, 33] have shown variable results (Table 1) .", [["Other studies", "TEST", 0, 13]]], ["However, study designs and populations were highly variable from one study to another and did not allow for relevant comparisons.", [["one study", "TEST", 65, 74]]], ["In an interesting recent study about face mask usage among pilgrims during the 5-day Hajj periods of 2009 and 2013, photos of the moving crowd taken from elevated areas revealed that significantly more pilgrims used face masks during the 2009 influenza A (H1N1) outbreak than during the 2013 MERS-CoV outbreak; however, compliance was low in both years [34] .", [["influenza A (H1N1) outbreak", "DISEASE", 243, 270], ["influenza A", "ORGANISM", 243, 254], ["MERS-CoV", "SPECIES", 292, 300], ["face mask", "TREATMENT", 37, 46], ["elevated areas", "PROBLEM", 154, 168], ["face masks", "TREATMENT", 216, 226], ["the 2009 influenza A (H1N1) outbreak", "PROBLEM", 234, 270], ["CoV outbreak", "PROBLEM", 297, 309]]], ["It must be noted that in this study, face masks were provided as part of a welcome kit to each arriving pilgrim at the international airport in Jeddah.Use of face masksThe effectiveness of face mask use in preventing respiratory illness during the Hajj has been evaluated in various studies (Table 1) .", [["respiratory", "ANATOMY", 217, 228], ["respiratory illness", "DISEASE", 217, 236], ["this study", "TEST", 25, 35], ["face masks", "TREATMENT", 37, 47], ["face masks", "TREATMENT", 158, 168], ["face mask", "TREATMENT", 189, 198], ["respiratory illness", "PROBLEM", 217, 236], ["respiratory illness", "OBSERVATION", 217, 236]]], ["However, the results of these studies were contradictory.", [["these studies", "TEST", 24, 37]]], ["One study conducted among Indonesian pilgrims reported that pilgrims who did not use a face mask (that were provided to pilgrims by the Indonesian Hajj committee free of charge) during the Hajj had a threefold greater risk of acquiring an acute upper respiratory tract infection compared to those using face masks [32] .", [["upper respiratory tract", "ANATOMY", 245, 268], ["respiratory tract infection", "DISEASE", 251, 278], ["upper respiratory", "ORGANISM_SUBDIVISION", 245, 262], ["tract", "ORGANISM_SUBDIVISION", 263, 268], ["One study", "TEST", 0, 9], ["a face mask", "TREATMENT", 85, 96], ["an acute upper respiratory tract infection", "PROBLEM", 236, 278], ["face masks", "TREATMENT", 303, 313], ["acute", "OBSERVATION_MODIFIER", 239, 244], ["upper", "ANATOMY_MODIFIER", 245, 250], ["respiratory tract", "ANATOMY", 251, 268], ["infection", "OBSERVATION", 269, 278]]], ["A significant reduction in respiratory symptoms was also observed in a Saudi [31] study, whereas several other studies reported no significant effect [5, 29, 33, 35] .", [["respiratory", "ANATOMY", 27, 38], ["A significant reduction in respiratory symptoms", "PROBLEM", 0, 47], ["] study", "TEST", 80, 87], ["several other studies", "TEST", 97, 118], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["reduction", "OBSERVATION_MODIFIER", 14, 23], ["respiratory symptoms", "OBSERVATION", 27, 47]]], ["A second Saudi study showed a significant reduction in respiratory symptoms with face mask use, but only in the male or total sample and not in the female group [24, 25] .", [["respiratory", "ANATOMY", 55, 66], ["A second Saudi study", "TEST", 0, 20], ["a significant reduction in respiratory symptoms", "PROBLEM", 28, 75], ["face mask", "TREATMENT", 81, 90], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["reduction", "OBSERVATION_MODIFIER", 42, 51], ["respiratory symptoms", "OBSERVATION", 55, 75]]], ["Two other studies have addressed the impact of face mask use during the Hajj on the prevalence of both respiratory symptoms and viral pathogens using PCR assays from pilgrim nasal samples, and no significant effect was observed [30, 3] .Hand hygieneCompliance with hand hygiene practices was assessed during the 1999 Hajj season in a cross-sectional survey on a large multinational sample of pilgrims staying in Mina using a self-administered questionnaire [22] .", [["respiratory", "ANATOMY", 103, 114], ["nasal samples", "ANATOMY", 174, 187], ["hand", "ANATOMY", 265, 269], ["respiratory symptoms", "DISEASE", 103, 123], ["nasal samples", "CANCER", 174, 187], ["hand", "ORGANISM_SUBDIVISION", 265, 269], ["Two other studies", "TEST", 0, 17], ["face mask", "TREATMENT", 47, 56], ["both respiratory symptoms", "PROBLEM", 98, 123], ["viral pathogens", "PROBLEM", 128, 143], ["PCR assays", "TEST", 150, 160], ["pilgrim nasal samples", "TEST", 166, 187], ["hand hygiene practices", "TREATMENT", 265, 287], ["respiratory", "ANATOMY", 103, 114], ["no", "UNCERTAINTY", 193, 195], ["significant", "OBSERVATION_MODIFIER", 196, 207]]], ["In a large prospective study of domestic pilgrims from Central Saudi Arabia, 90.3% and 45.5% reported, on their return from the 2010 Hajj, washing their hands more than 5 times per day and using hand sanitizer during the pilgrimage, respectively [31] .", [["hand", "ANATOMY", 195, 199], ["hand", "ORGANISM_SUBDIVISION", 195, 199], ["large", "OBSERVATION_MODIFIER", 5, 10], ["Central", "ANATOMY_MODIFIER", 55, 62]]], ["However, in this study, the pilgrims who received health education washed their hands significantly more frequently during the Hajj than those who did not [28] .", [["this study", "TEST", 12, 22], ["health education", "TREATMENT", 50, 66]]], ["A study assessing the compliance with protective measures among US pilgrims prior to and following travel to the 2009 Hajj reported that 67.2% of the respondents practiced hand hygiene during the pilgrimage [33] .", [["hand", "ANATOMY", 172, 176], ["hand", "ORGANISM_SUBDIVISION", 172, 176], ["A study", "TEST", 0, 7], ["protective measures", "TREATMENT", 38, 57]]], ["However, in a second study conducted among the same cohort of US pilgrims with the aim of evaluating the possible effects of knowledge acquired from taking the pre-travel survey, the impact of the pre-travel survey as an effective means of health communication or education for pilgrims remained unclear [36] .", [["a second study", "TEST", 12, 26]]], ["A large crosssectional survey conducted in 2009 among pilgrims arriving at the King Abdulaziz international airport in Jeddah showed that 48.1% and 28.5% of pilgrims were aware that frequent hand washing and use of hand sanitizer, respectively, could prevent H1N1 infection [30] .", [["hand", "ANATOMY", 191, 195], ["hand", "ANATOMY", 215, 219], ["infection", "DISEASE", 264, 273], ["hand", "ORGANISM_SUBDIVISION", 191, 195], ["hand", "ORGANISM_SUBDIVISION", 215, 219], ["frequent hand washing", "TREATMENT", 182, 203], ["hand sanitizer", "TREATMENT", 215, 229], ["H1N1 infection", "PROBLEM", 259, 273], ["large", "OBSERVATION_MODIFIER", 2, 7]]], ["The proportions were even lower among French pilgrims intending to perform the 2008 Hajj, with less than 10% and 3% of participants being aware prior to travel of frequent hand washing and use of hand disinfectant, respectively, as precautions against respiratory infections [26] .", [["hand", "ANATOMY", 172, 176], ["hand", "ANATOMY", 196, 200], ["respiratory", "ANATOMY", 252, 263], ["respiratory infections", "DISEASE", 252, 274], ["hand", "ORGANISM_SUBDIVISION", 172, 176], ["hand", "ORGANISM_SUBDIVISION", 196, 200], ["participants", "SPECIES", 119, 131], ["frequent hand washing", "TREATMENT", 163, 184], ["hand disinfectant", "TREATMENT", 196, 213], ["respiratory infections", "PROBLEM", 252, 274], ["lower", "OBSERVATION_MODIFIER", 26, 31]]], ["However, this study revealed high levels of acceptance of these measures among participants (>90%) after their importance was explained [26] .", [["participants", "SPECIES", 79, 91], ["this study", "TEST", 9, 19]]], ["Upon return from the 2009 Hajj, 69.7% and 77.4% of French pilgrims have self-reported increased hand washing and increased use of hand disinfectant, respectively, during the pilgrimage [29] .", [["hand", "ANATOMY", 96, 100], ["hand", "ANATOMY", 130, 134], ["hand", "ORGANISM_SUBDIVISION", 96, 100], ["hand", "ORGANISM_SUBDIVISION", 130, 134], ["increased hand washing", "TREATMENT", 86, 108], ["hand disinfectant", "TREATMENT", 130, 147], ["increased", "OBSERVATION_MODIFIER", 113, 122]]], ["More recently, the compliance with hand hygiene among French pilgrims during the 2012 Hajj was also assessed by a medical doctor traveling with them, and 40.3% and 46.3% of pilgrims actually washed their hands more than usual and used hand sanitizer, respectively, during the pilgrimage [3] .Hand hygieneThe effectiveness of hand hygiene practices in preventing respiratory illness during the Hajj has been evaluated in only a few studies (Table 1) .", [["hand", "ANATOMY", 35, 39], ["hand", "ANATOMY", 235, 239], ["hand", "ANATOMY", 325, 329], ["respiratory", "ANATOMY", 362, 373], ["respiratory illness", "DISEASE", 362, 381], ["hand", "ORGANISM_SUBDIVISION", 35, 39], ["pilgrims", "ORGANISM", 173, 181], ["hand", "ORGANISM_SUBDIVISION", 235, 239], ["hand", "ORGANISM_SUBDIVISION", 325, 329], ["hand hygiene practices", "TREATMENT", 325, 347], ["respiratory illness", "PROBLEM", 362, 381], ["hygiene", "OBSERVATION", 297, 304]]], ["A study conducted among US Hajj pilgrims during the 2009 Hajj confirmed that hand hygiene was associated with a reduced risk of respiratory illness [33] .", [["hand", "ANATOMY", 77, 81], ["respiratory", "ANATOMY", 128, 139], ["respiratory illness", "DISEASE", 128, 147], ["hand", "ORGANISM_SUBDIVISION", 77, 81], ["A study", "TEST", 0, 7], ["respiratory illness", "PROBLEM", 128, 147]]], ["By contrast, no positive effect of frequent hand washing or using hand sanitizer was observed among French pilgrims on the occurrence of respiratory symptoms during the 2009 Hajj [29] or on the prevalence of respiratory viruses as investigated by PCR assays on nasal swabs during the 2012 Hajj [3] .", [["hand", "ANATOMY", 44, 48], ["hand", "ANATOMY", 66, 70], ["respiratory", "ANATOMY", 137, 148], ["nasal swabs", "ANATOMY", 261, 272], ["respiratory symptoms", "DISEASE", 137, 157], ["respiratory viruses", "DISEASE", 208, 227], ["hand", "ORGANISM_SUBDIVISION", 44, 48], ["hand", "ORGANISM_SUBDIVISION", 66, 70], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 261, 272], ["frequent hand washing", "TREATMENT", 35, 56], ["hand sanitizer", "TREATMENT", 66, 80], ["respiratory symptoms", "PROBLEM", 137, 157], ["respiratory viruses", "PROBLEM", 208, 227], ["PCR assays", "TEST", 247, 257], ["nasal swabs", "TEST", 261, 272], ["respiratory", "ANATOMY", 208, 219], ["viruses", "OBSERVATION", 220, 227]]], ["On the contrary, hand washing was significantly associated with symptoms of influenza-like illness and with a higher prevalence of respiratory viruses during the 2012 Hajj [3] .Cough etiquette and disposable handkerchiefIn a large cross-sectional study from the KSA, pilgrims arriving at the King Abdulaziz International Airport in Jeddah for the 2009 Hajj were found to have low knowledge of cough etiquette as a way to prevent H1N1 infection (20.6%) [30] .", [["hand", "ANATOMY", 17, 21], ["influenza-like illness", "DISEASE", 76, 98], ["respiratory viruses", "DISEASE", 131, 150], ["cough etiquette", "DISEASE", 393, 408], ["H1N1 infection", "DISEASE", 429, 443], ["hand", "ORGANISM_SUBDIVISION", 17, 21], ["hand washing", "TREATMENT", 17, 29], ["symptoms", "PROBLEM", 64, 72], ["influenza", "PROBLEM", 76, 85], ["respiratory viruses", "PROBLEM", 131, 150], ["Cough etiquette", "PROBLEM", 177, 192], ["cough etiquette", "PROBLEM", 393, 408], ["H1N1 infection", "PROBLEM", 429, 443], ["influenza", "OBSERVATION", 76, 85], ["respiratory viruses", "OBSERVATION", 131, 150], ["large", "OBSERVATION_MODIFIER", 225, 230]]], ["In 2009, a study among US pilgrims showed that their compliance with cough etiquette was 46.2%, with, however, no significant beneficial effect on the prevalence of respiratory symptoms [33] .", [["respiratory", "ANATOMY", 165, 176], ["cough", "DISEASE", 69, 74], ["respiratory symptoms", "DISEASE", 165, 185], ["a study", "TEST", 9, 16], ["cough etiquette", "TEST", 69, 84], ["respiratory symptoms", "PROBLEM", 165, 185]]], ["A second study, conducted among the same cohort of US pilgrims, found no impact of taking the pre-travel survey on compliance with cough etiquette during the Hajj [36] .", [["cough", "DISEASE", 131, 136], ["A second study", "TEST", 0, 14], ["cough", "PROBLEM", 131, 136]]], ["In another study conducted among French pilgrims intending to perform the 2008 Hajj who attended a pre-Hajj meningococcal vaccination campaign, the knowledge prior to travel about disposable handkerchief use as a preventive measure against respiratory tract infections among the community was also very low (1.1%), but the willingness of pilgrims to use disposable handkerchiefs during the Hajj was excellent after the importance of their use was explained [26] .", [["respiratory tract", "ANATOMY", 240, 257], ["handkerchief", "CHEMICAL", 191, 203], ["respiratory tract infections", "DISEASE", 240, 268], ["tract", "ORGANISM_SUBDIVISION", 252, 257], ["a pre-Hajj meningococcal vaccination campaign", "TREATMENT", 97, 142], ["disposable handkerchief use", "TREATMENT", 180, 207], ["respiratory tract infections", "PROBLEM", 240, 268], ["disposable handkerchiefs", "TREATMENT", 354, 378]]], ["The use of disposable handkerchiefs among French pilgrims was 89.8% during the 2009 Hajj as self-reported by the pilgrims [29] and 87.6% during the 2012 Hajj as assessed by a medical doctor traveling with them [3] .", [["disposable handkerchiefs", "TREATMENT", 11, 35]]], ["However, the use of disposable handkerchiefs had no significant beneficial effect on the prevalence of either respiratory symptoms among pilgrims during the Hajj [29] or viral pathogens from their nasal samples, as recently reported [3] .Social distancing and contact avoidanceOnly 28% and 18.3% of pilgrims arriving at the King Abdulaziz International Airport in Jeddah for the 2009 Hajj were aware of the usefulness of staying away from sick people and avoiding crowds/public gatherings, respectively, in preventing H1N1 infection [30] .", [["respiratory", "ANATOMY", 110, 121], ["nasal samples", "ANATOMY", 197, 210], ["respiratory symptoms", "DISEASE", 110, 130], ["infection", "DISEASE", 523, 532], ["nasal samples", "CANCER", 197, 210], ["people", "ORGANISM", 444, 450], ["people", "SPECIES", 444, 450], ["disposable handkerchiefs", "TREATMENT", 20, 44], ["respiratory symptoms", "PROBLEM", 110, 130], ["viral pathogens", "PROBLEM", 170, 185], ["H1N1 infection", "PROBLEM", 518, 532], ["infection", "OBSERVATION", 523, 532]]], ["In a study conducted among US pilgrims during the 2009 Hajj, the observance rates of social distancing and contact avoidance were 34.4% and 24.2%, respectively, with a significant beneficial effect on the occurrence of respiratory symptoms during the Hajj [33] .", [["respiratory", "ANATOMY", 219, 230], ["respiratory symptoms", "DISEASE", 219, 239], ["a study", "TEST", 3, 10], ["contact avoidance", "TEST", 107, 124], ["respiratory symptoms", "PROBLEM", 219, 239]]], ["A second study, conducted among the same cohort of US pilgrims, found that pilgrims who took both pre-and post-travel surveys were more likely to report practicing social distancing during the Hajj (45.5%) than those who took only the post-travel survey (17.2%) [36] .", [["A second study", "TEST", 0, 14]]], ["However, the pre-travel survey had no impact on the observance of contact avoidance by pilgrims during the Hajj in this study (approximately 31% in both groups) [36] .", [["the pre-travel survey", "TEST", 9, 30], ["this study", "TEST", 115, 125]]], ["French pilgrims intending to perform the 2008 Hajj showed more knowledge about social distancing and contact avoidance as preventive measures for self-protection against respiratory tract infections (about 50%) [26] ; and the acceptability of these measures was approximately 62% after the importance of their observance was explained [26] .", [["respiratory tract", "ANATOMY", 170, 187], ["respiratory tract infections", "DISEASE", 170, 198], ["respiratory tract", "ORGANISM_SUBDIVISION", 170, 187], ["preventive measures", "TREATMENT", 122, 141], ["self-protection", "TREATMENT", 146, 161], ["respiratory tract infections", "PROBLEM", 170, 198], ["respiratory tract", "ANATOMY", 170, 187]]], ["However, in a recent nested caseecontrol study among Iranian pilgrims during the 2010 Hajj, the mean daily presence in holy places and direct contact with ill pilgrims in the same room appeared to have no effect on the incidence of respiratory tract infections [35] .Postponement of Hajj for at-risk populationsThe 2009 Hajj took place during the influenza A/H1N1 pandemic.", [["respiratory tract", "ANATOMY", 232, 249], ["respiratory tract infections", "DISEASE", 232, 260], ["influenza A/H1N1 pandemic", "DISEASE", 347, 372], ["respiratory tract", "ORGANISM_SUBDIVISION", 232, 249], ["H1N1 pandemic", "SPECIES", 359, 372], ["influenza A/H1N1 pandemic", "SPECIES", 347, 372], ["a recent nested caseecontrol study", "TEST", 12, 46], ["ill pilgrims", "TREATMENT", 155, 167], ["respiratory tract infections", "PROBLEM", 232, 260], ["H1N1 pandemic", "PROBLEM", 359, 372], ["respiratory tract", "ANATOMY", 232, 249]]], ["Among several recommendations, one of the most challenging was to ask the population groups considered to be at high risk of complications from influenza (pregnant women, people with underlying comorbidities, people older than 65 years and children younger than 12 years) to voluntarily refrain from participating in the 2009 Hajj.", [["influenza", "DISEASE", 144, 153], ["women", "ORGANISM", 164, 169], ["people", "ORGANISM", 171, 177], ["people", "ORGANISM", 209, 215], ["children", "ORGANISM", 240, 248], ["women", "SPECIES", 164, 169], ["people", "SPECIES", 171, 177], ["people", "SPECIES", 209, 215], ["children", "SPECIES", 240, 248], ["complications", "PROBLEM", 125, 138], ["influenza", "PROBLEM", 144, 153], ["complications", "OBSERVATION", 125, 138]]], ["An assessment of compliance with these recommendations among French pilgrims actually participating in the 2009 Hajj showed that at least one risk factor for complications from H1N1 virus infection was present in 49.5% of them [39] .", [["H1N1 virus infection", "DISEASE", 177, 197], ["H1N1 virus", "ORGANISM", 177, 187], ["H1N1 virus", "SPECIES", 177, 187], ["H1N1 virus", "SPECIES", 177, 187], ["An assessment", "TEST", 0, 13], ["complications", "PROBLEM", 158, 171], ["H1N1 virus infection", "PROBLEM", 177, 197]]], ["In 2013, because of concerns over the Middle East respiratory syndrome coronavirus (MERS-CoV) with the KSA identified as the epicenter of the outbreak, the WHO published the 2013 Hajj requirement [19] in which the Saudi Ministry of Health recommended that elderly people (older than 65 years); those with chronic diseases (such as heart disease, kidney disease, respiratory disease, and diabetes); and pilgrims with immune deficiency (congenital and acquired), malignant disease, and terminal illnesses, as well as pregnant women and children (younger than 12 years), not perform the Hajj and Umrah that year [19, 20] .", [["heart", "ANATOMY", 331, 336], ["kidney", "ANATOMY", 346, 352], ["respiratory", "ANATOMY", 362, 373], ["malignant disease", "ANATOMY", 461, 478], ["Middle East respiratory syndrome coronavirus", "DISEASE", 38, 82], ["chronic diseases", "DISEASE", 305, 321], ["heart disease", "DISEASE", 331, 344], ["kidney disease", "DISEASE", 346, 360], ["respiratory disease", "DISEASE", 362, 381], ["diabetes", "DISEASE", 387, 395], ["immune deficiency", "DISEASE", 416, 433], ["congenital and acquired), malignant disease", "DISEASE", 435, 478], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 38, 82], ["MERS-CoV", "ORGANISM", 84, 92], ["people", "ORGANISM", 264, 270], ["heart", "ORGAN", 331, 336], ["kidney", "ORGAN", 346, 352], ["malignant disease", "CANCER", 461, 478], ["women", "ORGANISM", 524, 529], ["children", "ORGANISM", 534, 542], ["people", "SPECIES", 264, 270], ["women", "SPECIES", 524, 529], ["children", "SPECIES", 534, 542], ["Middle East respiratory syndrome coronavirus", "SPECIES", 38, 82], ["MERS-CoV", "SPECIES", 84, 92], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 34, 82], ["chronic diseases", "PROBLEM", 305, 321], ["heart disease", "PROBLEM", 331, 344], ["kidney disease", "PROBLEM", 346, 360], ["respiratory disease", "PROBLEM", 362, 381], ["diabetes)", "PROBLEM", 387, 396], ["pilgrims", "PROBLEM", 402, 410], ["immune deficiency", "PROBLEM", 416, 433], ["congenital and acquired)", "PROBLEM", 435, 459], ["malignant disease", "PROBLEM", 461, 478], ["terminal illnesses", "PROBLEM", 484, 502], ["respiratory syndrome", "OBSERVATION", 50, 70], ["chronic", "OBSERVATION_MODIFIER", 305, 312], ["diseases", "OBSERVATION", 313, 321], ["heart", "ANATOMY", 331, 336], ["disease", "OBSERVATION", 337, 344], ["kidney", "ANATOMY", 346, 352], ["disease", "OBSERVATION", 353, 360], ["respiratory disease", "OBSERVATION", 362, 381], ["immune deficiency", "OBSERVATION", 416, 433], ["malignant", "OBSERVATION_MODIFIER", 461, 470], ["terminal", "OBSERVATION_MODIFIER", 484, 492], ["illnesses", "OBSERVATION", 493, 502]]], ["In a recent study, at least one of these risk factors was found in one out of two French pilgrims undertaking the 2013 Hajj season [40, 41] .", [["a recent study", "TEST", 3, 17], ["these risk factors", "PROBLEM", 35, 53]]], ["In another study of French pilgrims recruited during their pre-travel consultation before the 2013 Hajj season, it appears that two-thirds of the participants were aware of the MERS-CoV situation in Saudi Arabia, and one-third were aware of the Saudi recommendation for all individuals in these high-risk groups to postpone their participation in the 2013 Hajj; however, none of them decided to cancel their participation, even after this advice was given [41] .DiscussionMany non-pharmaceutical interventions are worth implementing on their own merit, even if the evidence for their effectiveness for preventing respiratory infectious diseases during the Hajj is sometimes weak and has rarely been studied in large populations.", [["respiratory infectious diseases", "DISEASE", 613, 644], ["participants", "ORGANISM", 146, 158], ["participants", "SPECIES", 146, 158], ["DiscussionMany non-pharmaceutical interventions", "TREATMENT", 462, 509], ["respiratory infectious diseases", "PROBLEM", 613, 644], ["infectious", "OBSERVATION", 625, 635], ["large", "OBSERVATION_MODIFIER", 710, 715], ["populations", "OBSERVATION", 716, 727]]], ["It is often difficult to assess the effect of one intervention independently from other interventions or other factors in infection control, such as environmental hygiene, crowding and education.", [["infection", "DISEASE", 122, 131], ["one intervention", "TREATMENT", 46, 62], ["other interventions", "TREATMENT", 82, 101], ["infection control", "TREATMENT", 122, 139], ["infection", "OBSERVATION", 122, 131]]], ["Moreover, most studies used different clinical criteria for evaluating the prevalence of respiratory symptoms in pilgrims during the Hajj and were conducted in different settings, including hospitals and airports, with possible bias in the inclusion process.", [["respiratory", "ANATOMY", 89, 100], ["respiratory symptoms", "DISEASE", 89, 109], ["respiratory symptoms", "PROBLEM", 89, 109], ["bias in the inclusion process", "PROBLEM", 228, 257], ["respiratory", "ANATOMY", 89, 100], ["symptoms", "OBSERVATION", 101, 109]]], ["Additionally, some of these studies were performed among small numbers of pilgrims and cannot be extrapolated.", [["these studies", "TEST", 22, 35], ["small", "OBSERVATION_MODIFIER", 57, 62]]], ["Because compliance with these preventive measures appears to be highly variable from one study to another, studying heterogeneous populations of pilgrims in different settings as well as the use of different methods may limit the ability to identify effective measures.", [["these preventive measures", "TREATMENT", 24, 49], ["different methods", "TREATMENT", 198, 215], ["heterogeneous", "OBSERVATION_MODIFIER", 116, 129]]], ["Future large-scale prospective intervention studies should be designed to accurately estimate the effectiveness of and adherence to each measure in preventing respiratory tract infections during the Hajj.DiscussionAt this time, the improvement of face mask use among pilgrims is a major challenge.", [["respiratory tract", "ANATOMY", 159, 176], ["respiratory tract infections", "DISEASE", 159, 187], ["respiratory tract", "ORGANISM_SUBDIVISION", 159, 176], ["Future large-scale prospective intervention", "TREATMENT", 0, 43], ["studies", "TEST", 44, 51], ["respiratory tract infections", "PROBLEM", 159, 187], ["face mask", "TREATMENT", 247, 256], ["respiratory tract", "ANATOMY", 159, 176], ["infections", "OBSERVATION", 177, 187]]], ["In fact, there appears to be a discrepancy between willingness, perceived compliance and actual compliance of pilgrims with respect to face mask use.", [["face mask", "TREATMENT", 135, 144], ["appears to be", "UNCERTAINTY", 15, 28]]], ["While several studies showed that face mask use is highly accepted by pilgrims providing that educational intervention is implemented, such intervention is impractical in the context of the Hajj.", [["several studies", "TEST", 6, 21], ["face mask", "TREATMENT", 34, 43], ["educational intervention", "TREATMENT", 94, 118], ["such intervention", "TREATMENT", 135, 152]]], ["Various reasons may partially explain the low compliance of face mask usage.", [["face mask usage", "TREATMENT", 60, 75], ["low compliance", "OBSERVATION", 42, 56]]], ["First, the stifling heat (in Mecca during October, the average temperature is >38 C during the day and >25 C at night) makes conditions worse and the continuous wearing of masks more difficult to achieve, especially for elderly pilgrims.", [["the average temperature", "TEST", 51, 74], ["masks", "TREATMENT", 172, 177]]], ["In addition, pilgrims must carry out the ritual washing (which involves washing the face with water) before each of the five obligatory prayers, forcing them to remove their masks several times per day.", [["pilgrims", "TREATMENT", 13, 21], ["the ritual washing", "TREATMENT", 37, 55], ["the five obligatory prayers", "TREATMENT", 116, 143]]], ["Finally, due to the overcrowded conditions in the tent camps where pilgrims spend most of their time during the 5-day period of the Hajj, they are encouraged to take minimum personal belongings with them in a small bag, making it much more difficult for them to transport a large number of disposable face masks.", [["the overcrowded conditions", "PROBLEM", 16, 42], ["a small bag", "TREATMENT", 207, 218], ["disposable face masks", "TREATMENT", 290, 311]]], ["The effectiveness of face masks in preventing the transmission of influenza and ARIs is dependent on various factors, including setting and compliance.", [["influenza", "DISEASE", 66, 75], ["ARIs", "DISEASE", 80, 84], ["face masks", "TREATMENT", 21, 31], ["influenza", "PROBLEM", 66, 75], ["ARIs", "PROBLEM", 80, 84], ["influenza", "OBSERVATION", 66, 75]]], ["Thus, the role of face mask use has been advocated in a number of studies conducted in multiple settings, including health care facilities, household contacts of index case patients, and university residents.", [["patients", "ORGANISM", 173, 181], ["patients", "SPECIES", 173, 181], ["face mask", "TREATMENT", 18, 27]]], ["Although most studies have found that the use of masks was associated with a reduced risk of severe acute respiratory syndrome, none of the studies established a conclusive relationship between mask use and protection against influenza infection [42, 43] .", [["acute respiratory syndrome", "DISEASE", 100, 126], ["influenza infection", "DISEASE", 226, 245], ["masks", "TREATMENT", 49, 54], ["severe acute respiratory syndrome", "PROBLEM", 93, 126], ["the studies", "TEST", 136, 147], ["mask use", "TREATMENT", 194, 202], ["protection", "TREATMENT", 207, 217], ["influenza infection", "PROBLEM", 226, 245], ["severe", "OBSERVATION_MODIFIER", 93, 99], ["acute", "OBSERVATION_MODIFIER", 100, 105], ["respiratory syndrome", "OBSERVATION", 106, 126]]], ["Moreover, metadata from these studies indicated that wearing surgical masks did not change the frequency of laboratoryconfirmed influenza [44] .", [["influenza", "DISEASE", 128, 137], ["these studies", "TEST", 24, 37], ["surgical masks", "TREATMENT", 61, 75], ["laboratoryconfirmed influenza", "PROBLEM", 108, 137]]], ["As the effectiveness of face masks is likely linked to early, consistent and correct usage, we continue to recommend their use, although available studies do not provide strong evidence for their effectiveness in the prevention of the viral respiratory infection known as \"Hajj cough\".", [["respiratory", "ANATOMY", 241, 252], ["viral respiratory infection", "DISEASE", 235, 262], ["cough", "DISEASE", 278, 283], ["face masks", "TREATMENT", 24, 34], ["available studies", "TEST", 137, 154], ["the viral respiratory infection", "PROBLEM", 231, 262], ["viral", "OBSERVATION_MODIFIER", 235, 240], ["respiratory infection", "OBSERVATION", 241, 262]]], ["Some actions that may be taken to improve compliance with face mask use are the launch of recall campaigns during the Hajj to inform pilgrims of the importance of face mask and how to use it properly, and free mask distribution to pilgrims, particularly during their stay in Mina.DiscussionDespite their poor knowledge of the usefulness of hand hygiene in preventing respiratory infections, hand washing compliance of pilgrims during the Hajj is usually quite good.", [["hand", "ANATOMY", 340, 344], ["respiratory", "ANATOMY", 367, 378], ["hand", "ANATOMY", 391, 395], ["respiratory infections", "DISEASE", 367, 389], ["hand", "ORGANISM_SUBDIVISION", 340, 344], ["hand", "ORGANISM_SUBDIVISION", 391, 395], ["face mask", "TREATMENT", 58, 67], ["face mask", "TREATMENT", 163, 172], ["hand hygiene", "TREATMENT", 340, 352], ["respiratory infections", "PROBLEM", 367, 389], ["respiratory", "ANATOMY", 367, 378], ["infections", "OBSERVATION", 379, 389]]], ["This finding is not surprising because in several cultures and religions, hand hygiene is not only an action aimed at body care.", [["hand", "ANATOMY", 74, 78], ["body", "ANATOMY", 118, 122], ["hand", "ORGANISM_SUBDIVISION", 74, 78], ["body", "ORGANISM_SUBDIVISION", 118, 122], ["several cultures", "TEST", 42, 58], ["not surprising", "UNCERTAINTY", 16, 30]]], ["In Islam, the ritual purification takes the form of ablution (Wudu), which is, in most cases, repeated before the five daily obligatory prayers.", [["the ritual purification", "TREATMENT", 10, 33]]], ["Ablution consists of the methodical washing of the hands, mouth, nose, face, forearm, head, ears, and feet three times each with running water.", [["mouth", "ANATOMY", 58, 63], ["nose", "ANATOMY", 65, 69], ["face", "ANATOMY", 71, 75], ["forearm", "ANATOMY", 77, 84], ["head", "ANATOMY", 86, 90], ["ears", "ANATOMY", 92, 96], ["hands", "ORGANISM_SUBDIVISION", 51, 56], ["mouth", "ORGANISM_SUBDIVISION", 58, 63], ["nose", "ORGANISM_SUBDIVISION", 65, 69], ["face", "ORGANISM_SUBDIVISION", 71, 75], ["forearm", "ORGANISM_SUBDIVISION", 77, 84], ["head", "ORGANISM_SUBDIVISION", 86, 90], ["ears", "ORGAN", 92, 96], ["Ablution", "TREATMENT", 0, 8], ["the methodical washing", "TREATMENT", 21, 43], ["mouth, nose, face, forearm, head, ears, and feet", "TEST", 58, 106], ["hands", "ANATOMY", 51, 56], ["mouth", "ANATOMY", 58, 63], ["nose", "ANATOMY", 65, 69], ["face", "ANATOMY", 71, 75], ["forearm", "ANATOMY", 77, 84], ["head", "ANATOMY", 86, 90], ["ears", "ANATOMY", 92, 96], ["feet", "ANATOMY", 102, 106]]], ["The effectiveness of hand hygiene interventions varies depending on setting, context and compliance [45] .", [["hand", "ANATOMY", 21, 25], ["hand", "ORGANISM_SUBDIVISION", 21, 25], ["hand hygiene interventions", "TREATMENT", 21, 47]]], ["Several reviews of published work have been conducted to evaluate the effect of hand hygiene in preventing respiratory tract infections, especially in the health care setting [46e48].", [["hand", "ANATOMY", 80, 84], ["respiratory tract", "ANATOMY", 107, 124], ["respiratory tract infections", "DISEASE", 107, 135], ["hand", "ORGANISM_SUBDIVISION", 80, 84], ["respiratory tract", "ORGANISM_SUBDIVISION", 107, 124], ["hand hygiene", "TREATMENT", 80, 92], ["respiratory tract infections", "PROBLEM", 107, 135], ["respiratory tract", "ANATOMY", 107, 124], ["infections", "OBSERVATION", 125, 135]]], ["Available evidence suggests that hand hygiene might help reduce the transmission of a range of important nosocomial pathogens [47] and acute respiratory tract infections [45] .", [["hand", "ANATOMY", 33, 37], ["respiratory tract", "ANATOMY", 141, 158], ["acute respiratory tract infections", "DISEASE", 135, 169], ["hand", "ORGANISM_SUBDIVISION", 33, 37], ["hand hygiene", "TREATMENT", 33, 45], ["important nosocomial pathogens", "PROBLEM", 95, 125], ["acute respiratory tract infections", "PROBLEM", 135, 169], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["respiratory tract", "ANATOMY", 141, 158]]], ["However, hygienic hand disinfection has better efficacy than hand washing [47, 49] .", [["hand", "ANATOMY", 18, 22], ["hand", "ANATOMY", 61, 65], ["hand", "ORGANISM_SUBDIVISION", 18, 22], ["hand", "ORGANISM_SUBDIVISION", 61, 65], ["hygienic hand disinfection", "PROBLEM", 9, 35], ["disinfection", "OBSERVATION", 23, 35]]], ["During their stay in Mina, pilgrims live in crowded tent camps where the water and sanitation that are available outside the tents are to be used collectively.", [["sanitation", "TREATMENT", 83, 93]]], ["Frequent hand washing outside the ritual context of ablution may be difficult in these conditions.", [["hand", "ANATOMY", 9, 13], ["Frequent hand washing", "TREATMENT", 0, 21], ["ablution", "TREATMENT", 52, 60]]], ["Additionally, during a few days of the Hajj, when pilgrims are in the state of \"Ihram\" (a sacred state that pilgrims must enter to perform the pilgrimage), they are not allowed to use scented soap, and although unscented soap may be available, pilgrims most commonly wash their hands only with water.", [["pilgrims", "TREATMENT", 244, 252]]], ["Alcohol-based hand rubs may be better than traditional hand washing, as they require less time, act more rapidly, and contribute to sustained improvement in compliance associated with decreased infection rates [47, 49] .", [["hand", "ANATOMY", 14, 18], ["hand", "ANATOMY", 55, 59], ["Alcohol", "CHEMICAL", 0, 7], ["infection", "DISEASE", 194, 203], ["hand", "ORGANISM_SUBDIVISION", 55, 59], ["based hand rubs", "PROBLEM", 8, 23], ["traditional hand washing", "TREATMENT", 43, 67], ["decreased infection rates", "PROBLEM", 184, 209], ["decreased", "OBSERVATION_MODIFIER", 184, 193], ["infection", "OBSERVATION", 194, 203]]], ["Therefore, as alcohol is permitted as a medicinal agent within Islam [50, 51] , the implementation of effective hand hygiene practices focusing on the regular use of alcohol-based hand rubs is recommended.", [["hand", "ANATOMY", 112, 116], ["hand", "ANATOMY", 180, 184], ["alcohol", "CHEMICAL", 14, 21], ["alcohol", "CHEMICAL", 166, 173], ["alcohol", "CHEMICAL", 14, 21], ["alcohol", "CHEMICAL", 166, 173], ["alcohol", "SIMPLE_CHEMICAL", 14, 21], ["hand", "ORGANISM_SUBDIVISION", 112, 116], ["alcohol", "SIMPLE_CHEMICAL", 166, 173], ["hand", "ORGANISM_SUBDIVISION", 180, 184], ["a medicinal agent", "TREATMENT", 38, 55], ["effective hand hygiene practices", "TREATMENT", 102, 134]]], ["Promotion of hand hygiene among pilgrims attending the Hajj should continue as a preventive measure against both respiratory and diarrheal diseases [52] .DiscussionBoth social distancing and contact avoidance may reduce the transmission of respiratory tract infections; however, these recommendations cannot be assiduously implemented in the context of the Hajj given the extremely high density to which pilgrims are exposed when performing the Hajj rituals.", [["hand", "ANATOMY", 13, 17], ["respiratory", "ANATOMY", 113, 124], ["respiratory tract", "ANATOMY", 240, 257], ["respiratory and diarrheal diseases", "DISEASE", 113, 147], ["respiratory tract infections", "DISEASE", 240, 268], ["hand", "ORGANISM_SUBDIVISION", 13, 17], ["respiratory tract", "ORGANISM_SUBDIVISION", 240, 257], ["both respiratory and diarrheal diseases", "PROBLEM", 108, 147], ["respiratory tract infections", "PROBLEM", 240, 268], ["hand", "ANATOMY", 13, 17], ["respiratory", "ANATOMY", 113, 124], ["respiratory tract", "ANATOMY", 240, 257], ["high", "OBSERVATION_MODIFIER", 382, 386], ["density", "OBSERVATION", 387, 394]]], ["In particular, there is a very dense crowd when performing the Tawaf in the Grand Mosque, with up to eight pilgrims per square meter near the Kaaba [53, 54] .", [["a very dense crowd", "PROBLEM", 24, 42], ["very", "OBSERVATION_MODIFIER", 26, 30], ["dense", "OBSERVATION_MODIFIER", 31, 36], ["crowd", "OBSERVATION", 37, 42]]], ["Moreover, pilgrims are accommodated in tents during the 5day Hajj, living in close contact with others (some with up to 50e100 people per tent) in the pilgrims' camp in Mina outside the holy city of Mecca.DiscussionThe recommendation for pilgrims in high-risk groups to postpone their plans to perform the Hajj and Umrah should be maintained, as postponement is an effective measure to protect these individuals from the risk of respiratory tract infections during the stay; however, we do not believe that this recommendation will be followed by pilgrims with the intention to perform the Hajj.", [["respiratory tract", "ANATOMY", 429, 446], ["respiratory tract infections", "DISEASE", 429, 457], ["respiratory tract", "ORGANISM_SUBDIVISION", 429, 446], ["people", "SPECIES", 127, 133], ["pilgrims", "TREATMENT", 238, 246], ["Umrah", "TREATMENT", 315, 320], ["respiratory tract infections", "PROBLEM", 429, 457], ["respiratory tract", "ANATOMY", 429, 446]]], ["Therefore, particularly considering the advanced age of most pilgrims, it must be a very difficult decision for them to voluntarily cancel or postpone their plans to perform the Hajj.DiscussionPending further rigorous scientific evidence on effectiveness, it is important for local, national and international health agencies and those providing health care services and advice to pilgrims to work with communities using effective communication strategies, before and during the pilgrimage, to increase awareness of the health hazards during the Hajj.", [["effective communication strategies", "TREATMENT", 421, 455]]], ["To be successful in this role, health agencies must work in partnership with community leaders, travel agents and imams by spreading awareness, especially through educational campaigns, among pilgrims about these measures and discouraging those at high risk from attending Hajj.DiscussionRespiratory diseases continue to be a major concern during the Hajj.", [["DiscussionRespiratory diseases", "DISEASE", 278, 308], ["DiscussionRespiratory diseases", "PROBLEM", 278, 308], ["successful", "OBSERVATION", 6, 16]]], ["It is expected that public health research projects developed through international collaboration will provide key information about the dynamics of infectious diseases spread during the Hajj and the implications for their global spread.", [["infectious diseases", "DISEASE", 149, 168], ["infectious diseases spread", "PROBLEM", 149, 175], ["their global spread", "PROBLEM", 217, 236], ["infectious", "OBSERVATION", 149, 159], ["global", "OBSERVATION_MODIFIER", 223, 229], ["spread", "OBSERVATION", 230, 236]]], ["Some large cohort studies on the risk of acquiring pathogens during the Hajj are ongoing among multinational samples of pilgrims.", [["Some large cohort studies", "PROBLEM", 0, 25], ["acquiring pathogens", "PROBLEM", 41, 60], ["large", "OBSERVATION_MODIFIER", 5, 10], ["cohort", "OBSERVATION", 11, 17]]], ["The roles of host (e.g., age, underlying chronic diseases, vaccination status) and environmental factors in pathogen transmission will also be addressed.", [["chronic diseases", "DISEASE", 41, 57], ["underlying chronic diseases", "PROBLEM", 30, 57], ["chronic", "OBSERVATION_MODIFIER", 41, 48], ["diseases", "OBSERVATION", 49, 57]]], ["Interventional studies assessing the effectiveness of non-pharmaceutical individual measures in preventing the spread of respiratory infectious diseases will be conducted.", [["respiratory infectious diseases", "DISEASE", 121, 152], ["Interventional studies", "TEST", 0, 22], ["non-pharmaceutical individual measures", "TREATMENT", 54, 92], ["respiratory infectious diseases", "PROBLEM", 121, 152], ["respiratory", "ANATOMY", 121, 132], ["infectious", "OBSERVATION", 133, 143]]], ["In particular, large randomized controlled trials on face mask use will be conducted among cohorts of pilgrims from several countries [44] .", [["large randomized controlled trials", "TREATMENT", 15, 49], ["face mask", "TREATMENT", 53, 62], ["large", "OBSERVATION_MODIFIER", 15, 20]]], ["It is expected that the results of these studies will lead to the implementation of evidence-based recommendations on preventive measures such as face mask use, hand hygiene and other individual measures for pilgrims participating in the Hajj in the next years.", [["hand", "ANATOMY", 161, 165], ["hand", "ORGANISM_SUBDIVISION", 161, 165], ["these studies", "TEST", 35, 48], ["preventive measures", "TREATMENT", 118, 137], ["face mask use", "TREATMENT", 146, 159], ["hand hygiene", "TREATMENT", 161, 173]]], ["Investigations exploring the link between communication and behavior will also be conducted to provide the evidence base for the adoption of effective approaches to improving communication with pilgrims and to better meet the needs of diverse communities.DiscussionThe recently established Global Centre for Mass Gathering Medicine, in partnership and collaboration with other WHO collaborating centers and between states, international organizations and scientific centers, with the aim of sharing experience and knowledge through global health diplomacy will therefore play a central role in achieving these goals [55] .DiscussionThus, it is hoped that this review will help relevant authorities in providing recommendations for prevention of respiratory infectious diseases during the Hajj, particularly for prevention of MERS-CoV transmission [56] .FundingNone.", [["respiratory infectious diseases", "DISEASE", 745, 776], ["MERS-CoV", "ORGANISM", 825, 833], ["MERS-CoV", "SPECIES", 825, 833], ["respiratory infectious diseases", "PROBLEM", 745, 776], ["respiratory", "ANATOMY", 745, 756], ["infectious", "OBSERVATION", 757, 767]]]], "PMC7369338": [["IntroductionIn December 2019, a series of respiratory illnesses caused by a novel coronavirus, officially named Coronavirus Disease 2019 (COVID-19), was detected in Wuhan city, Hubei Province of China, and this disease spread rapidly around the country and the world.", [["respiratory", "ANATOMY", 42, 53], ["respiratory illnesses", "DISEASE", 42, 63], ["coronavirus", "DISEASE", 82, 93], ["COVID-19", "CHEMICAL", 138, 146], ["coronavirus", "ORGANISM", 82, 93], ["COVID-19", "CELL", 138, 146], ["coronavirus", "SPECIES", 82, 93], ["Coronavirus Disease 2019 (COVID-19", "SPECIES", 112, 146], ["respiratory illnesses", "PROBLEM", 42, 63], ["a novel coronavirus", "PROBLEM", 74, 93], ["Coronavirus Disease", "PROBLEM", 112, 131], ["COVID", "TEST", 138, 143], ["this disease spread", "PROBLEM", 206, 225], ["Coronavirus Disease", "OBSERVATION", 112, 131]]], ["As of 30 March 2020, 693 282 patients with COVID-19 have been reported, and 33 106 deaths have been confirmed worldwide [1].", [["deaths", "DISEASE", 83, 89], ["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["COVID", "TEST", 43, 48]]], ["The disease is believed to be transmitted mostly via droplets or close contact, and the incubation period ranges from 2 to 14 days [2].", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11], ["believed to be", "UNCERTAINTY", 15, 29]]], ["The typical symptoms are fever, dry cough, myalgia and fatigue [2].", [["fever", "DISEASE", 25, 30], ["dry cough", "DISEASE", 32, 41], ["myalgia", "DISEASE", 43, 50], ["fatigue", "DISEASE", 55, 62], ["The typical symptoms", "PROBLEM", 0, 20], ["fever", "PROBLEM", 25, 30], ["dry cough", "PROBLEM", 32, 41], ["myalgia", "PROBLEM", 43, 50], ["fatigue", "PROBLEM", 55, 62], ["myalgia", "OBSERVATION", 43, 50]]], ["COVID-19 has the characteristics of rapid transmission, atypical clinical symptoms and easily affecting both lungs, leading to missed diagnoses and misdiagnoses [3\u20137].IntroductionAccording to the \u2018Prevention & Control Program for Novel Coronavirus Pneumonia (Trial) 6th Edition\u2019 enacted by China's National Health Commission [8], close contacts are defined as those who did not use effective protection and had close contact with suspected or confirmed cases 2 days before the onset of symptoms.", [["lungs", "ANATOMY", 109, 114], ["COVID-19", "CHEMICAL", 0, 8], ["Pneumonia", "DISEASE", 248, 257], ["lungs", "ORGAN", 109, 114], ["COVID", "TEST", 0, 5], ["rapid transmission", "PROBLEM", 36, 54], ["atypical clinical symptoms", "PROBLEM", 56, 82], ["Novel Coronavirus Pneumonia", "PROBLEM", 230, 257], ["symptoms", "PROBLEM", 486, 494], ["rapid", "OBSERVATION_MODIFIER", 36, 41], ["lungs", "ANATOMY", 109, 114], ["Pneumonia", "OBSERVATION", 248, 257]]], ["To date, accumulated evidence has indicated person-to-person transmission to be the cause of most infections [3, 9\u201311].", [["infections", "DISEASE", 98, 108], ["person", "SPECIES", 44, 50], ["person", "SPECIES", 54, 60], ["most infections", "PROBLEM", 93, 108]]], ["Li had demonstrated that person-to-person transmission occurred among close contacts since the mid-December 2019 [10].IntroductionThe massive levels of human movement that occurred during the traditional Chinese New Year holidays fuelled the epidemic.", [["Li", "CHEMICAL", 0, 2], ["human", "ORGANISM", 152, 157], ["person", "SPECIES", 25, 31], ["person", "SPECIES", 35, 41], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157], ["massive", "OBSERVATION_MODIFIER", 134, 141], ["human movement", "OBSERVATION", 152, 166]]], ["Cases had also been reported in other provinces of China, as well as in other countries with no history of travel to Wuhan, which suggested that local person-to-person transmission was occurring in these areas.", [["person", "SPECIES", 151, 157]]], ["At present, a total of 42 confirmed cases of COVID-19 have been reported in Dazhou, Sichuan Province, China, among which are many family cluster cases [12].", [["COVID", "TEST", 45, 50]]], ["With the development of the epidemic, the proportion of clustered outbreaks is increasing.", [["the epidemic", "PROBLEM", 24, 36], ["clustered outbreaks", "PROBLEM", 56, 75], ["epidemic", "OBSERVATION_MODIFIER", 28, 36], ["proportion", "OBSERVATION_MODIFIER", 42, 52], ["clustered", "OBSERVATION_MODIFIER", 56, 65], ["outbreaks", "OBSERVATION", 66, 75], ["increasing", "OBSERVATION_MODIFIER", 79, 89]]], ["Cluster outbreaks have become a major component of outbreak development throughout the country [13, 14].", [["Cluster outbreaks", "PROBLEM", 0, 17], ["major", "OBSERVATION_MODIFIER", 32, 37], ["component", "OBSERVATION_MODIFIER", 38, 47], ["outbreak", "OBSERVATION_MODIFIER", 51, 59]]], ["It is important to note that while, at present, the number of new cases has recently been reduced in China, they have increased exponentially in other countries, including South Korea, Italy and the United States [15\u201317], which is a major threat to public health [18].", [["reduced", "OBSERVATION_MODIFIER", 90, 97], ["increased", "OBSERVATION_MODIFIER", 118, 127], ["exponentially", "OBSERVATION_MODIFIER", 128, 141]]], ["Here, we report the epidemiological, clinical, radiological and laboratory findings of a family cluster of five patients and provide guidance for the management of this outbreak.Study design and patients ::: MethodsWe performed a retrospective study of a family cluster of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection involving five patients admitted to the isolation ward of Dazhou Central Hospital in February 2020.", [["acute respiratory syndrome coronavirus", "DISEASE", 280, 318], ["SARS-CoV-2) infection", "DISEASE", 322, 343], ["patients", "ORGANISM", 112, 120], ["patients", "ORGANISM", 195, 203], ["SARS-CoV-2", "ORGANISM", 322, 332], ["patients", "ORGANISM", 359, 367], ["patients", "SPECIES", 112, 120], ["patients", "SPECIES", 195, 203], ["patients", "SPECIES", 359, 367], ["severe acute respiratory syndrome coronavirus", "SPECIES", 273, 318], ["SARS-CoV-2", "SPECIES", 322, 332], ["the management", "TREATMENT", 146, 160], ["this outbreak", "PROBLEM", 164, 177], ["a retrospective study", "TEST", 228, 249], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 273, 318], ["SARS", "PROBLEM", 322, 326], ["infection", "PROBLEM", 334, 343], ["severe", "OBSERVATION_MODIFIER", 273, 279], ["acute", "OBSERVATION_MODIFIER", 280, 285], ["respiratory syndrome", "OBSERVATION", 286, 306]]], ["This study was reviewed and approved by the Medical Ethics Committee of Dazhou Central Hospital (approval number 2020014).Determination of cluster epidemic ::: Definitions ::: MethodsIn reference to the Guidelines for Epidemiological Survey of Cluster Epidemic of COVID-19 (Tentative, 1st edition), a cluster epidemic refers to 2 or more confirmed cases or asymptomatic infected cases identified in a small area (e.g. a family, a construction site, an organisation) within 14 days, and there is the possibility of person-to-person transmission due to close contact or a possibility of infection due to common exposure.Epidemiological survey ::: Definitions ::: MethodsIn reference to the Guidelines for Epidemiological Survey of Cluster Epidemic of COVID-19 (Tentative, 1st edition), a first-generation case normally refers to the earliest affected case, i.e., the first case in the cluster epidemic.", [["infection", "DISEASE", 585, 594], ["person", "SPECIES", 514, 520], ["This study", "TEST", 0, 10], ["Methods", "TREATMENT", 176, 183], ["COVID", "TEST", 264, 269], ["asymptomatic infected cases", "PROBLEM", 357, 384], ["infection", "PROBLEM", 585, 594], ["Methods", "TREATMENT", 661, 668], ["COVID", "TEST", 749, 754], ["cluster", "OBSERVATION_MODIFIER", 139, 146], ["epidemic", "OBSERVATION", 147, 155], ["asymptomatic", "OBSERVATION_MODIFIER", 357, 369], ["infected", "OBSERVATION", 370, 378], ["small", "OBSERVATION_MODIFIER", 401, 406], ["infection", "OBSERVATION", 585, 594]]], ["To determine a third- or later-generation case, reference can be made to the criteria for determining a second-generation case.Data collection ::: MethodsWe obtained epidemiological, clinical, laboratory, management and outcome data from the hospital's electronic record system.", [["a second-generation case", "TREATMENT", 102, 126], ["outcome data", "TEST", 220, 232]]], ["Throat-swab specimens from the upper respiratory tract were obtained from the patients and sent to the Dazhou Centre for Disease Control and Prevention (CDC) to detect COVID-19 by applying quantitative polymerase chain reaction analysis [3].", [["Throat-swab specimens", "ANATOMY", 0, 21], ["upper respiratory tract", "ANATOMY", 31, 54], ["Throat-swab specimens", "TISSUE", 0, 21], ["upper respiratory", "ORGANISM_SUBDIVISION", 31, 48], ["tract", "ORGANISM_SUBDIVISION", 49, 54], ["patients", "ORGANISM", 78, 86], ["COVID-19", "DNA", 168, 176], ["patients", "SPECIES", 78, 86], ["Throat-swab specimens from the upper respiratory tract", "TEST", 0, 54], ["Disease Control", "TREATMENT", 121, 136], ["COVID", "TEST", 168, 173], ["upper", "ANATOMY_MODIFIER", 31, 36], ["respiratory tract", "ANATOMY", 37, 54]]], ["All patients were tested for respiratory pathogens and for the nucleic acid of influenza viruses A and B. For each case, computed tomography (CT) was performed upon admission.", [["respiratory pathogens", "DISEASE", 29, 50], ["nucleic acid", "CHEMICAL", 63, 75], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["respiratory pathogens", "PROBLEM", 29, 50], ["the nucleic acid", "TEST", 59, 75], ["influenza viruses", "PROBLEM", 79, 96], ["computed tomography (CT)", "TEST", 121, 145]]], ["Laboratory assessments include a complete blood count and serum biochemistry.Diagnostic standard ::: MethodsDiagnoses were performed according to the \u2018Diagnosis & Treatment Scheme for Novel Coronavirus Pneumonia (Trial) 6th edition\u2019 enacted by the National Health Commission of the People's Republic of China [19].General information ::: ResultsThe family cluster comprised five patients aged 28\u201382 years, median age 52 years, including 1 (20%) patient with underlying diseases (hypertension and coronary heart disease) (Table 1).", [["blood", "ANATOMY", 42, 47], ["serum", "ANATOMY", 58, 63], ["coronary", "ANATOMY", 496, 504], ["heart", "ANATOMY", 505, 510], ["Pneumonia", "DISEASE", 202, 211], ["hypertension", "DISEASE", 479, 491], ["coronary heart disease", "DISEASE", 496, 518], ["blood", "ORGANISM_SUBSTANCE", 42, 47], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["patients", "ORGANISM", 379, 387], ["patient", "ORGANISM", 445, 452], ["heart", "ORGAN", 505, 510], ["patients", "SPECIES", 379, 387], ["patient", "SPECIES", 445, 452], ["Laboratory assessments", "TEST", 0, 22], ["a complete blood count", "TEST", 31, 53], ["serum biochemistry", "TEST", 58, 76], ["Treatment Scheme", "TREATMENT", 163, 179], ["Novel Coronavirus Pneumonia", "PROBLEM", 184, 211], ["underlying diseases", "PROBLEM", 458, 477], ["hypertension", "PROBLEM", 479, 491], ["coronary heart disease)", "PROBLEM", 496, 519], ["Pneumonia", "OBSERVATION", 202, 211], ["diseases", "OBSERVATION", 469, 477], ["hypertension", "OBSERVATION", 479, 491], ["coronary heart", "ANATOMY", 496, 510], ["disease", "OBSERVATION", 511, 518]]]], "eb03929ece5b5824a14de0c7d28a6e5620a554f4": [["in the CNS are comprised of macrophages, lymphocytes, monocytes, and plasma cells (8) .", [["CNS", "ANATOMY", 7, 10], ["macrophages", "ANATOMY", 28, 39], ["lymphocytes", "ANATOMY", 41, 52], ["monocytes", "ANATOMY", 54, 63], ["plasma cells", "ANATOMY", 69, 81], ["CNS", "ANATOMICAL_SYSTEM", 7, 10], ["macrophages", "CELL", 28, 39], ["lymphocytes", "CELL", 41, 52], ["monocytes", "CELL", 54, 63], ["plasma cells", "CELL", 69, 81], ["macrophages", "CELL_TYPE", 28, 39], ["lymphocytes", "CELL_TYPE", 41, 52], ["monocytes", "CELL_TYPE", 54, 63], ["plasma cells", "CELL_TYPE", 69, 81], ["macrophages", "TEST", 28, 39], ["lymphocytes", "TEST", 41, 52], ["monocytes", "TEST", 54, 63], ["plasma cells", "TEST", 69, 81], ["CNS", "ANATOMY", 7, 10], ["macrophages", "OBSERVATION", 28, 39], ["lymphocytes", "ANATOMY", 41, 52], ["monocytes", "ANATOMY", 54, 63], ["plasma cells", "OBSERVATION", 69, 81]]], ["During the chronic stage of the disease most pathologic processes are limited to the CNS (11) .", [["CNS", "ANATOMY", 85, 88], ["CNS", "ANATOMICAL_SYSTEM", 85, 88], ["the disease most pathologic processes", "PROBLEM", 28, 65], ["chronic", "OBSERVATION_MODIFIER", 11, 18], ["disease", "OBSERVATION", 32, 39], ["most", "OBSERVATION_MODIFIER", 40, 44], ["pathologic", "OBSERVATION", 45, 55]]], ["The demyelination parallels incomplete CNS-type remyelination by oligodendrocytes (10, 12) .", [["CNS", "ANATOMY", 39, 42], ["oligodendrocytes", "ANATOMY", 65, 81], ["demyelination", "DISEASE", 4, 17], ["oligodendrocytes", "CELL", 65, 81], ["oligodendrocytes", "CELL_TYPE", 65, 81], ["The demyelination parallels", "PROBLEM", 0, 27], ["demyelination", "OBSERVATION", 4, 17], ["CNS", "ANATOMY", 39, 42], ["type", "OBSERVATION_MODIFIER", 43, 47], ["remyelination", "OBSERVATION", 48, 61]]]], "PMC7384774": [["The world urgently needs a planetary health perspective to properly address the challenge posed by COVID-19.1 The COVID-19 pandemic and extreme heat events are already coinciding, further threatening community health in many cities across the globe.", [["a planetary health perspective", "TREATMENT", 25, 55], ["COVID", "TEST", 99, 104], ["The COVID", "TEST", 110, 119], ["extreme heat events", "PROBLEM", 136, 155], ["globe", "ANATOMY", 243, 248]]], ["The onset of the hot season presents individuals and local decision makers with new challenges on the optimal ways to stay safe from both heat stress and COVID-19.", [["both heat stress", "TEST", 133, 149], ["COVID", "TEST", 154, 159]]]], "6ea2532aacbdcea4609067523e9e72fa8cd73200": [["IntroductionThe bacterial pathogens Neisseria meningitidis (Nm) and Haemophilus influenzae (Hi) are frequently found in the nasopharynx of a substantial proportion of the healthy population but are capable of causing serious infections in susceptible individuals (Turk, 1984; Foxwell et al., 1998) .", [["nasopharynx", "ANATOMY", 124, 135], ["Neisseria meningitidis", "DISEASE", 36, 58], ["Haemophilus influenzae", "DISEASE", 68, 90], ["infections", "DISEASE", 225, 235], ["bacterial pathogens", "ORGANISM", 16, 35], ["Neisseria meningitidis", "ORGANISM", 36, 58], ["Haemophilus influenzae", "ORGANISM", 68, 90], ["nasopharynx", "ORGAN", 124, 135], ["Neisseria meningitidis", "SPECIES", 36, 58], ["Haemophilus influenzae", "SPECIES", 68, 90], ["Neisseria meningitidis", "SPECIES", 36, 58], ["Haemophilus influenzae", "SPECIES", 68, 90], ["The bacterial pathogens Neisseria meningitidis (Nm)", "PROBLEM", 12, 63], ["Haemophilus influenzae", "PROBLEM", 68, 90], ["serious infections in susceptible individuals", "PROBLEM", 217, 262], ["bacterial", "OBSERVATION_MODIFIER", 16, 25], ["pathogens", "OBSERVATION_MODIFIER", 26, 35], ["Haemophilus influenzae", "OBSERVATION", 68, 90], ["nasopharynx", "ANATOMY", 124, 135], ["serious", "OBSERVATION_MODIFIER", 217, 224], ["infections", "OBSERVATION", 225, 235]]], ["Nm and typable Hi (THi) can invade the nasopharyngeal epithelial barrier to cause septicaemia and meningitis, which in the case of Nm, may rapidly become life threatening (van Deuren et al., 2000) .", [["nasopharyngeal epithelial", "ANATOMY", 39, 64], ["septicaemia", "DISEASE", 82, 93], ["meningitis", "DISEASE", 98, 108], ["typable Hi (THi)", "GENE_OR_GENE_PRODUCT", 7, 23], ["nasopharyngeal epithelial barrier", "TISSUE", 39, 72], ["typable Hi (THi)", "PROBLEM", 7, 23], ["the nasopharyngeal epithelial barrier", "TREATMENT", 35, 72], ["septicaemia", "PROBLEM", 82, 93], ["meningitis", "PROBLEM", 98, 108], ["nasopharyngeal epithelial", "ANATOMY", 39, 64], ["septicaemia", "OBSERVATION", 82, 93], ["meningitis", "OBSERVATION", 98, 108]]], ["Non-typable Hi (NTHi), which lack a polysaccharide capsule, are associated with localized respiratory tract and conjunctival infections (Foxwell et al., 1998) .", [["capsule", "ANATOMY", 51, 58], ["respiratory tract", "ANATOMY", 90, 107], ["conjunctival", "ANATOMY", 112, 124], ["respiratory tract and conjunctival infections", "DISEASE", 90, 135], ["NTHi", "GENE_OR_GENE_PRODUCT", 16, 20], ["capsule", "CANCER", 51, 58], ["respiratory tract", "ORGANISM_SUBDIVISION", 90, 107], ["conjunctival", "ORGAN", 112, 124], ["Non-typable Hi (NTHi", "PROBLEM", 0, 20], ["a polysaccharide capsule", "PROBLEM", 34, 58], ["localized respiratory tract", "PROBLEM", 80, 107], ["conjunctival infections", "PROBLEM", 112, 135], ["polysaccharide capsule", "OBSERVATION_MODIFIER", 36, 58], ["respiratory tract", "ANATOMY", 90, 107], ["conjunctival", "ANATOMY", 112, 124], ["infections", "OBSERVATION", 125, 135]]], ["Strains belonging to Hi-biogroup aegyptius (Hi-aeg) are also associated with Brazilian purpuric fever (Foxwell et al., 1998) .", [["purpuric fever", "DISEASE", 87, 101], ["Hi-biogroup aegyptius", "ORGANISM", 21, 42], ["Hi-aeg", "CANCER", 44, 50], ["Hi-biogroup aegyptius", "SPECIES", 21, 42], ["Hi-biogroup aegyptius", "SPECIES", 21, 42], ["Brazilian purpuric fever", "PROBLEM", 77, 101]]], ["The factors that determine susceptibility to infection by these frequent colonizers are not entirely clear.IntroductionFor both colonization and pathogenesis, the first essential step is adherence to mucosal epithelial cells.", [["mucosal epithelial cells", "ANATOMY", 200, 224], ["infection", "DISEASE", 45, 54], ["mucosal epithelial cells", "CELL", 200, 224], ["mucosal epithelial cells", "CELL_TYPE", 200, 224], ["susceptibility to infection", "PROBLEM", 27, 54], ["these frequent colonizers", "PROBLEM", 58, 83], ["both colonization", "PROBLEM", 123, 140], ["pathogenesis", "PROBLEM", 145, 157], ["mucosal epithelial cells", "PROBLEM", 200, 224], ["infection", "OBSERVATION", 45, 54], ["clear", "OBSERVATION", 101, 106], ["colonization", "OBSERVATION", 128, 140], ["mucosal epithelial cells", "OBSERVATION", 200, 224]]], ["Many investigations have shown bacterial targeting of specific human signalling molecules such as integrins, sialic acid binding Ig like lectins (Siglecs) and carcinoembryonic antigen (CEA)-related cell adhesion molecules (CEACAMs) can lead to cellular invasion (Virji et al., 1995; 1999; Hauck and Meyer, 2003; Jones et al., 2003) .", [["cell", "ANATOMY", 198, 202], ["cellular", "ANATOMY", 244, 252], ["sialic acid", "CHEMICAL", 109, 120], ["sialic acid", "CHEMICAL", 109, 120], ["human", "ORGANISM", 63, 68], ["integrins", "GENE_OR_GENE_PRODUCT", 98, 107], ["sialic acid binding Ig like lectins", "GENE_OR_GENE_PRODUCT", 109, 144], ["Siglecs", "GENE_OR_GENE_PRODUCT", 146, 153], ["carcinoembryonic antigen", "GENE_OR_GENE_PRODUCT", 159, 183], ["CEA)-related cell adhesion molecules", "GENE_OR_GENE_PRODUCT", 185, 221], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 223, 230], ["cellular", "CELL", 244, 252], ["human signalling molecules", "PROTEIN", 63, 89], ["integrins", "PROTEIN", 98, 107], ["sialic acid binding Ig like lectins", "PROTEIN", 109, 144], ["Siglecs", "PROTEIN", 146, 153], ["carcinoembryonic antigen (CEA)-related cell adhesion molecules", "PROTEIN", 159, 221], ["CEACAMs", "PROTEIN", 223, 230], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["Many investigations", "TEST", 0, 19], ["bacterial targeting of specific human signalling molecules", "PROBLEM", 31, 89], ["sialic acid binding Ig like lectins (Siglecs) and carcinoembryonic antigen (CEA)", "PROBLEM", 109, 189], ["cell adhesion molecules", "PROBLEM", 198, 221], ["cellular invasion", "PROBLEM", 244, 261], ["bacterial", "OBSERVATION_MODIFIER", 31, 40], ["cell adhesion", "OBSERVATION", 198, 211], ["cellular", "OBSERVATION_MODIFIER", 244, 252], ["invasion", "OBSERVATION", 253, 261]]], ["Of these, CEACAMs have emerged as common targets of several respiratory mucosal pathogens and include Nm, Hi, Moraxella catarrhalis, as well as the urogenital pathogen Neisseria gonorrhoeae and enteric pathogens Escherichia coli and Salmonella (Leusch et al., 1991; Virji et al., 1996a; Chen et al., 1997; Gray-Owen et al., 1997; Hill and Virji, 2003) .IntroductionCarcinoembryonic antigen-related cell adhesion molecules belong to the immunoglobulin (Ig) superfamily.", [["respiratory mucosal", "ANATOMY", 60, 79], ["cell", "ANATOMY", 398, 402], ["Neisseria gonorrhoeae", "DISEASE", 168, 189], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 10, 17], ["Moraxella catarrhalis", "ORGANISM", 110, 131], ["urogenital pathogen", "ORGANISM", 148, 167], ["Neisseria gonorrhoeae", "ORGANISM", 168, 189], ["Escherichia coli", "ORGANISM", 212, 228], ["Carcinoembryonic antigen-related cell adhesion molecules", "GENE_OR_GENE_PRODUCT", 365, 421], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 436, 450], ["Ig", "GENE_OR_GENE_PRODUCT", 452, 454], ["CEACAMs", "PROTEIN", 10, 17], ["Carcinoembryonic antigen-related cell adhesion molecules", "PROTEIN", 365, 421], ["immunoglobulin (Ig) superfamily", "PROTEIN", 436, 467], ["Moraxella catarrhalis", "SPECIES", 110, 131], ["Neisseria gonorrhoeae", "SPECIES", 168, 189], ["Escherichia coli", "SPECIES", 212, 228], ["Moraxella catarrhalis", "SPECIES", 110, 131], ["Neisseria gonorrhoeae", "SPECIES", 168, 189], ["Escherichia coli", "SPECIES", 212, 228], ["several respiratory mucosal pathogens", "PROBLEM", 52, 89], ["Nm", "PROBLEM", 102, 104], ["Hi", "PROBLEM", 106, 108], ["Moraxella catarrhalis", "PROBLEM", 110, 131], ["the urogenital pathogen Neisseria gonorrhoeae", "PROBLEM", 144, 189], ["enteric pathogens Escherichia coli", "PROBLEM", 194, 228], ["Salmonella", "PROBLEM", 233, 243], ["IntroductionCarcinoembryonic antigen", "TEST", 353, 389], ["related cell adhesion molecules", "TREATMENT", 390, 421], ["respiratory mucosal", "ANATOMY", 60, 79], ["pathogens", "OBSERVATION", 80, 89], ["Moraxella catarrhalis", "OBSERVATION", 110, 131], ["urogenital", "ANATOMY", 148, 158], ["cell adhesion", "OBSERVATION", 398, 411]]], ["Several members of the CEACAM subgroup are expressed on human epithelial cells and include the widely expressed transmembrane CEACAM1 as well as GPI-anchored CEA and CEACAM6.", [["epithelial cells", "ANATOMY", 62, 78], ["transmembrane", "ANATOMY", 112, 125], ["CEACAM", "GENE_OR_GENE_PRODUCT", 23, 29], ["human", "ORGANISM", 56, 61], ["epithelial cells", "CELL", 62, 78], ["transmembrane", "CELLULAR_COMPONENT", 112, 125], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 126, 133], ["GPI-anchored CEA", "GENE_OR_GENE_PRODUCT", 145, 161], ["CEACAM6", "GENE_OR_GENE_PRODUCT", 166, 173], ["CEACAM subgroup", "PROTEIN", 23, 38], ["human epithelial cells", "CELL_TYPE", 56, 78], ["transmembrane CEACAM1", "PROTEIN", 112, 133], ["GPI", "PROTEIN", 145, 148], ["CEA", "PROTEIN", 158, 161], ["CEACAM6", "PROTEIN", 166, 173], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["human epithelial cells", "TREATMENT", 56, 78], ["transmembrane CEACAM1", "TREATMENT", 112, 133], ["GPI-anchored CEA", "TREATMENT", 145, 161], ["CEACAM6", "PROBLEM", 166, 173], ["epithelial cells", "OBSERVATION", 62, 78], ["CEACAM1", "OBSERVATION", 126, 133]]], ["All CEACAMs have an N-terminal IgV-like domain and variable numbers of IgC2-like A and B domains.", [["CEACAMs", "CANCER", 4, 11], ["IgC2-like A", "GENE_OR_GENE_PRODUCT", 71, 82], ["CEACAMs", "PROTEIN", 4, 11], ["N-terminal IgV-like domain", "PROTEIN", 20, 46], ["IgC2", "PROTEIN", 71, 75], ["A and B domains", "PROTEIN", 81, 96], ["an N-terminal IgV-like domain", "PROBLEM", 17, 46], ["IgC2", "TEST", 71, 75], ["terminal", "OBSERVATION_MODIFIER", 22, 30], ["IgV", "OBSERVATION", 31, 34], ["variable", "OBSERVATION_MODIFIER", 51, 59], ["numbers", "OBSERVATION_MODIFIER", 60, 67]]], ["CEACAM1 comprises up to four extracellular domains: N, A1, B and A2 and either a long or a short cytoplasmic tail (Tsutsumi et al., 1990; Prall et al., 1996; Hammarstrom, 1999) .", [["extracellular", "ANATOMY", 29, 42], ["cytoplasmic", "ANATOMY", 97, 108], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 0, 7], ["N, A1", "GENE_OR_GENE_PRODUCT", 52, 57], ["B", "GENE_OR_GENE_PRODUCT", 59, 60], ["A2", "GENE_OR_GENE_PRODUCT", 65, 67], ["cytoplasmic", "ORGANISM_SUBSTANCE", 97, 108], ["CEACAM1", "PROTEIN", 0, 7], ["extracellular domains", "PROTEIN", 29, 50], ["N", "PROTEIN", 52, 53], ["A1", "PROTEIN", 55, 57], ["B", "PROTEIN", 59, 60], ["A2", "PROTEIN", 65, 67], ["cytoplasmic tail", "PROTEIN", 97, 113], ["CEACAM1", "TEST", 0, 7], ["A2", "ANATOMY", 65, 67]]], ["Various functions have been attributed to CEACAM1 including cell-cell adhesion, insulin regulation and angiogenesis (Obrink, 1997; Hammarstrom, 1999; Wagener and Ergun, 2000; Najjar, 2002) .", [["cell", "ANATOMY", 60, 64], ["cell", "ANATOMY", 65, 69], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 42, 49], ["cell", "CELL", 60, 64], ["cell", "CELL", 65, 69], ["insulin", "GENE_OR_GENE_PRODUCT", 80, 87], ["CEACAM1", "PROTEIN", 42, 49], ["CEACAM1", "PROBLEM", 42, 49], ["cell-cell adhesion", "TREATMENT", 60, 78], ["insulin regulation", "TREATMENT", 80, 98], ["Hammarstrom", "TEST", 131, 142], ["attributed to", "UNCERTAINTY", 28, 41], ["CEACAM1", "OBSERVATION", 42, 49], ["cell adhesion", "OBSERVATION", 65, 78]]], ["Targeting of CEACAMs by N. gonorrhoeae, as well as Nm and Hi leads to cellular invasion and passage across polarized monolayers (Virji et al., 1999; Gray-Owen, 2003; M. Soriani, K. Setchfield, D.J. Hill, and M. Virji, unpublished data) .IntroductionA wide range of bacterial adhesins are involved in targeting the CEACAM N-terminal domains and includes Opa proteins, a major adhesin family of pathogenic Neisseria and P5 proteins of Hi (Chen and Gotschlich, 1996; Virji et al., 1996a; Hill et al., 2001) .", [["cellular", "ANATOMY", 70, 78], ["monolayers", "ANATOMY", 117, 127], ["N", "CHEMICAL", 321, 322], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 13, 20], ["N. gonorrhoeae", "ORGANISM", 24, 38], ["cellular", "CELL", 70, 78], ["monolayers", "CELL", 117, 127], ["Opa", "GENE_OR_GENE_PRODUCT", 353, 356], ["P5", "GENE_OR_GENE_PRODUCT", 418, 420], ["CEACAMs", "PROTEIN", 13, 20], ["bacterial adhesins", "PROTEIN", 265, 283], ["CEACAM N-terminal domains", "PROTEIN", 314, 339], ["Opa proteins", "PROTEIN", 353, 365], ["major adhesin family", "PROTEIN", 369, 389], ["pathogenic Neisseria and P5 proteins", "PROTEIN", 393, 429], ["N. gonorrhoeae", "SPECIES", 24, 38], ["N. gonorrhoeae", "SPECIES", 24, 38], ["CEACAMs", "PROBLEM", 13, 20], ["cellular invasion", "PROBLEM", 70, 87], ["bacterial adhesins", "PROBLEM", 265, 283], ["Opa proteins", "PROBLEM", 353, 365], ["gonorrhoeae", "OBSERVATION", 27, 38], ["cellular", "OBSERVATION_MODIFIER", 70, 78], ["invasion", "OBSERVATION", 79, 87], ["polarized", "OBSERVATION_MODIFIER", 107, 116], ["monolayers", "OBSERVATION_MODIFIER", 117, 127]]], ["Nm and N. gonorrhoeae contain multiple copies of Opa genes that encode conserved domains which form b-barrel structures in bacterial membranes and variable domains that form surface exposed loops.", [["membranes", "ANATOMY", 133, 142], ["surface", "ANATOMY", 174, 181], ["N. gonorrhoeae", "ORGANISM", 7, 21], ["Opa", "GENE_OR_GENE_PRODUCT", 49, 52], ["bacterial membranes", "CELLULAR_COMPONENT", 123, 142], ["Opa genes", "DNA", 49, 58], ["N. gonorrhoeae", "SPECIES", 7, 21], ["N. gonorrhoeae", "SPECIES", 7, 21], ["bacterial membranes", "PROBLEM", 123, 142], ["variable domains", "PROBLEM", 147, 163], ["gonorrhoeae", "OBSERVATION", 10, 21], ["bacterial membranes", "OBSERVATION", 123, 142], ["surface", "OBSERVATION_MODIFIER", 174, 181], ["loops", "OBSERVATION_MODIFIER", 190, 195]]], ["In spite of the surface diversity afforded by the hyper-variable domains of the loops, the majority of the Opa proteins are capable of targeting CEACAMs (Virji et al., 1996a; Hauck and Meyer, 2003) .", [["surface", "ANATOMY", 16, 23], ["surface", "CELLULAR_COMPONENT", 16, 23], ["Opa", "GENE_OR_GENE_PRODUCT", 107, 110], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 145, 152], ["hyper-variable domains", "PROTEIN", 50, 72], ["Opa proteins", "PROTEIN", 107, 119], ["the surface diversity", "TREATMENT", 12, 33], ["the hyper-variable domains of the loops", "PROBLEM", 46, 85], ["hyper", "OBSERVATION", 50, 55], ["loops", "ANATOMY_MODIFIER", 80, 85]]], ["The P5 proteins of Hi are similar b-barrel forming proteins, also with surface variable loops (Webb and Cripps, 1998; Vandeputte-Rutten et al., 2003) .", [["surface", "ANATOMY", 71, 78], ["P5", "GENE_OR_GENE_PRODUCT", 4, 6], ["Hi", "GENE_OR_GENE_PRODUCT", 19, 21], ["b-barrel forming proteins", "GENE_OR_GENE_PRODUCT", 34, 59], ["P5 proteins", "PROTEIN", 4, 15], ["Hi", "PROTEIN", 19, 21], ["b-barrel forming proteins", "PROTEIN", 34, 59], ["The P5 proteins", "TEST", 0, 15], ["Hi", "PROBLEM", 19, 21], ["similar b-barrel forming proteins", "PROBLEM", 26, 59], ["surface variable loops", "PROBLEM", 71, 93], ["b-barrel forming proteins", "OBSERVATION", 34, 59], ["surface", "OBSERVATION_MODIFIER", 71, 78], ["variable", "OBSERVATION_MODIFIER", 79, 87], ["loops", "OBSERVATION", 88, 93]]], ["The interactions between these bacterial ligands and CEACAMs are complex and the binding domain appears to involve more than one variable loop of the bacterial adhesins (Virji et al., 1999; Bos et al., 2002; de Jonge et al., 2003) .", [["CEACAMs", "GENE_OR_GENE_PRODUCT", 53, 60], ["CEACAMs", "PROTEIN", 53, 60], ["binding domain", "PROTEIN", 81, 95], ["bacterial adhesins", "PROTEIN", 150, 168], ["these bacterial ligands", "PROBLEM", 25, 48], ["the binding domain", "PROBLEM", 77, 95], ["bacterial ligands", "OBSERVATION", 31, 48], ["bacterial", "OBSERVATION_MODIFIER", 150, 159]]], ["Interestingly, antibody inhibition studies have shown that the diverse ligands of neisseria and haemophilus bind to an overlapping site on the N-domain.", [["neisseria", "GENE_OR_GENE_PRODUCT", 82, 91], ["haemophilus", "GENE_OR_GENE_PRODUCT", 96, 107], ["N-domain", "PROTEIN", 143, 151], ["antibody inhibition studies", "TEST", 15, 42], ["neisseria", "PROBLEM", 82, 91], ["haemophilus bind", "PROBLEM", 96, 112], ["an overlapping site", "PROBLEM", 116, 135]]], ["In addition, mutational analysis of the N-domain of CEACAM1 has identified several critical residues particularly Ile-91.", [["Ile-91", "CHEMICAL", 114, 120], ["Ile", "CHEMICAL", 114, 117], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 52, 59], ["Ile-91", "AMINO_ACID", 114, 120], ["N-domain", "PROTEIN", 40, 48], ["CEACAM1", "PROTEIN", 52, 59], ["mutational analysis", "TEST", 13, 32], ["the N-domain of CEACAM1", "TREATMENT", 36, 59], ["several", "OBSERVATION_MODIFIER", 75, 82], ["critical residues", "OBSERVATION", 83, 100]]], ["Alanine substitutions at these sites abrogated binding of most Opa-and P5-expressing bacteria to CEACAM1.", [["Alanine", "CHEMICAL", 0, 7], ["Alanine", "CHEMICAL", 0, 7], ["Alanine", "AMINO_ACID", 0, 7], ["Opa-and P5", "GENE_OR_GENE_PRODUCT", 63, 73], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 97, 104], ["Opa-and P5", "PROTEIN", 63, 73], ["CEACAM1", "PROTEIN", 97, 104], ["Alanine substitutions", "PROBLEM", 0, 21], ["expressing bacteria to CEACAM1", "PROBLEM", 74, 104]]], ["Additional residues such as Tyr-34, Ser-32, Val-39, Gln-44 and Gln-89, most of which located in the vicinity of Ile-91, appear to determine the efficiency of interactions of various Opa and P5 molecules (Virji et al., 1999; .", [["Val-39, Gln-44", "CHEMICAL", 44, 58], ["Gln-89", "CHEMICAL", 63, 69], ["Ile-91", "CHEMICAL", 112, 118], ["Tyr", "CHEMICAL", 28, 31], ["Ser", "CHEMICAL", 36, 39], ["Val", "CHEMICAL", 44, 47], ["Gln", "CHEMICAL", 52, 55], ["Gln", "CHEMICAL", 63, 66], ["Ile-91", "CHEMICAL", 112, 118], ["Tyr-34", "SIMPLE_CHEMICAL", 28, 34], ["Ser-32", "AMINO_ACID", 36, 42], ["Val-39", "SIMPLE_CHEMICAL", 44, 50], ["Gln-44", "SIMPLE_CHEMICAL", 52, 58], ["Gln-89", "AMINO_ACID", 63, 69], ["Opa", "GENE_OR_GENE_PRODUCT", 182, 185], ["Opa", "PROTEIN", 182, 185], ["P5 molecules", "PROTEIN", 190, 202], ["Additional residues", "TEST", 0, 19], ["Tyr", "TEST", 28, 31], ["Ser", "TEST", 36, 39], ["Val", "TEST", 44, 47], ["Gln", "TEST", 52, 55], ["Gln", "TEST", 63, 66]]], ["The bacterial binding surface on the CEACAM1 N-domain is the protein face composed of the beta strands C\u2032\u2032, C\u2032, C, F and G (CFG for brevity).", [["surface", "ANATOMY", 22, 29], ["surface", "CELLULAR_COMPONENT", 22, 29], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 37, 44], ["G", "GENE_OR_GENE_PRODUCT", 121, 122], ["CEACAM1 N-domain", "PROTEIN", 37, 53], ["beta strands", "PROTEIN", 90, 102], ["C\u2032\u2032", "PROTEIN", 103, 106], ["C\u2032", "PROTEIN", 108, 110], ["C", "PROTEIN", 112, 113], ["F", "PROTEIN", 115, 116], ["G", "PROTEIN", 121, 122], ["CFG", "PROTEIN", 124, 127], ["The bacterial binding surface", "PROBLEM", 0, 29], ["the CEACAM1 N", "TEST", 33, 46], ["the protein face", "TEST", 57, 73], ["the beta strands C\u2032\u2032", "TEST", 86, 106], ["C\u2032", "TEST", 108, 110], ["bacterial binding", "OBSERVATION", 4, 21], ["surface", "OBSERVATION_MODIFIER", 22, 29]]], ["Despite the extensive investigations in a number of laboratories particularly on neisserial Opa proteins, it remains unclear as to precisely how CEACAM-binding ligands engage with the receptors.IntroductionA three dimensional structural model of the human CEACAM1 N-domain has been previously generated based on other Ig family molecules (Virji et al., 1999) .", [["Opa", "GENE_OR_GENE_PRODUCT", 92, 95], ["CEACAM", "GENE_OR_GENE_PRODUCT", 145, 151], ["human", "ORGANISM", 250, 255], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 256, 263], ["Ig", "GENE_OR_GENE_PRODUCT", 318, 320], ["neisserial Opa proteins", "PROTEIN", 81, 104], ["CEACAM", "PROTEIN", 145, 151], ["human CEACAM1 N-domain", "PROTEIN", 250, 272], ["Ig family molecules", "PROTEIN", 318, 337], ["human", "SPECIES", 250, 255], ["human", "SPECIES", 250, 255], ["the extensive investigations", "TEST", 8, 36], ["neisserial Opa proteins", "TEST", 81, 104], ["the human CEACAM1 N", "TREATMENT", 246, 265]]], ["In the current investigation, we have refined our previous model based on murine CEACAM1 crystal structure (Tan et al., 2002) .", [["murine", "ORGANISM", 74, 80], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 81, 88], ["CEACAM1", "PROTEIN", 81, 88], ["murine", "SPECIES", 74, 80]]], ["Examination of this model showed a better confluence of the above residues into a continuous binding site and suggested that substitutions at positions 34 and 89 at the core of the binding region may affect bacterial access to the implicated key binding residue Ile-91.", [["Ile-91", "CHEMICAL", 262, 268], ["Ile", "CHEMICAL", 262, 265], ["Ile-91", "AMINO_ACID", 262, 268], ["continuous binding site", "DNA", 82, 105], ["binding region", "PROTEIN", 181, 195], ["Examination of this model", "TEST", 0, 25], ["a continuous binding site", "PROBLEM", 80, 105], ["substitutions at positions", "PROBLEM", 125, 151], ["bacterial access", "TREATMENT", 207, 223]]], ["By introducing conservative and non-conservative substitutions at positions 34, 89 and 91, we have examined the binding of a variety of bacterial strains to the receptor constructs.", [["conservative and non-conservative substitutions at positions", "TREATMENT", 15, 75], ["bacterial strains", "PROBLEM", 136, 153], ["non-conservative substitutions", "OBSERVATION", 32, 62]]], ["The data suggest that single nucleotide polymorphisms (SNPs) in individuals or populations that may introduce substitutions in CEACAM sequence particularly at the bacterial binding site, could not only decrease but also significantly increase the functional affinity of pathogen interactions.", [["CEACAM", "GENE_OR_GENE_PRODUCT", 127, 133], ["CEACAM sequence", "DNA", 127, 142], ["bacterial binding site", "DNA", 163, 185], ["The data", "TEST", 0, 8], ["single nucleotide polymorphisms (SNPs)", "PROBLEM", 22, 60], ["substitutions in CEACAM sequence", "PROBLEM", 110, 142], ["bacterial binding", "OBSERVATION", 163, 180]]], ["Increased binding affinity may result in increased cellular invasion and thus may lead to increased host susceptibility to infection by CEACAM-targeting bacteria.Molecular modelling and mutations of the CEACAM1 N-domainA three-dimensional model of CEACAM1 N-domain was previously produced based on the Ig family molecules REI, CD2 and CD4 (Fig. 1A ) (Virji et al., 1999) .", [["cellular", "ANATOMY", 51, 59], ["infection", "DISEASE", 123, 132], ["cellular", "CELL", 51, 59], ["CEACAM", "GENE_OR_GENE_PRODUCT", 136, 142], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 203, 210], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 248, 255], ["Ig", "GENE_OR_GENE_PRODUCT", 302, 304], ["CD2", "GENE_OR_GENE_PRODUCT", 327, 330], ["CD4", "GENE_OR_GENE_PRODUCT", 335, 338], ["CEACAM", "PROTEIN", 136, 142], ["CEACAM1 N-domainA", "PROTEIN", 203, 220], ["CEACAM1 N-domain", "PROTEIN", 248, 264], ["Ig family molecules", "PROTEIN", 302, 321], ["REI", "PROTEIN", 322, 325], ["CD2", "PROTEIN", 327, 330], ["CD4", "PROTEIN", 335, 338], ["Fig. 1A", "PROTEIN", 340, 347], ["Increased binding affinity", "PROBLEM", 0, 26], ["increased cellular invasion", "PROBLEM", 41, 68], ["increased host susceptibility to infection", "PROBLEM", 90, 132], ["CEACAM", "TEST", 136, 142], ["targeting bacteria", "PROBLEM", 143, 161], ["CEACAM1 N", "TREATMENT", 248, 257], ["binding affinity", "OBSERVATION", 10, 26], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["cellular invasion", "OBSERVATION", 51, 68], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["host susceptibility", "OBSERVATION_MODIFIER", 100, 119], ["infection", "OBSERVATION", 123, 132], ["bacteria", "OBSERVATION_MODIFIER", 153, 161]]], ["In this model, whilst most mutations affecting binding of Nm and Hi were located centrally on the CFG face of the protein, Val-39 involved in Opa binding, was located at a distance towards the bottom of the CFG face (Fig. 1A) .", [["Val-39", "CHEMICAL", 123, 129], ["Val", "CHEMICAL", 123, 126], ["Nm", "GENE_OR_GENE_PRODUCT", 58, 60], ["Hi", "GENE_OR_GENE_PRODUCT", 65, 67], ["Val-39", "GENE_OR_GENE_PRODUCT", 123, 129], ["Opa", "GENE_OR_GENE_PRODUCT", 142, 145], ["Nm", "PROTEIN", 58, 60], ["Hi", "DNA", 65, 67], ["Val-39", "PROTEIN", 123, 129], ["Opa", "PROTEIN", 142, 145], ["bottom", "ANATOMY_MODIFIER", 193, 199]]], ["Subsequently, a crystal structure of murine soluble CEACAM1a domains 1 and 4 was reported (Tan et al., 2002) .", [["murine", "ORGANISM", 37, 43], ["CEACAM1a domains 1", "GENE_OR_GENE_PRODUCT", 52, 70], ["murine soluble CEACAM1a domains 1 and 4", "PROTEIN", 37, 76], ["murine", "SPECIES", 37, 43], ["a crystal structure of murine soluble CEACAM1a domains", "TREATMENT", 14, 68]]], ["Based on this, we have remodelled the human CEACAM1 Ndomain.", [["human", "ORGANISM", 38, 43], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 44, 51], ["human CEACAM1 Ndomain", "PROTEIN", 38, 59], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["the human CEACAM1 Ndomain", "TREATMENT", 34, 59], ["CEACAM1", "OBSERVATION", 44, 51]]], ["The CC\u2032 loop that contains Val-39 folds back against the CFG face of this model such that it lies in close proximity to the other critical residues involved in bacterial adhesion (Fig. 1B) .", [["CC", "CHEMICAL", 4, 6], ["Val-39", "CHEMICAL", 27, 33], ["Val-39", "CHEMICAL", 27, 33], ["The CC\u2032 loop", "TREATMENT", 0, 12], ["Val", "TEST", 27, 30], ["bacterial adhesion", "PROBLEM", 160, 178], ["loop", "OBSERVATION_MODIFIER", 8, 12], ["bacterial adhesion", "OBSERVATION", 160, 178]]], ["Further examination of this model suggested that the bacterial binding pocket forms a rather flat surface in the centre of the CFG face.", [["surface", "ANATOMY", 98, 105], ["bacterial binding pocket", "PROTEIN", 53, 77], ["Further examination", "TEST", 0, 19], ["the bacterial binding pocket", "PROBLEM", 49, 77], ["bacterial", "OBSERVATION", 53, 62], ["binding pocket", "OBSERVATION", 63, 77], ["flat", "OBSERVATION_MODIFIER", 93, 97], ["surface", "OBSERVATION_MODIFIER", 98, 105], ["centre", "ANATOMY_MODIFIER", 113, 119], ["CFG face", "ANATOMY", 127, 135]]], ["It also appears that substituting neighbouring residues Tyr-34 and Gln-89 by Phe and Asn, respectively, could result in a further flattening of the bacterial binding surface (Fig. 1C-E) , providing increased access to the key Ile-91.", [["Gln-89", "CHEMICAL", 67, 73], ["Phe", "CHEMICAL", 77, 80], ["Asn", "CHEMICAL", 85, 88], ["Ile-91", "CHEMICAL", 226, 232], ["Tyr", "CHEMICAL", 56, 59], ["Gln", "CHEMICAL", 67, 70], ["Phe", "CHEMICAL", 77, 80], ["Asn", "CHEMICAL", 85, 88], ["Ile-91", "CHEMICAL", 226, 232], ["Tyr-34", "AMINO_ACID", 56, 62], ["Gln-89", "AMINO_ACID", 67, 73], ["Phe", "AMINO_ACID", 77, 80], ["Asn", "AMINO_ACID", 85, 88], ["surface", "CELLULAR_COMPONENT", 166, 173], ["Ile-91", "PROTEIN", 226, 232], ["neighbouring residues Tyr", "TEST", 34, 59], ["Gln", "TEST", 67, 70], ["Phe and Asn", "TEST", 77, 88], ["a further flattening of the bacterial binding surface", "PROBLEM", 120, 173], ["flattening", "OBSERVATION_MODIFIER", 130, 140], ["bacterial binding", "OBSERVATION", 148, 165]]], ["These residue changes also increase the size of the hydrophobic patch centred on I91 (Fig. 1C-E) .", [["I91", "PROTEIN", 81, 84], ["These residue changes", "PROBLEM", 0, 21], ["the hydrophobic patch", "TREATMENT", 48, 69], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["size", "OBSERVATION_MODIFIER", 40, 44], ["hydrophobic patch", "OBSERVATION", 52, 69]]], ["Both of these effects might facilitate binding of some bacterial ligands to the target receptor.Molecular modelling and mutations of the CEACAM1 N-domainIn order to assess the importance of these residues in interactions with mucosal pathogens, substitutions were introduced by site-directed mutagenesis at three sites (91, 34 and 89) on the N-domain.", [["mucosal", "ANATOMY", 226, 233], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 137, 144], ["target receptor", "PROTEIN", 80, 95], ["CEACAM1 N", "PROTEIN", 137, 146], ["N-domain", "PROTEIN", 342, 350], ["some bacterial ligands", "PROBLEM", 50, 72], ["these residues", "PROBLEM", 190, 204], ["mucosal pathogens", "PROBLEM", 226, 243], ["substitutions", "TREATMENT", 245, 258], ["bacterial ligands", "OBSERVATION", 55, 72]]], ["The substitutions introduced in CEACAM1 [NA1B]-Fc are shown in Fig. 2 .", [["CEACAM1", "GENE_OR_GENE_PRODUCT", 32, 39], ["NA1B]-Fc", "GENE_OR_GENE_PRODUCT", 41, 49], ["CEACAM1", "PROTEIN", 32, 39], ["NA1B", "PROTEIN", 41, 45], ["Fc", "PROTEIN", 47, 49], ["The substitutions", "TREATMENT", 0, 17], ["CEACAM1 [NA1B]-Fc", "TREATMENT", 32, 49]]], ["Chimeric receptors proteins with the native sequence or with sub- (Virji et al., 1999) .", [["Chimeric receptors proteins", "PROTEIN", 0, 27]]], ["(B) New model based on the murine CEACAM1a N-domain crystal structure (Tan et al., 2002) .", [["murine", "ORGANISM", 27, 33], ["murine CEACAM1a N", "PROTEIN", 27, 44], ["murine", "SPECIES", 27, 33]]], ["In the latter case V39 locates more centrally with the other critical residues for bacterial binding.", [["V39", "DNA", 19, 22], ["bacterial binding", "PROBLEM", 83, 100], ["bacterial binding", "OBSERVATION", 83, 100]]], ["(C-E, left) Stereo pairs presented are ribbon diagrams for CEACAM1 N-domain in the native form (C), with Y34F (D) or Q89N (E) substitutions show a flattening of the bacterial binding region on CEACAM1 and improving accessibility of the primary binding residue I91.", [["CEACAM1", "GENE_OR_GENE_PRODUCT", 59, 66], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 193, 200], ["CEACAM1 N-domain", "PROTEIN", 59, 75], ["C", "PROTEIN", 96, 97], ["bacterial binding region", "PROTEIN", 165, 189], ["CEACAM1", "PROTEIN", 193, 200], ["primary binding residue I91", "PROTEIN", 236, 263], ["CEACAM1 N", "TREATMENT", 59, 68], ["substitutions", "PROBLEM", 126, 139], ["a flattening of the bacterial binding region", "PROBLEM", 145, 189], ["CEACAM1", "TREATMENT", 193, 200], ["the primary binding residue", "PROBLEM", 232, 259], ["left", "ANATOMY_MODIFIER", 6, 10], ["flattening", "OBSERVATION_MODIFIER", 147, 157], ["bacterial binding", "OBSERVATION", 165, 182]]], ["The side-chain atom colouring (C-green, O-red, N-blue) show the increased hydrophobic nature of the binding site around I91 in the mutant structures.", [["C-green", "CHEMICAL", 31, 38], ["N-blue", "CHEMICAL", 47, 53], ["C-green", "CHEMICAL", 31, 38], ["O-red", "CHEMICAL", 40, 45], ["N-blue", "CHEMICAL", 47, 53], ["C-green", "SIMPLE_CHEMICAL", 31, 38], ["O-red", "SIMPLE_CHEMICAL", 40, 45], ["I91", "GENE_OR_GENE_PRODUCT", 120, 123], ["I91", "PROTEIN", 120, 123], ["The side-chain atom colouring", "TEST", 0, 29], ["the increased hydrophobic nature of the binding site", "PROBLEM", 60, 112], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["hydrophobic nature", "OBSERVATION", 74, 92], ["binding site", "OBSERVATION", 100, 112]]], ["(C-E, right) Surface presentations of the binding site (views corresponding to a 90\u00b0rotation of the stereo images in the horizontal axis) coloured according to hydrophobicity. stitutions were produced by transient transfection of COS cells for functional studies described below.Binding of anti-CEACAM antibodies to receptor constructsThe N-domain specific monoclonal antibody (mAb) YTH71.3 has been shown to require Gln-89 and Ile-91 for receptor recognition and substitution of these amino acids had no effect on the binding of the polyclonal anti-CEACAM antibody A0115 (Virji et al., 1999) .", [["COS cells", "ANATOMY", 230, 239], ["YTH71.3", "CHEMICAL", 383, 390], ["Gln-89", "CHEMICAL", 417, 423], ["Ile-91", "CHEMICAL", 428, 434], ["amino acids", "CHEMICAL", 486, 497], ["Gln", "CHEMICAL", 417, 420], ["Ile", "CHEMICAL", 428, 431], ["amino acids", "CHEMICAL", 486, 497], ["COS cells", "CELL", 230, 239], ["anti-CEACAM antibodies", "GENE_OR_GENE_PRODUCT", 290, 312], ["Gln-89", "SIMPLE_CHEMICAL", 417, 423], ["Ile-91", "AMINO_ACID", 428, 434], ["amino acids", "AMINO_ACID", 486, 497], ["binding site", "DNA", 42, 54], ["COS cells", "CELL_LINE", 230, 239], ["anti-CEACAM antibodies", "PROTEIN", 290, 312], ["receptor constructs", "DNA", 316, 335], ["N-domain specific monoclonal antibody (mAb) YTH71.3", "PROTEIN", 339, 390], ["polyclonal anti-CEACAM antibody A0115", "PROTEIN", 534, 571], ["the stereo images", "TEST", 96, 113], ["transient transfection of COS cells", "PROBLEM", 204, 239], ["functional studies", "TEST", 244, 262], ["anti-CEACAM antibodies", "TREATMENT", 290, 312], ["receptor constructs", "TREATMENT", 316, 335], ["The N-domain specific monoclonal antibody (mAb)", "TEST", 335, 382], ["Gln", "TEST", 417, 420], ["Ile", "TEST", 428, 431], ["receptor recognition", "TEST", 439, 459], ["these amino acids", "TEST", 480, 497], ["the polyclonal anti-CEACAM antibody", "TEST", 530, 565], ["right", "ANATOMY_MODIFIER", 6, 11]]], ["The novel receptor constructs produced in the current studies were first examined for their ability to bind to YTH71.3, A0115 as well as Kat4c.", [["YTH71.3", "GENE_OR_GENE_PRODUCT", 111, 118], ["A0115", "GENE_OR_GENE_PRODUCT", 120, 125], ["Kat4c", "GENE_OR_GENE_PRODUCT", 137, 142], ["novel receptor constructs", "DNA", 4, 29], ["YTH71.3", "DNA", 111, 118], ["Kat4c", "PROTEIN", 137, 142], ["the current studies", "TEST", 42, 61]]], ["The latter mAb recognizes the A and B domains of the receptor (Jones et al., 1995) .", [["mAb", "GENE_OR_GENE_PRODUCT", 11, 14], ["mAb", "PROTEIN", 11, 14], ["A and B domains", "PROTEIN", 30, 45], ["mAb", "OBSERVATION", 11, 14]]], ["AO115 and Kat4c bound to various receptor constructs and to the native NA1B-Fc molecule with equal efficiency.", [["AO115", "CHEMICAL", 0, 5], ["Kat4c", "CHEMICAL", 10, 15], ["AO115", "GENE_OR_GENE_PRODUCT", 0, 5], ["Kat4c", "GENE_OR_GENE_PRODUCT", 10, 15], ["NA1B", "GENE_OR_GENE_PRODUCT", 71, 75], ["AO115", "PROTEIN", 0, 5], ["Kat4c", "PROTEIN", 10, 15], ["NA1B", "PROTEIN", 71, 75], ["Fc molecule", "PROTEIN", 76, 87], ["Kat4c bound to various receptor constructs", "PROBLEM", 10, 52], ["equal efficiency", "OBSERVATION", 93, 109]]], ["For YTH71.3, Leu but not Thr at position 91 supported binding to the same extent as Ile of the native molecule.", [["Leu", "CHEMICAL", 13, 16], ["Thr", "CHEMICAL", 25, 28], ["YTH71.3", "CHEMICAL", 4, 11], ["Leu", "CHEMICAL", 13, 16], ["Thr", "CHEMICAL", 25, 28], ["Ile", "CHEMICAL", 84, 87], ["Leu", "AMINO_ACID", 13, 16], ["Thr at position 91", "AMINO_ACID", 25, 43], ["native molecule", "PROTEIN", 95, 110], ["Leu", "TEST", 13, 16], ["not", "UNCERTAINTY", 21, 24], ["Thr", "OBSERVATION", 25, 28], ["native molecule", "OBSERVATION", 95, 110]]], ["Similarly at position 34, only Phe could be effectively substituted for Tyr.", [["Phe", "CHEMICAL", 31, 34], ["Phe", "CHEMICAL", 31, 34], ["Phe", "AMINO_ACID", 31, 34]]], ["Finally Q89A and Q89N completely abrogated the antibody binding.Neisseria meningitidis binding to CEACAM1 constructsOpa-expressing phenotypes of two Nm strains (C751 and MC58) were used to investigate their binding to the modified NA1B-Fc receptors.", [["Neisseria meningitidis", "ORGANISM", 64, 86], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 98, 105], ["NA1B-Fc receptors", "GENE_OR_GENE_PRODUCT", 231, 248], ["CEACAM1 constructs", "DNA", 98, 116], ["NA1B", "PROTEIN", 231, 235], ["Fc receptors", "PROTEIN", 236, 248], ["Neisseria meningitidis", "SPECIES", 64, 86], ["Neisseria meningitidis", "SPECIES", 64, 86], ["the antibody binding", "PROBLEM", 43, 63], ["Neisseria meningitidis binding", "PROBLEM", 64, 94], ["CEACAM1 constructs", "TREATMENT", 98, 116], ["two Nm strains", "PROBLEM", 145, 159], ["meningitidis", "OBSERVATION", 74, 86], ["CEACAM1 constructs", "OBSERVATION", 98, 116], ["two Nm", "OBSERVATION_MODIFIER", 145, 151]]], ["Three C751 derivatives express-ing distinct Opa proteins (OpaA, OpaB and OpaD) and the MC58 derivative expressing an Opa protein designated OpaX (Virji et al., 1999) were assessed by receptor overlay experiments (Fig. 3) .Neisseria meningitidis binding to CEACAM1 constructsAll the Nm isolates showed reduced binding to the soluble receptor with Y34A and I91A substitutions whilst Q89A affected OpaD binding most significantly confirming previous studies (Virji et al., 1999) .", [["Opa", "GENE_OR_GENE_PRODUCT", 44, 47], ["OpaA", "GENE_OR_GENE_PRODUCT", 58, 62], ["OpaB", "GENE_OR_GENE_PRODUCT", 64, 68], ["OpaD", "GENE_OR_GENE_PRODUCT", 73, 77], ["Opa", "GENE_OR_GENE_PRODUCT", 117, 120], ["Neisseria meningitidis", "ORGANISM", 222, 244], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 256, 263], ["Y34A", "GENE_OR_GENE_PRODUCT", 346, 350], ["OpaD", "GENE_OR_GENE_PRODUCT", 395, 399], ["Opa proteins", "PROTEIN", 44, 56], ["OpaA", "PROTEIN", 58, 62], ["OpaB", "PROTEIN", 64, 68], ["OpaD", "PROTEIN", 73, 77], ["MC58 derivative", "PROTEIN", 87, 102], ["Opa protein", "PROTEIN", 117, 128], ["OpaX", "PROTEIN", 140, 144], ["CEACAM1 constructs", "DNA", 256, 274], ["soluble receptor", "PROTEIN", 324, 340], ["OpaD", "PROTEIN", 395, 399], ["Neisseria meningitidis", "SPECIES", 222, 244], ["Neisseria meningitidis", "SPECIES", 222, 244], ["Three C751 derivatives", "TREATMENT", 0, 22], ["OpaA", "TEST", 58, 62], ["the MC58 derivative", "TREATMENT", 83, 102], ["Neisseria meningitidis binding", "PROBLEM", 222, 252], ["CEACAM1 constructs", "TREATMENT", 256, 274], ["the Nm isolates", "TEST", 278, 293], ["reduced binding", "PROBLEM", 301, 316], ["the soluble receptor", "TREATMENT", 320, 340], ["I91A substitutions", "TREATMENT", 355, 373], ["previous studies", "TEST", 438, 454], ["meningitidis", "OBSERVATION", 232, 244], ["CEACAM1 constructs", "OBSERVATION", 256, 274]]], ["Introduction of a Leu or Thr residue at position 91 was generally less disruptive to Opa interactions.", [["Leu", "CHEMICAL", 18, 21], ["Thr", "CHEMICAL", 25, 28], ["Leu", "CHEMICAL", 18, 21], ["Thr", "CHEMICAL", 25, 28], ["Leu", "AMINO_ACID", 18, 21], ["Thr residue", "AMINO_ACID", 25, 36], ["position 91", "AMINO_ACID", 40, 51], ["Opa", "GENE_OR_GENE_PRODUCT", 85, 88], ["Opa", "PROTEIN", 85, 88], ["a Leu or Thr residue", "TREATMENT", 16, 36]]], ["I91T substitution either did not affect binding (OpaB and OpaX) or reduced binding by 50-60% (OpaD and OpaA).", [["OpaB", "GENE_OR_GENE_PRODUCT", 49, 53], ["OpaX", "GENE_OR_GENE_PRODUCT", 58, 62], ["OpaD", "GENE_OR_GENE_PRODUCT", 94, 98], ["OpaB", "PROTEIN", 49, 53], ["OpaX", "PROTEIN", 58, 62], ["OpaD", "PROTEIN", 94, 98], ["OpaA", "PROTEIN", 103, 107], ["reduced binding", "PROBLEM", 67, 82]]], ["I91L substitution had no effect on OpaD or OpaB whilst having opposite effects on OpaA (~50% reduction) and OpaX (twofold increase) binding.Neisseria meningitidis binding to CEACAM1 constructsSubstitutions at position 34 other than Ala also supported binding of some but not all Opa proteins.", [["I91L", "CHEMICAL", 0, 4], ["OpaB", "CHEMICAL", 43, 47], ["OpaA", "CHEMICAL", 82, 86], ["OpaX", "CHEMICAL", 108, 112], ["Ala", "CHEMICAL", 232, 235], ["I91L", "SIMPLE_CHEMICAL", 0, 4], ["OpaD", "SIMPLE_CHEMICAL", 35, 39], ["OpaB", "SIMPLE_CHEMICAL", 43, 47], ["OpaA", "SIMPLE_CHEMICAL", 82, 86], ["OpaX", "SIMPLE_CHEMICAL", 108, 112], ["Neisseria meningitidis", "ORGANISM", 140, 162], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 174, 181], ["Ala", "AMINO_ACID", 232, 235], ["Opa", "GENE_OR_GENE_PRODUCT", 279, 282], ["OpaD", "PROTEIN", 35, 39], ["OpaB", "PROTEIN", 43, 47], ["OpaX", "PROTEIN", 108, 112], ["CEACAM1 constructs", "DNA", 174, 192], ["Opa proteins", "PROTEIN", 279, 291], ["Neisseria meningitidis", "SPECIES", 140, 162], ["Neisseria meningitidis", "SPECIES", 140, 162], ["OpaD", "TREATMENT", 35, 39], ["OpaB", "TREATMENT", 43, 47], ["OpaA", "TREATMENT", 82, 86], ["OpaX (twofold increase) binding", "PROBLEM", 108, 139], ["Neisseria meningitidis binding", "PROBLEM", 140, 170], ["CEACAM1 constructs", "TREATMENT", 174, 192], ["Substitutions at position", "TREATMENT", 192, 217], ["increase", "OBSERVATION_MODIFIER", 122, 130], ["meningitidis", "OBSERVATION", 150, 162], ["CEACAM1 constructs", "OBSERVATION", 174, 192]]], ["Y34S substitution was unsuitable for the three Opa proteins of strain C751 but was tolerated by OpaX of MC58.", [["Y34S", "SIMPLE_CHEMICAL", 0, 4], ["Opa", "GENE_OR_GENE_PRODUCT", 47, 50], ["Opa proteins", "PROTEIN", 47, 59], ["OpaX", "PROTEIN", 96, 100], ["MC58", "PROTEIN", 104, 108], ["Y34S substitution", "TREATMENT", 0, 17]]], ["Interestingly, Phe proved to be a more favoured residue in at least two cases with OpaX as well as OpaB binding to Y34F construct at threefold higher levels than the native receptor.", [["Phe", "CHEMICAL", 15, 18], ["Phe", "CHEMICAL", 15, 18], ["OpaX", "CHEMICAL", 83, 87], ["Phe", "AMINO_ACID", 15, 18], ["OpaX", "SIMPLE_CHEMICAL", 83, 87], ["OpaB", "GENE_OR_GENE_PRODUCT", 99, 103], ["Y34F", "GENE_OR_GENE_PRODUCT", 115, 119], ["OpaX", "PROTEIN", 83, 87], ["OpaB", "PROTEIN", 99, 103], ["Y34F construct", "DNA", 115, 129], ["native receptor", "PROTEIN", 166, 181], ["a more favoured residue", "PROBLEM", 32, 55], ["OpaX", "TREATMENT", 83, 87]]], ["Substitutions of Asn at Gln-89 revealed distinct patterns of interactions and binding reduced in the order OpaA > OpaX > OpaB/D (Fig. 3) .Neisseria meningitidis binding to CEACAM1 constructsOverall, the data suggest that Opa binding to the receptor requires an extended aliphatic chain at position 91 and certain arrangements of the chain may facilitate binding of most Opa proteins (Ile = leu > Thr).", [["Asn", "CHEMICAL", 17, 20], ["Gln-89", "CHEMICAL", 24, 30], ["Asn", "CHEMICAL", 17, 20], ["Gln", "CHEMICAL", 24, 27], ["Ile", "CHEMICAL", 384, 387], ["Thr", "CHEMICAL", 396, 399], ["Asn", "AMINO_ACID", 17, 20], ["Gln-89", "AMINO_ACID", 24, 30], ["OpaA", "SIMPLE_CHEMICAL", 107, 111], ["OpaX", "SIMPLE_CHEMICAL", 114, 118], ["Neisseria meningitidis", "ORGANISM", 138, 160], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 172, 179], ["Opa", "GENE_OR_GENE_PRODUCT", 221, 224], ["Opa", "GENE_OR_GENE_PRODUCT", 370, 373], ["Thr", "AMINO_ACID", 396, 399], ["OpaX", "PROTEIN", 114, 118], ["OpaB", "PROTEIN", 121, 125], ["CEACAM1 constructs", "DNA", 172, 190], ["Opa", "PROTEIN", 221, 224], ["Opa proteins", "PROTEIN", 370, 382], ["leu", "PROTEIN", 390, 393], ["Thr", "PROTEIN", 396, 399], ["Neisseria meningitidis", "SPECIES", 138, 160], ["Neisseria meningitidis", "SPECIES", 138, 160], ["Asn at Gln", "TEST", 17, 27], ["binding reduced", "PROBLEM", 78, 93], ["OpaA", "TEST", 107, 111], ["Neisseria meningitidis binding", "PROBLEM", 138, 168], ["CEACAM1 constructs", "TREATMENT", 172, 190], ["Opa binding", "PROBLEM", 221, 232], ["an extended aliphatic chain", "TREATMENT", 258, 285], ["distinct", "OBSERVATION_MODIFIER", 40, 48], ["meningitidis", "OBSERVATION", 148, 160], ["CEACAM1 constructs", "OBSERVATION", 172, 190]]], ["At position \u0391,\u0392 D, E \u03b2\u2212strand: (Virji et al., 1999) .", [["\u0392 D", "SIMPLE_CHEMICAL", 14, 17]]], ["Side chains of the residues introduced at positions 34, 89 and 91 in this study are shown in B for comparison 34, the removal of the hydroxyl residue (Y43F) is tolerated or preferred whereas the absence of aromatic ring (Y34S) has an overall deleterious effect on Opa binding.", [["hydroxyl", "CHEMICAL", 133, 141], ["Y43F", "CHEMICAL", 151, 155], ["Y34S", "CHEMICAL", 221, 225], ["hydroxyl", "CHEMICAL", 133, 141], ["Y34S", "SIMPLE_CHEMICAL", 221, 225], ["Opa", "GENE_OR_GENE_PRODUCT", 264, 267], ["Opa", "PROTEIN", 264, 267], ["this study", "TEST", 69, 79], ["the removal", "TREATMENT", 114, 125], ["the hydroxyl residue (Y43F)", "TREATMENT", 129, 156], ["an overall deleterious effect on Opa binding", "PROBLEM", 231, 275], ["hydroxyl residue", "OBSERVATION", 133, 149], ["aromatic ring", "OBSERVATION", 206, 219], ["deleterious effect", "OBSERVATION", 242, 260]]], ["Finally, reduction of the side chain extension (Q89N) reduces binding of three of the four Opa proteins.Neisseria meningitidis binding to CEACAM1 constructsComparison of C751 Opa-A, -B and -D in which the differences exist only between their surface exposed loop structures (HV1 and HV2, shown in Fig. 9 ), suggests further that a combination of the two loop structures must be involved in presenting the appropriate binding partners for the distinct residues of the receptor.Haemophilus influenzae binding to CEACAM1 constructsOne non-typable (A950002) and two THi strains (Rd and Eagan) were used in receptor overlay experiments as above (Fig. 4) .", [["surface", "ANATOMY", 242, 249], ["Opa", "GENE_OR_GENE_PRODUCT", 91, 94], ["Neisseria meningitidis", "ORGANISM", 104, 126], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 138, 145], ["Opa-A", "GENE_OR_GENE_PRODUCT", 175, 180], ["-B", "GENE_OR_GENE_PRODUCT", 182, 184], ["-D", "GENE_OR_GENE_PRODUCT", 189, 191], ["Haemophilus influenzae", "ORGANISM", 476, 498], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 510, 517], ["Opa proteins", "PROTEIN", 91, 103], ["CEACAM1 constructs", "DNA", 138, 156], ["C751 Opa", "PROTEIN", 170, 178], ["A", "PROTEIN", 179, 180], ["B", "PROTEIN", 183, 184], ["HV1", "PROTEIN", 275, 278], ["HV2", "PROTEIN", 283, 286], ["CEACAM1 constructs", "DNA", 510, 528], ["Neisseria meningitidis", "SPECIES", 104, 126], ["Haemophilus influenzae", "SPECIES", 476, 498], ["Neisseria meningitidis", "SPECIES", 104, 126], ["Haemophilus influenzae", "SPECIES", 476, 498], ["the side chain extension", "PROBLEM", 22, 46], ["Neisseria meningitidis binding", "PROBLEM", 104, 134], ["CEACAM1 constructs", "TREATMENT", 138, 156], ["Opa", "TEST", 175, 178], ["the two loop structures", "PROBLEM", 346, 369], ["Haemophilus influenzae binding", "PROBLEM", 476, 506], ["CEACAM1 constructs", "TREATMENT", 510, 528], ["two THi strains (Rd and Eagan)", "TREATMENT", 558, 588], ["reduction", "OBSERVATION_MODIFIER", 9, 18], ["side chain", "OBSERVATION_MODIFIER", 26, 36], ["meningitidis", "OBSERVATION", 114, 126], ["CEACAM1 constructs", "OBSERVATION", 138, 156], ["loop", "OBSERVATION", 258, 262], ["loop", "OBSERVATION", 354, 358], ["influenzae", "OBSERVATION", 488, 498], ["CEACAM1 constructs", "OBSERVATION", 510, 528]]], ["Alanine substitutions at Ile-91 confirmed previous results (Virji et al., 2000) .", [["Alanine", "CHEMICAL", 0, 7], ["Ile-91", "CHEMICAL", 25, 31], ["Alanine", "CHEMICAL", 0, 7], ["Ile", "CHEMICAL", 25, 28], ["Alanine", "AMINO_ACID", 0, 7], ["Ile-91", "AMINO_ACID", 25, 31], ["Alanine substitutions", "TEST", 0, 21]]], ["Taken individually, substitutions of Ile-91 for Ala or Thr abrogated binding of Fig. 3 .", [["Ile-91", "CHEMICAL", 37, 43], ["Ala", "CHEMICAL", 48, 51], ["Thr", "CHEMICAL", 55, 58], ["Ile", "CHEMICAL", 37, 40], ["Ala", "CHEMICAL", 48, 51], ["Thr", "CHEMICAL", 55, 58], ["Ile-91", "AMINO_ACID", 37, 43], ["Ala", "AMINO_ACID", 48, 51], ["Thr", "AMINO_ACID", 55, 58], ["substitutions of Ile", "TREATMENT", 20, 40], ["Ala or Thr abrogated binding of Fig", "TREATMENT", 48, 83]]], ["Relative binding of CEACAM1-Fc constructs to N. meningitidis isolates expressing distinct Opa proteins.", [["CEACAM1", "GENE_OR_GENE_PRODUCT", 20, 27], ["Fc", "GENE_OR_GENE_PRODUCT", 28, 30], ["N. meningitidis", "ORGANISM", 45, 60], ["Opa", "GENE_OR_GENE_PRODUCT", 90, 93], ["CEACAM1", "PROTEIN", 20, 27], ["Fc constructs", "DNA", 28, 41], ["Opa proteins", "PROTEIN", 90, 102], ["N. meningitidis", "SPECIES", 45, 60], ["N. meningitidis", "SPECIES", 45, 60], ["CEACAM1-Fc constructs", "TREATMENT", 20, 41], ["meningitidis isolates", "PROBLEM", 48, 69]]], ["Bacterial lysates were dotted on to nitrocellulose and overlaid with NA1B-Fc constructs as indicated.", [["lysates", "ANATOMY", 10, 17], ["nitrocellulose", "CHEMICAL", 36, 50], ["lysates", "ORGANISM_SUBSTANCE", 10, 17], ["NA1B-Fc", "GENE_OR_GENE_PRODUCT", 69, 76], ["NA1B", "PROTEIN", 69, 73], ["Fc constructs", "DNA", 74, 87], ["Bacterial lysates", "PROBLEM", 0, 17], ["nitrocellulose", "TREATMENT", 36, 50], ["NA1B-Fc constructs", "TREATMENT", 69, 87], ["lysates", "OBSERVATION", 10, 17]]], ["Binding relative to the native receptor was determined by densitometric analysis of immno-blots using NIH Scion Image programme.", [["densitometric analysis", "TEST", 58, 80]]], ["One hundred per cent binding level is indicated by the horizontal line allowing comparison to native receptor binding.", [["horizontal line", "OBSERVATION", 55, 70]]], ["Mean values and SE of > 3 replicates are shown in each case, except Q89A (n = 1) for OpaA, B and X. However, alanine substitution at all three positions confirm previous observations (Virji et al., 1999) .", [["alanine", "CHEMICAL", 109, 116], ["alanine", "CHEMICAL", 109, 116], ["alanine", "AMINO_ACID", 109, 116], ["OpaA", "PROTEIN", 85, 89], ["B", "PROTEIN", 91, 92], ["Mean values", "TEST", 0, 11], ["OpaA", "PROBLEM", 85, 89], ["alanine substitution", "TREATMENT", 109, 129]]], ["Black inserts in C show the levels of binding of the various receptor constructs to Opaisolate of strain C751; experiments were conducted simultaneously with C751OpaD in the presence of the receptors shown. all three strains.", [["C751OpaD", "CHEMICAL", 158, 166], ["C751OpaD", "PROTEIN", 158, 166], ["Black inserts in C", "PROBLEM", 0, 18], ["C751OpaD", "TREATMENT", 158, 166], ["inserts", "OBSERVATION_MODIFIER", 6, 13]]], ["However, substitution I91L reduced binding only of the THi strain Eagan, suggesting a requirement for the extended hydrophobic arm of Ile in Eagan binding.", [["I91L", "CHEMICAL", 22, 26], ["Eagan", "CHEMICAL", 66, 71], ["Ile", "CHEMICAL", 134, 137], ["Eagan", "CHEMICAL", 141, 146], ["Ile", "CHEMICAL", 134, 137], ["I91L", "AMINO_ACID", 22, 26], ["Ile", "AMINO_ACID", 134, 137], ["Eagan", "SIMPLE_CHEMICAL", 141, 146], ["Eagan", "PROTEIN", 141, 146], ["the THi strain Eagan", "PROBLEM", 51, 71], ["the extended hydrophobic arm of Ile in Eagan binding", "TREATMENT", 102, 154]]], ["Alanine substitution of Tyr-34 abrogated the binding of Rd and Eagan, whereas no effect on NTHi A950002 was observed.", [["Alanine", "CHEMICAL", 0, 7], ["Tyr-34", "CHEMICAL", 24, 30], ["Alanine", "CHEMICAL", 0, 7], ["Tyr", "CHEMICAL", 24, 27], ["Alanine", "AMINO_ACID", 0, 7], ["Tyr-34", "AMINO_ACID", 24, 30], ["Rd", "GENE_OR_GENE_PRODUCT", 56, 58], ["Eagan", "GENE_OR_GENE_PRODUCT", 63, 68], ["Alanine substitution", "TREATMENT", 0, 20], ["Tyr", "TEST", 24, 27], ["Eagan", "TREATMENT", 63, 68], ["NTHi", "PROBLEM", 91, 95]]], ["In contrast, Y34F substitution led to an increased binding of all three strains varying from 45 to 80% above native receptor binding levels, whereas Y34S had a differential effect on the three strains tested, ranging from no binding of Rd to a slight increase in the binding of A950002.", [["Y34F", "CHEMICAL", 13, 17], ["A950002", "CHEMICAL", 278, 285], ["Y34F", "CHEMICAL", 13, 17], ["A950002", "CHEMICAL", 278, 285], ["A950002", "SIMPLE_CHEMICAL", 278, 285], ["an increased binding", "PROBLEM", 38, 58], ["all three strains", "PROBLEM", 62, 79], ["a differential effect", "PROBLEM", 158, 179], ["the three strains", "PROBLEM", 183, 200], ["a slight increase", "PROBLEM", 242, 259], ["increased", "OBSERVATION_MODIFIER", 41, 50], ["varying", "OBSERVATION_MODIFIER", 80, 87], ["differential", "OBSERVATION_MODIFIER", 160, 172], ["effect", "OBSERVATION_MODIFIER", 173, 179], ["slight", "OBSERVATION_MODIFIER", 244, 250], ["increase", "OBSERVATION_MODIFIER", 251, 259]]], ["These data broadly reflect results with neisserial Opa binding.", [["Opa", "GENE_OR_GENE_PRODUCT", 51, 54], ["Opa", "PROTEIN", 51, 54], ["neisserial Opa binding", "PROBLEM", 40, 62]]], ["Finally substitutions at Gln-89 show that reduction or abrogation of the side chain (Q89N and Q89A) has no deleterious effect, rather its effect is often that of enhanced binding (Fig. 4) .OpaAIn summary, Hi strains primarily require Ile-91 to enable receptor targeting.", [["Gln-89", "CHEMICAL", 25, 31], ["Ile-91", "CHEMICAL", 234, 240], ["Gln-89", "CHEMICAL", 25, 31], ["Ile", "CHEMICAL", 234, 237], ["Gln-89", "SIMPLE_CHEMICAL", 25, 31], ["Ile-91", "GENE_OR_GENE_PRODUCT", 234, 240], ["side chain", "PROTEIN", 73, 83], ["Q89A", "PROTEIN", 94, 98], ["substitutions at Gln", "TREATMENT", 8, 28], ["abrogation of the side chain", "TREATMENT", 55, 83], ["deleterious effect", "PROBLEM", 107, 125], ["enhanced binding (Fig", "PROBLEM", 162, 183], ["reduction", "OBSERVATION_MODIFIER", 42, 51], ["no", "UNCERTAINTY", 104, 106], ["deleterious effect", "OBSERVATION", 107, 125]]], ["Tyr-34 influences binding of THi and as for Nm, removal of the OH (Y34F) provides a more favourable environment.", [["Tyr-34", "CHEMICAL", 0, 6], ["OH", "CHEMICAL", 63, 65], ["Y34F", "CHEMICAL", 67, 71], ["Tyr", "CHEMICAL", 0, 3], ["THi", "CHEMICAL", 29, 32], ["OH (Y34F)", "CHEMICAL", 63, 72], ["Tyr-34", "SIMPLE_CHEMICAL", 0, 6], ["THi", "GENE_OR_GENE_PRODUCT", 29, 32], ["OH", "SIMPLE_CHEMICAL", 63, 65], ["THi", "PROTEIN", 29, 32], ["Tyr", "TEST", 0, 3], ["Nm, removal of the OH (Y34F)", "TREATMENT", 44, 72]]], ["Gln-89 side chain also limits bacterial interaction and its substitution to shorter side chains (Q89A and Q89N) is more favourable especially for Rd-CEACAM binding.Interactions of Hi biogroup aegyptius isolates to CEACAM1 constructsIn previous studies, interactions of Hi-aeg strains were shown to be more analogous to Nm (Virji et al., 2000) .", [["Gln-89", "CHEMICAL", 0, 6], ["Gln-89", "CHEMICAL", 0, 6], ["Gln", "AMINO_ACID", 0, 3], ["Rd-CEACAM", "GENE_OR_GENE_PRODUCT", 146, 155], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 214, 221], ["Hi-aeg", "GENE_OR_GENE_PRODUCT", 269, 275], ["CEACAM", "PROTEIN", 149, 155], ["CEACAM1 constructs", "DNA", 214, 232], ["Hi biogroup aegyptius", "SPECIES", 180, 201], ["Gln", "TEST", 0, 3], ["bacterial interaction", "PROBLEM", 30, 51], ["its substitution to shorter side chains", "TREATMENT", 56, 95], ["Rd-CEACAM binding", "PROBLEM", 146, 163], ["Hi biogroup aegyptius isolates", "TREATMENT", 180, 210], ["CEACAM1 constructs", "TREATMENT", 214, 232], ["previous studies", "TEST", 235, 251], ["Hi-aeg strains", "PROBLEM", 269, 283], ["89 side chain", "OBSERVATION_MODIFIER", 4, 17], ["bacterial interaction", "OBSERVATION", 30, 51]]], ["The current studies accordingly demonstrated a requirement both for Ile-91 and Tyr-34 for all Hi-aeg (Fig. 5) .", [["Ile-91", "CHEMICAL", 68, 74], ["Tyr-34", "CHEMICAL", 79, 85], ["Ile-91", "SIMPLE_CHEMICAL", 68, 74], ["Tyr-34", "GENE_OR_GENE_PRODUCT", 79, 85], ["The current studies", "TEST", 0, 19], ["Ile", "TEST", 68, 71], ["Tyr", "TEST", 79, 82]]], ["In addition, as with some Nm strains, the requirement for hydrophobic and aliphatic chains was partly fulfilled by Leu and to a lesser extent by Thr.", [["Leu", "CHEMICAL", 115, 118], ["Leu", "CHEMICAL", 115, 118], ["Thr", "CHEMICAL", 145, 148], ["Leu", "AMINO_ACID", 115, 118], ["some Nm strains", "PROBLEM", 21, 36], ["hydrophobic and aliphatic chains", "TREATMENT", 58, 90], ["aliphatic chains", "OBSERVATION", 74, 90], ["lesser extent", "OBSERVATION_MODIFIER", 128, 141], ["Thr", "OBSERVATION", 145, 148]]], ["Substitutions of residue Tyr-34 with Phe or Ser produced a complex profile.", [["Tyr-34", "CHEMICAL", 25, 31], ["Phe", "CHEMICAL", 37, 40], ["Ser", "CHEMICAL", 44, 47], ["Tyr", "CHEMICAL", 25, 28], ["Phe", "CHEMICAL", 37, 40], ["Ser", "CHEMICAL", 44, 47], ["Tyr-34", "AMINO_ACID", 25, 31], ["Phe", "AMINO_ACID", 37, 40], ["Ser", "AMINO_ACID", 44, 47], ["residue Tyr", "TEST", 17, 28]]], ["Phe generally created a suitable or better environment but the loss of the aromatic ring was also tolerated (Y34S).", [["Phe", "CHEMICAL", 0, 3], ["Phe", "CHEMICAL", 0, 3], ["Phe", "AMINO_ACID", 0, 3], ["the aromatic ring", "TREATMENT", 71, 88], ["aromatic ring", "OBSERVATION", 75, 88]]], ["At position 89, Q > N substitution enhanced binding dramatically for Ha3.Interactions of Hi biogroup aegyptius isolates to CEACAM1 constructsOverall, the three strains tested exhibited similar binding to all receptor constructs that had substitutions at residueInteractions of Hi biogroup aegyptius isolates to CEACAM1 constructsIle-91 as well as those with alanine substitution at residue Tyr-34 (Fig. 5) .", [["alanine", "CHEMICAL", 358, 365], ["N", "CHEMICAL", 20, 21], ["alanine", "CHEMICAL", 358, 365], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 123, 130], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 311, 318], ["alanine", "AMINO_ACID", 358, 365], ["Ha3", "PROTEIN", 69, 72], ["CEACAM1 constructs", "DNA", 123, 141], ["CEACAM1", "PROTEIN", 311, 318], ["Hi biogroup aegyptius", "SPECIES", 89, 110], ["Hi biogroup aegyptius", "SPECIES", 277, 298], ["Q > N substitution enhanced binding", "TREATMENT", 16, 51], ["Ha3", "PROBLEM", 69, 72], ["Hi biogroup aegyptius isolates", "TREATMENT", 89, 119], ["CEACAM1 constructs", "TREATMENT", 123, 141], ["Hi biogroup aegyptius", "TREATMENT", 277, 298], ["CEACAM1 constructsIle", "TEST", 311, 332], ["alanine substitution", "TREATMENT", 358, 378]]], ["However, strains exhibited differences in binding to the receptors with substitutions Y34F and Q89N demonstrating the structural diversity of the CEACAM1-binding ligands of distinct Hi-aeg strains also.Q89N substitution alters the affinity and the hierarchy of receptor occupation by Hi and NmFrom the above data, it is clear that receptor constructs with Q89N substitution have the capacity to increase the binding of some Hi over that of Nm.", [["Q89N", "CHEMICAL", 202, 206], ["Q89N", "CHEMICAL", 202, 206], ["Q89N", "CHEMICAL", 356, 360], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 146, 153], ["Hi-aeg", "GENE_OR_GENE_PRODUCT", 182, 188], ["Q89N", "SIMPLE_CHEMICAL", 202, 206], ["Q89N", "GENE_OR_GENE_PRODUCT", 356, 360], ["CEACAM1", "PROTEIN", 146, 153], ["NmFrom", "PROTEIN", 291, 297], ["strains", "PROBLEM", 9, 16], ["substitutions Y34F", "TREATMENT", 72, 90], ["distinct Hi-aeg strains", "PROBLEM", 173, 196], ["receptor constructs", "TREATMENT", 331, 350], ["Q89N substitution", "TREATMENT", 356, 373], ["the capacity", "PROBLEM", 379, 391], ["CEACAM1", "OBSERVATION", 146, 153], ["aeg strains", "OBSERVATION", 185, 196]]], ["In previous investigations, we have shown that certain isolates of the two bacteria are capable of competing with the native receptor and that Nm C751 derivatives can displace Ha3 as well as Eagan from the receptor (Virji et al., 2000) .", [["C751", "CHEMICAL", 146, 150], ["Nm C751 derivatives", "SIMPLE_CHEMICAL", 143, 162], ["Ha3", "GENE_OR_GENE_PRODUCT", 176, 179], ["Eagan", "SIMPLE_CHEMICAL", 191, 196], ["native receptor", "PROTEIN", 118, 133], ["Ha3", "PROTEIN", 176, 179], ["Eagan", "PROTEIN", 191, 196], ["previous investigations", "TEST", 3, 26], ["the two bacteria", "PROBLEM", 67, 83], ["the native receptor", "TREATMENT", 114, 133], ["Nm C751 derivatives", "TREATMENT", 143, 162]]], ["Here we investigated how changes in receptor structure at position 89 may influence this phenomenon.", [["this phenomenon", "PROBLEM", 84, 99]]], ["We used receptor dot blot overlay in the presence of varying amounts of the soluble receptor constructs to estimate the ability of C751OpaB and Ha3 to selectively adsorb the receptor.", [["C751OpaB", "SIMPLE_CHEMICAL", 131, 139], ["Ha3", "SIMPLE_CHEMICAL", 144, 147], ["C751OpaB", "PROTEIN", 131, 139], ["Ha3", "PROTEIN", 144, 147], ["receptor dot blot", "TREATMENT", 8, 25], ["the soluble receptor constructs", "TREATMENT", 72, 103], ["C751OpaB", "TREATMENT", 131, 139]]], ["Consistent with the lower affinity of Ha3 compared with C751OpaB/D for CEACAM1 (Virji et al., 2000) , the proportion of the native CEACAM1 that interacted with Ha3 compared with C751OpaB was lower and declined further at limiting concentrations of the receptor (Fig. 6A ).", [["Ha3", "GENE_OR_GENE_PRODUCT", 38, 41], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 71, 78], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 131, 138], ["Ha3", "GENE_OR_GENE_PRODUCT", 160, 163], ["C751OpaB", "GENE_OR_GENE_PRODUCT", 178, 186], ["Ha3", "PROTEIN", 38, 41], ["C751OpaB", "PROTEIN", 56, 64], ["CEACAM1", "PROTEIN", 71, 78], ["CEACAM1", "PROTEIN", 131, 138], ["Ha3", "PROTEIN", 160, 163], ["C751OpaB", "PROTEIN", 178, 186], ["CEACAM1", "PROBLEM", 71, 78], ["the native CEACAM1", "PROBLEM", 120, 138], ["CEACAM1", "OBSERVATION", 131, 138]]], ["In contrast, Ha3 and C751OpaB had similar affinities for the receptor when the Q89N construct was present in excess (> 0.13 mg ml -1 ; Fig. 6B ).", [["C751OpaB", "CHEMICAL", 21, 29], ["Ha3", "GENE_OR_GENE_PRODUCT", 13, 16], ["C751OpaB", "GENE_OR_GENE_PRODUCT", 21, 29], ["Ha3", "PROTEIN", 13, 16], ["C751OpaB", "PROTEIN", 21, 29], ["Q89N construct", "DNA", 79, 93], ["Ha3", "TEST", 13, 16]]], ["Further, at limiting concentrations of Q89N, the greater affinity of Ha3 was apparent and bound this construct threefold more than the Nm derivative (Fig. 6B ).", [["Q89N", "CHEMICAL", 39, 43], ["Ha3", "CHEMICAL", 69, 72], ["Q89N", "CHEMICAL", 39, 43], ["Q89N", "SIMPLE_CHEMICAL", 39, 43], ["Ha3", "GENE_OR_GENE_PRODUCT", 69, 72], ["Ha3", "PROTEIN", 69, 72], ["the Nm derivative", "TREATMENT", 131, 148]]], ["The data demonstrate the potential influence of structural modulations at the bacterial binding site in changing the colonization profile of the target tissue.Antibody and bacterial targeting of transfected COS cells expressing CEACAM1 constructsTo assess whether CEACAM mutations that either significantly increase or decrease bacterial binding to the soluble constructs also affect bacterial binding to cellexpressed receptor constructs, we analysed COS cells transiently transfected with CEACAM1-4L containing Q89A, Q89N and I91A substitutions.", [["tissue", "ANATOMY", 152, 158], ["COS cells", "ANATOMY", 207, 216], ["COS cells", "ANATOMY", 452, 461], ["tissue", "TISSUE", 152, 158], ["COS cells", "CELL", 207, 216], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 228, 235], ["CEACAM", "GENE_OR_GENE_PRODUCT", 264, 270], ["COS cells", "CELL", 452, 461], ["CEACAM1-4L", "GENE_OR_GENE_PRODUCT", 491, 501], ["Q89A", "GENE_OR_GENE_PRODUCT", 513, 517], ["bacterial binding site", "DNA", 78, 100], ["COS cells", "CELL_LINE", 207, 216], ["CEACAM1 constructs", "DNA", 228, 246], ["CEACAM", "PROTEIN", 264, 270], ["soluble constructs", "DNA", 353, 371], ["cellexpressed receptor constructs", "DNA", 405, 438], ["COS cells", "CELL_LINE", 452, 461], ["CEACAM1", "PROTEIN", 491, 498], ["Q89A, Q89N and I91A substitutions", "DNA", 513, 546], ["The data", "TEST", 0, 8], ["structural modulations at the bacterial binding site", "PROBLEM", 48, 100], ["Antibody", "TEST", 159, 167], ["transfected COS cells", "PROBLEM", 195, 216], ["CEACAM1 constructs", "TREATMENT", 228, 246], ["CEACAM mutations", "PROBLEM", 264, 280], ["decrease bacterial binding", "PROBLEM", 319, 345], ["the soluble constructs", "TREATMENT", 349, 371], ["bacterial binding", "PROBLEM", 384, 401], ["cellexpressed receptor constructs", "TREATMENT", 405, 438], ["CEACAM1", "TEST", 491, 498], ["structural modulations", "OBSERVATION", 48, 70], ["bacterial binding", "OBSERVATION", 78, 95], ["colonization", "OBSERVATION", 117, 129], ["target tissue", "OBSERVATION", 145, 158], ["transfected COS cells", "OBSERVATION", 195, 216], ["CEACAM1 constructs", "OBSERVATION", 228, 246]]], ["Initially, binding of the anti-CEACAM antibodies to transfected CHO cells was examined and their binding was as observed for the soluble receptors (Fig. 7) .", [["CHO cells", "ANATOMY", 64, 73], ["anti-CEACAM", "GENE_OR_GENE_PRODUCT", 26, 37], ["CHO cells", "CELL", 64, 73], ["anti-CEACAM antibodies", "PROTEIN", 26, 48], ["transfected CHO cells", "CELL_LINE", 52, 73], ["soluble receptors", "PROTEIN", 129, 146], ["the anti-CEACAM antibodies", "TREATMENT", 22, 48], ["transfected CHO cells", "PROBLEM", 52, 73], ["CHO cells", "OBSERVATION", 64, 73]]], ["However, bacterially expressed ligands may overcome decreased affinity for specific mutant proteins due to multiple ligand-receptor engagement at the target cell surface.", [["cell surface", "ANATOMY", 157, 169], ["cell surface", "CELLULAR_COMPONENT", 157, 169], ["mutant proteins", "PROTEIN", 84, 99], ["bacterially expressed ligands", "PROBLEM", 9, 38], ["decreased affinity", "PROBLEM", 52, 70], ["specific mutant proteins", "PROBLEM", 75, 99], ["multiple ligand-receptor engagement", "TREATMENT", 107, 142], ["target cell", "OBSERVATION", 150, 161], ["surface", "OBSERVATION_MODIFIER", 162, 169]]], ["Examination of adherent bacteria and levels of receptor expression by microscopy revealed that bacteria bound to all transfectants other than sham-transfected cells (Fig. 8) .", [["transfectants", "ANATOMY", 117, 130], ["cells", "ANATOMY", 159, 164], ["transfectants", "CELL", 117, 130], ["cells", "CELL", 159, 164], ["sham-transfected cells", "CELL_LINE", 142, 164], ["Examination", "TEST", 0, 11], ["adherent bacteria", "PROBLEM", 15, 32], ["receptor expression", "TEST", 47, 66], ["microscopy", "TEST", 70, 80], ["bacteria bound", "PROBLEM", 95, 109], ["all transfectants", "TEST", 113, 130], ["sham", "TEST", 142, 146], ["transfected cells", "PROBLEM", 147, 164], ["adherent", "OBSERVATION_MODIFIER", 15, 23], ["bacteria", "OBSERVATION", 24, 32], ["transfected cells", "OBSERVATION", 147, 164]]], ["However, receptor expression levels had to be considerably high in the case of I91A for significant bacterial numbers to bind the transfectants.", [["transfectants", "ANATOMY", 130, 143], ["transfectants", "CELL", 130, 143], ["I91A", "PROTEIN", 79, 83], ["receptor expression levels", "TEST", 9, 35], ["significant bacterial numbers", "PROBLEM", 88, 117]]], ["Whereas for Q89A and Q89N, bacteria could bind to cells with barely detectable levels of receptors (Fig. 8) .Competition between cell-expressed and soluble receptors, the role of receptor densityUsing CHO cells expressing full length CC1 or CC1(Q89N), the ability of the soluble native (CC1-Fc) or CC1(Q89N)-Fc to inhibit bacterial binding was assessed using C751 OpaB bacteria (Fig. 9 ).", [["cells", "ANATOMY", 50, 55], ["cell", "ANATOMY", 129, 133], ["CHO cells", "ANATOMY", 201, 210], ["cells", "CELL", 50, 55], ["cell", "CELL", 129, 133], ["CHO cells", "CELL", 201, 210], ["CC1", "GENE_OR_GENE_PRODUCT", 234, 237], ["CC1", "GENE_OR_GENE_PRODUCT", 241, 244], ["CC1-Fc", "GENE_OR_GENE_PRODUCT", 287, 293], ["CC1(Q89N)-Fc", "GENE_OR_GENE_PRODUCT", 298, 310], ["soluble receptors", "PROTEIN", 148, 165], ["CHO cells", "CELL_LINE", 201, 210], ["CC1", "PROTEIN", 234, 237], ["CC1", "PROTEIN", 241, 244], ["Q89N", "PROTEIN", 245, 249], ["CC1", "PROTEIN", 287, 290], ["Fc", "PROTEIN", 291, 293], ["CC1", "PROTEIN", 298, 301], ["Q89N", "PROTEIN", 302, 306], ["Fc", "PROTEIN", 308, 310], ["bacteria", "PROBLEM", 27, 35], ["barely detectable levels of receptors", "PROBLEM", 61, 98], ["bacterial binding", "PROBLEM", 322, 339]]], ["Data show the following: (i) Binding to CHO cells as reported previously (Virji et al., 1996b) was observed only with Opa+ and not Opa-bacteria and no binding was seen with untransfected cells (not shown), (ii) Despite the low levels of binding of the isolate to the soluble CC1 construct carrying the Q89N mutation in the dot immunoblot analysis (Fig. 3B) , bacterial binding to the receptor expressed on the cells was clearly visible (Fig. 9D) , (iii) As in the case of THi Rd described above, association was only significantly high with cells expressing high levels of the receptor (assessed in parallel experiments, not shown), (iv) CC1-Fc could compete with bacterial binding to the homologous native structure expressed on CHO cells (Fig. 9B) , confirming previous results (Virji et al., 1996b) , (v) In comparison, CC1-Fc could more efficiently compete out C751 OpaB binding to the CC1(Q89N) receptor expressed on CHO cells (Fig. 9E) , consistent with its higher affinity for the isolate than CC1(Q89N)-Fc (Fig. 3B) , (vi) CC1(Q89N)-Fc construct was largely ineffective in competing with either cell-expressed receptor ( Fig. 9C and F) ent bacterial numbers are thus also low (cf. Fig. 9D and F: lack of low level binding in F compared with D).", [["CHO cells", "ANATOMY", 40, 49], ["cells", "ANATOMY", 187, 192], ["cells", "ANATOMY", 410, 415], ["cells", "ANATOMY", 541, 546], ["CHO cells", "ANATOMY", 730, 739], ["CHO cells", "ANATOMY", 922, 931], ["cell", "ANATOMY", 1103, 1107], ["CHO cells", "CELL", 40, 49], ["Opa", "GENE_OR_GENE_PRODUCT", 118, 121], ["cells", "CELL", 187, 192], ["CC1", "GENE_OR_GENE_PRODUCT", 275, 278], ["Q89N", "GENE_OR_GENE_PRODUCT", 302, 306], ["cells", "CELL", 410, 415], ["THi Rd", "GENE_OR_GENE_PRODUCT", 472, 478], ["cells", "CELL", 541, 546], ["CC1-Fc", "GENE_OR_GENE_PRODUCT", 638, 644], ["CHO cells", "CELL", 730, 739], ["Fig. 9B", "CELL", 741, 748], ["CC1-Fc", "GENE_OR_GENE_PRODUCT", 823, 829], ["OpaB", "GENE_OR_GENE_PRODUCT", 870, 874], ["CC1(Q89N) receptor", "GENE_OR_GENE_PRODUCT", 890, 908], ["CHO cells", "CELL", 922, 931], ["Fig. 9E", "CELL", 933, 940], ["CC1(Q89N)-Fc", "GENE_OR_GENE_PRODUCT", 1001, 1013], ["Fig. 3B", "GENE_OR_GENE_PRODUCT", 1015, 1022], ["(vi) CC1", "GENE_OR_GENE_PRODUCT", 1026, 1034], ["cell", "CELL", 1103, 1107], ["CHO cells", "CELL_LINE", 40, 49], ["Opa", "PROTEIN", 118, 121], ["Opa-bacteria", "PROTEIN", 131, 143], ["untransfected cells", "CELL_LINE", 173, 192], ["CC1", "PROTEIN", 275, 278], ["Q89N", "DNA", 302, 306], ["THi Rd", "PROTEIN", 472, 478], ["CC1", "PROTEIN", 638, 641], ["Fc", "PROTEIN", 642, 644], ["CHO cells", "CELL_LINE", 730, 739], ["CC1", "PROTEIN", 823, 826], ["Fc", "PROTEIN", 827, 829], ["C751 OpaB", "PROTEIN", 865, 874], ["CC1(Q89N) receptor", "PROTEIN", 890, 908], ["CHO cells", "CELL_LINE", 922, 931], ["CC1", "PROTEIN", 1001, 1004], ["Q89N", "PROTEIN", 1005, 1009], ["Fc", "PROTEIN", 1011, 1013], ["CC1", "PROTEIN", 1031, 1034], ["Q89N", "PROTEIN", 1035, 1039], ["Fc construct", "DNA", 1041, 1053], ["Opa", "TEST", 118, 121], ["Opa-bacteria", "PROBLEM", 131, 143], ["binding", "PROBLEM", 151, 158], ["untransfected cells", "PROBLEM", 173, 192], ["the Q89N mutation", "PROBLEM", 298, 315], ["the dot immunoblot analysis", "TEST", 319, 346], ["bacterial binding", "PROBLEM", 359, 376], ["bacterial binding", "PROBLEM", 664, 681], ["CHO cells", "TEST", 922, 931], ["its higher affinity", "PROBLEM", 960, 979], ["ent bacterial numbers", "TEST", 1144, 1165], ["low level binding", "PROBLEM", 1212, 1229]]], ["The data emphasize the importance of cell presentation of receptor in addition to receptor structure in bacterial interactions.Competition between cell-expressed and soluble receptors, the role of receptor densityThe final outcome of this depends on the balance between the effects exerted by residue substitutions and receptor density.", [["cell", "ANATOMY", 37, 41], ["cell", "ANATOMY", 147, 151], ["cell", "CELL", 37, 41], ["cell", "CELL", 147, 151], ["soluble receptors", "PROTEIN", 166, 183], ["receptor", "TREATMENT", 58, 66], ["bacterial interactions", "PROBLEM", 104, 126], ["residue substitutions and receptor density", "PROBLEM", 293, 335], ["bacterial interactions", "OBSERVATION", 104, 126], ["density", "OBSERVATION", 206, 213], ["residue substitutions", "OBSERVATION", 293, 314], ["receptor density", "OBSERVATION", 319, 335]]], ["Both can affect functional affinity of bacteria-host interactions.Overall analysis of modified receptor targetingTo assess the relative importance and the degree of influence of each substitution on bacterial interactions, degrees of receptor recognition were assigned several categories as shown in Fig. 10A .", [["bacteria", "PROBLEM", 39, 47], ["modified receptor targeting", "TREATMENT", 86, 113], ["each substitution", "PROBLEM", 178, 195], ["bacterial interactions", "TREATMENT", 199, 221], ["receptor recognition", "TREATMENT", 234, 254]]], ["The data show that substitution I91A has a profound effect on the interactions of all strains and whilst the side chain of Ile-91 is best suited to all, Leu can effectively substitute for Ile for several strains, whilst the polar Thr is less well tolerated.", [["I91A", "CHEMICAL", 32, 36], ["Ile-91", "CHEMICAL", 123, 129], ["Leu", "CHEMICAL", 153, 156], ["Ile", "CHEMICAL", 188, 191], ["Ile-91", "CHEMICAL", 123, 129], ["Leu", "CHEMICAL", 153, 156], ["Ile", "CHEMICAL", 188, 191], ["Thr", "CHEMICAL", 230, 233], ["Ile-91", "SIMPLE_CHEMICAL", 123, 129], ["The data", "TEST", 0, 8], ["all strains", "PROBLEM", 82, 93], ["several strains", "PROBLEM", 196, 211], ["profound", "OBSERVATION_MODIFIER", 43, 51], ["effect", "OBSERVATION_MODIFIER", 52, 58], ["less", "OBSERVATION_MODIFIER", 237, 241]]], ["However, some Nm Opa proteins can also tolerate I91T substitution.", [["Nm Opa", "GENE_OR_GENE_PRODUCT", 14, 20], ["Nm Opa proteins", "PROTEIN", 14, 29], ["I91T", "PROTEIN", 48, 52], ["some Nm Opa proteins", "PROBLEM", 9, 29], ["I91T substitution", "TREATMENT", 48, 65]]], ["Tyr-34 is also required in most cases.", [["Tyr-34", "CHEMICAL", 0, 6], ["Tyr", "CHEMICAL", 0, 3], ["Tyr-34", "GENE_OR_GENE_PRODUCT", 0, 6], ["Tyr", "TEST", 0, 3]]], ["Interestingly, Phe-34 is preferred in general at this position over the native Tyr.", [["Phe-34", "CHEMICAL", 15, 21], ["Phe", "CHEMICAL", 15, 18], ["Phe-34", "SIMPLE_CHEMICAL", 15, 21], ["Phe", "TEST", 15, 18]]], ["Substitutions at Gln-89 have a delete- For the native receptor, expression levels and bacterial binding correlated more frequently than for the mutated molecules.", [["Gln-89", "CHEMICAL", 17, 23], ["Gln", "CHEMICAL", 17, 20], ["Gln-89", "AMINO_ACID", 17, 23], ["mutated molecules", "PROTEIN", 144, 161], ["Substitutions at Gln", "TEST", 0, 20], ["expression levels", "TEST", 64, 81], ["bacterial binding", "PROBLEM", 86, 103], ["the mutated molecules", "PROBLEM", 140, 161], ["bacterial binding", "OBSERVATION", 86, 103]]], ["In the case of substitutions at position 89, bacterial binding could be seen at very low levels of receptor expression (arrows in Q89A and Q89N panels).", [["substitutions at position", "TREATMENT", 15, 40], ["bacterial binding", "PROBLEM", 45, 62], ["Q89N panels", "TEST", 139, 150]]], ["The reverse was the case with I91A, where even at high receptor levels (arrowhead, left panel), bacterial binding (arrowhead middle panel) was relatively low.", [["left panel", "TEST", 83, 93], ["bacterial binding (arrowhead middle panel", "PROBLEM", 96, 137], ["left", "ANATOMY_MODIFIER", 83, 87], ["bacterial binding", "OBSERVATION", 96, 113], ["low", "OBSERVATION_MODIFIER", 154, 157]]], ["In sampling of 100 cells, c.", [["cells", "ANATOMY", 19, 24], ["cells", "CELL", 19, 24]]], ["50% exhibited this phenomenon.", [["this phenomenon", "PROBLEM", 14, 29]]], ["Note that the receptor recognition by Kat4C was not affected by mutations in the N-domain as determined by immunoblotting or by immunofluorescence microscopy (Fig. 7) .Overall analysis of modified receptor targetingrious effect on binding of some Nm Opa derivatives and the smaller Q89N apparently is better suited overall for binding by Hi and especially Hi-aeg strains.", [["Kat4C", "GENE_OR_GENE_PRODUCT", 38, 43], ["Opa", "GENE_OR_GENE_PRODUCT", 250, 253], ["Hi-aeg", "GENE_OR_GENE_PRODUCT", 356, 362], ["Kat4C", "PROTEIN", 38, 43], ["N-domain", "PROTEIN", 81, 89], ["Q89N", "PROTEIN", 282, 286], ["immunofluorescence microscopy", "TEST", 128, 157], ["Overall analysis", "TEST", 168, 184], ["modified receptor targetingrious effect", "PROBLEM", 188, 227], ["some Nm Opa derivatives", "TREATMENT", 242, 265], ["Hi-aeg strains", "PROBLEM", 356, 370]]], ["The data emphasize the extensive inter-and intraspecies ligand variations in this receptor targeting, perhaps with greater interstrain differences in Nm.", [["Nm.", "GENE_OR_GENE_PRODUCT", 150, 153], ["Nm.", "SPECIES", 150, 153], ["extensive", "OBSERVATION_MODIFIER", 23, 32], ["Nm.", "OBSERVATION_MODIFIER", 150, 153]]], ["Structural aspects of bacterial ligands that affect the receptor recognition can be considered for strain C751 Opa proteins whose structures are known (Fig. 9B ) (Hobbs et al., 1994) .", [["C751 Opa", "GENE_OR_GENE_PRODUCT", 106, 114], ["C751 Opa proteins", "PROTEIN", 106, 123], ["bacterial ligands", "PROBLEM", 22, 39], ["the receptor recognition", "TEST", 52, 76], ["bacterial ligands", "OBSERVATION", 22, 39]]], ["The hypervariable loops HV1 and HV2 of Opa proteins have been implicated in the binding of CEACAMs (Virji et al., 1999; Bos et al., 2002; de Jonge et al., 2003) .", [["HV1", "GENE_OR_GENE_PRODUCT", 24, 27], ["Opa", "GENE_OR_GENE_PRODUCT", 39, 42], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 91, 98], ["HV1", "PROTEIN", 24, 27], ["HV2", "PROTEIN", 32, 35], ["Opa proteins", "PROTEIN", 39, 51], ["The hypervariable loops HV1", "PROBLEM", 0, 27], ["hypervariable", "OBSERVATION_MODIFIER", 4, 17], ["loops HV1", "OBSERVATION", 18, 27]]], ["Given that the combinations of HV regions of OpaA, B and D of strain C751 provide three distinct combinations (Fig. 10C) , this is consistent with the distinct patterns of targeting of the variant receptor molecules observed in the study.", [["OpaA", "GENE_OR_GENE_PRODUCT", 45, 49], ["B", "GENE_OR_GENE_PRODUCT", 51, 52], ["strain C751", "ORGANISM", 62, 73], ["HV regions", "DNA", 31, 41], ["OpaA", "PROTEIN", 45, 49], ["B", "PROTEIN", 51, 52], ["variant receptor molecules", "PROTEIN", 189, 215], ["HV regions of OpaA", "PROBLEM", 31, 49], ["B and D of strain C751", "PROBLEM", 51, 73], ["the variant receptor molecules", "PROBLEM", 185, 215], ["the study", "TEST", 228, 237], ["consistent with", "UNCERTAINTY", 131, 146], ["receptor molecules", "OBSERVATION", 197, 215]]], ["However, the proteins must all contain sufficient similarity to bind the hydrophobic region around I91.DiscussionThe N-terminal domains of the cell-expressed CEA family of molecules are highly homologous and the majority of CEACAMs are targeted by one or more pathogenic neisserial adhesins belonging to the Opa family of proteins (Virji et al., 1996a; Chen et al., 1997; Gray-Owen et al., 1997) .", [["cell", "ANATOMY", 143, 147], ["cell", "CELL", 143, 147], ["CEA", "GENE_OR_GENE_PRODUCT", 158, 161], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 224, 231], ["Opa", "GENE_OR_GENE_PRODUCT", 308, 311], ["hydrophobic region", "PROTEIN", 73, 91], ["I91", "PROTEIN", 99, 102], ["N-terminal domains", "PROTEIN", 117, 135], ["CEA family", "PROTEIN", 158, 168], ["CEACAMs", "PROTEIN", 224, 231], ["neisserial adhesins", "PROTEIN", 271, 290], ["Opa family", "PROTEIN", 308, 318], ["the proteins", "PROBLEM", 9, 21], ["hydrophobic", "OBSERVATION_MODIFIER", 73, 84]]], ["Despite the structural variability, all Opa proteins target a common site on the receptors whose centre of binding appears to be Ile-91 on the CFG face of the N-domains.", [["Ile-91", "CHEMICAL", 129, 135], ["Ile", "CHEMICAL", 129, 132], ["Opa", "GENE_OR_GENE_PRODUCT", 40, 43], ["Opa proteins", "PROTEIN", 40, 52], ["N-domains", "PROTEIN", 159, 168], ["the structural variability", "PROBLEM", 8, 34], ["variability", "OBSERVATION_MODIFIER", 23, 34]]], ["Ile-91 is conserved throughout the CEA members.", [["Ile-91", "CHEMICAL", 0, 6], ["Ile", "AMINO_ACID", 0, 3], ["CEA", "GENE_OR_GENE_PRODUCT", 35, 38], ["CEA members", "PROTEIN", 35, 46]]], ["Most of the other important residues on CEACAM1 identified by alanine scanning mutagenesis located in a close proximity of Ile-91 (Virji et al., 1999) .", [["alanine", "CHEMICAL", 62, 69], ["Ile-91", "CHEMICAL", 123, 129], ["alanine", "CHEMICAL", 62, 69], ["Ile-91", "CHEMICAL", 123, 129], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 40, 47], ["alanine", "AMINO_ACID", 62, 69], ["CEACAM1", "PROTEIN", 40, 47], ["CEACAM1", "TEST", 40, 47], ["alanine scanning mutagenesis", "TEST", 62, 90]]], ["Precisely how variant Opa proteins can bind to a common receptor site is not entirely clear but a complementary set of sequences of more than one variable domains of Opa proteins may be involved.", [["Opa", "GENE_OR_GENE_PRODUCT", 22, 25], ["Opa", "GENE_OR_GENE_PRODUCT", 166, 169], ["Opa proteins", "PROTEIN", 22, 34], ["Opa proteins", "PROTEIN", 166, 178], ["Opa proteins", "TEST", 166, 178], ["not entirely", "UNCERTAINTY", 73, 85], ["clear", "OBSERVATION", 86, 91]]], ["This variability of the ligands may determine the binding preference for distinct members of the CEA family which represents one mechanism that may determine tissue tropism (Virji et al., 1999; Bos et al., 2002; Gray-Owen, 2003; Hauck and Meyer, 2003; de Jonge et al., 2003) .DiscussionDiverse strains of typable and NTHi lineages including the biogroup aegyptius also bind to the CFG face of the N-domain of CEACAM1 (Virji et al., 2000) .", [["tissue", "ANATOMY", 158, 164], ["CEA", "GENE_OR_GENE_PRODUCT", 97, 100], ["tissue", "TISSUE", 158, 164], ["biogroup aegyptius", "ORGANISM", 345, 363], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 409, 416], ["CEA family", "PROTEIN", 97, 107], ["CFG face", "PROTEIN", 381, 389], ["N-domain", "PROTEIN", 397, 405], ["CEACAM1", "PROTEIN", 409, 416], ["biogroup aegyptius", "SPECIES", 345, 363], ["typable", "PROBLEM", 305, 312], ["NTHi lineages", "PROBLEM", 317, 330], ["the biogroup aegyptius", "TREATMENT", 341, 363], ["CEA", "ANATOMY", 97, 100]]], ["In our previous analysis of receptor binding, THi isolates were shown to behave similarly: each strain tested having a primary requirement for Ile-91 and in addition, was affected by Y34A and Q44A substitutions.", [["Ile-91", "CHEMICAL", 143, 149], ["Ile-91", "CHEMICAL", 143, 149], ["THi", "GENE_OR_GENE_PRODUCT", 46, 49], ["Ile-91", "SIMPLE_CHEMICAL", 143, 149], ["Y34A", "GENE_OR_GENE_PRODUCT", 183, 187], ["Q44A", "GENE_OR_GENE_PRODUCT", 192, 196], ["receptor binding", "PROBLEM", 28, 44], ["THi isolates", "PROBLEM", 46, 58], ["Ile", "TEST", 143, 146]]], ["In the current study also, the THi strain Rd and Eagan demonstrate similar overall binding patterns.", [["the current study", "TEST", 3, 20], ["similar", "OBSERVATION_MODIFIER", 67, 74], ["overall binding patterns", "OBSERVATION", 75, 99]]], ["Binding of N. meningitidis isolate C751OpaB to cell-expressed receptors: competition between cell-expressed and soluble receptors.", [["cell", "ANATOMY", 47, 51], ["cell", "ANATOMY", 93, 97], ["N. meningitidis", "ORGANISM", 11, 26], ["C751OpaB", "GENE_OR_GENE_PRODUCT", 35, 43], ["cell", "CELL", 47, 51], ["cell", "CELL", 93, 97], ["C751OpaB to cell-expressed receptors", "PROTEIN", 35, 71], ["soluble receptors", "PROTEIN", 112, 129], ["N. meningitidis", "SPECIES", 11, 26], ["N. meningitidis", "SPECIES", 11, 26], ["N. meningitidis isolate", "TEST", 11, 34]]], ["Bacterial binding to cell-expressed CC1 or Q89N construct was detected using anti-Nm antisera and TRITC-conjugated secondary antibodies.", [["Bacterial", "ANATOMY", 0, 9], ["cell", "ANATOMY", 21, 25], ["cell", "CELL", 21, 25], ["CC1", "GENE_OR_GENE_PRODUCT", 36, 39], ["Q89N", "GENE_OR_GENE_PRODUCT", 43, 47], ["TRITC", "SIMPLE_CHEMICAL", 98, 103], ["CC1", "PROTEIN", 36, 39], ["Q89N", "PROTEIN", 43, 47], ["TRITC-conjugated secondary antibodies", "PROTEIN", 98, 135], ["Bacterial binding to cell", "PROBLEM", 0, 25], ["anti-Nm antisera", "TREATMENT", 77, 93], ["TRITC", "TEST", 98, 103]]], ["The interactions of bacteria with the cell-expressed receptors were investigated in the absence (A, D) or presence of competing soluble receptors.", [["cell", "ANATOMY", 38, 42], ["cell", "CELL", 38, 42], ["cell-expressed receptors", "PROTEIN", 38, 62], ["soluble receptors", "PROTEIN", 128, 145], ["bacteria", "PROBLEM", 20, 28]]], ["Although binding to the soluble receptor Q89N is much lower than the native CC1 in dot-blots (Fig. 3B) , it is relatively high on certain cells (presumably, on those expressing high levels of the receptor) (D).", [["cells", "ANATOMY", 138, 143], ["Q89N", "GENE_OR_GENE_PRODUCT", 41, 45], ["cells", "CELL", 138, 143], ["soluble receptor Q89N", "PROTEIN", 24, 45], ["CC1", "PROTEIN", 76, 79], ["the soluble receptor Q89N", "TEST", 20, 45], ["relatively", "OBSERVATION_MODIFIER", 111, 121], ["high", "OBSERVATION", 122, 126]]], ["In competitive experiments, the native CC1-Fc (B, E) and the CC1(Q89N)-Fc (C, F) were preincubated at 10 ug ml -1 with bacteria for 15 min, prior to infection of target cells.", [["cells", "ANATOMY", 169, 174], ["infection", "DISEASE", 149, 158], ["CC1-Fc", "GENE_OR_GENE_PRODUCT", 39, 45], ["cells", "CELL", 169, 174], ["CC1", "PROTEIN", 39, 42], ["Fc", "PROTEIN", 43, 45], ["B", "PROTEIN", 47, 48], ["E", "PROTEIN", 50, 51], ["CC1", "PROTEIN", 61, 64], ["Q89N", "PROTEIN", 65, 69], ["Fc", "PROTEIN", 71, 73], ["C, F)", "PROTEIN", 75, 80], ["target cells", "CELL_TYPE", 162, 174], ["the CC1", "TEST", 57, 64], ["bacteria", "PROBLEM", 119, 127], ["infection of target cells", "PROBLEM", 149, 174], ["infection", "OBSERVATION", 149, 158], ["target cells", "OBSERVATION", 162, 174]]], ["CC1-Fc inhibited bacterial binding to the homologous receptor significantly (B), and almost abrogated binding to cell-expressed Q89N (E); whereas the soluble Q89N was inefficient at inhibiting bacterial binding to CHO-CC1 (C).", [["cell", "ANATOMY", 113, 117], ["CC1", "CHEMICAL", 0, 3], ["CC1-Fc", "GENE_OR_GENE_PRODUCT", 0, 6], ["B", "GENE_OR_GENE_PRODUCT", 77, 78], ["cell", "CELL", 113, 117], ["Q89N", "GENE_OR_GENE_PRODUCT", 128, 132], ["Q89N", "GENE_OR_GENE_PRODUCT", 158, 162], ["CC1", "PROTEIN", 0, 3], ["Fc", "PROTEIN", 4, 6], ["Q89N (E)", "PROTEIN", 128, 136], ["soluble Q89N", "PROTEIN", 150, 162], ["bacterial binding", "PROBLEM", 17, 34]]], ["However, a level of homologous inhibition was apparent when examining the adhesion of bacteria to cells expressing low levels of the receptor (e.g. 'peppered' areas shown in D are less evident in F).CHO-CC1CHO-CC1(Q89N)Molecular analysis of bacterial ligand-CEACAM1 interactions 339ferences in response to different amino acid substitutions were apparent.", [["cells", "ANATOMY", 98, 103], ["amino acid", "CHEMICAL", 316, 326], ["amino acid", "CHEMICAL", 316, 326], ["cells", "CELL", 98, 103], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 258, 265], ["amino acid", "AMINO_ACID", 316, 326], ["bacterial ligand", "PROTEIN", 241, 257], ["CEACAM1", "PROTEIN", 258, 265], ["a level of homologous inhibition", "PROBLEM", 9, 41], ["the adhesion of bacteria", "PROBLEM", 70, 94], ["'peppered' areas", "TREATMENT", 148, 164], ["Molecular analysis", "TEST", 219, 237], ["bacterial ligand", "PROBLEM", 241, 257], ["CEACAM1 interactions", "PROBLEM", 258, 278], ["different amino acid substitutions", "PROBLEM", 306, 340], ["bacterial ligand", "OBSERVATION", 241, 257], ["amino acid substitutions", "OBSERVATION", 316, 340]]], ["One consistency between all species and strains tested was the dramatic loss of binding following I91A substitution which, as observed previously, appears to be central in an overlapping bacterial binding footprint on CEACAM1 (Virji et al., 1999; .", [["I91A", "GENE_OR_GENE_PRODUCT", 98, 102], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 218, 225], ["I91A", "PROTEIN", 98, 102], ["CEACAM1", "PROTEIN", 218, 225], ["all species", "PROBLEM", 24, 35], ["strains", "PROBLEM", 40, 47], ["the dramatic loss of binding", "PROBLEM", 59, 87], ["I91A substitution", "TREATMENT", 98, 115], ["an overlapping bacterial binding footprint", "PROBLEM", 172, 214], ["appears to be", "UNCERTAINTY", 147, 160], ["central", "OBSERVATION_MODIFIER", 161, 168], ["bacterial binding footprint", "OBSERVATION", 187, 214]]], ["A similar situation occurs on the mouse CEACAM1a (MHVR1a) N-terminal domain, in which Ile-41 appears to engage with the mouse hepatitis virus spike protein.", [["Ile-41", "CHEMICAL", 86, 92], ["hepatitis", "DISEASE", 126, 135], ["Ile", "CHEMICAL", 86, 89], ["mouse", "ORGANISM", 34, 39], ["CEACAM1a", "GENE_OR_GENE_PRODUCT", 40, 48], ["mouse hepatitis virus", "ORGANISM", 120, 141], ["mouse CEACAM1a (MHVR1a) N-terminal domain", "PROTEIN", 34, 75], ["mouse hepatitis virus spike protein", "PROTEIN", 120, 155], ["mouse", "SPECIES", 34, 39], ["mouse", "SPECIES", 120, 125], ["hepatitis virus", "SPECIES", 126, 141], ["mouse", "SPECIES", 34, 39], ["mouse hepatitis virus", "SPECIES", 120, 141], ["A similar situation", "PROBLEM", 0, 19], ["the mouse CEACAM1a", "TREATMENT", 30, 48], ["N-terminal domain", "PROBLEM", 58, 75], ["the mouse hepatitis virus spike protein", "PROBLEM", 116, 155]]], ["Replacement of Ile-41 by Thr in the MHVR1b allele reduces virus binding significantly (Tan et al., 2002) .", [["Ile-41", "CHEMICAL", 15, 21], ["Thr", "CHEMICAL", 25, 28], ["Ile-41", "CHEMICAL", 15, 21], ["Thr", "CHEMICAL", 25, 28], ["Ile-41", "AMINO_ACID", 15, 21], ["Thr", "AMINO_ACID", 25, 28], ["MHVR1b", "GENE_OR_GENE_PRODUCT", 36, 42], ["MHVR1b allele", "DNA", 36, 49], ["Replacement of Ile", "TREATMENT", 0, 18], ["Thr in the MHVR1b allele reduces", "TREATMENT", 25, 57], ["virus binding", "PROBLEM", 58, 71]]], ["Cell surface receptor interactions with their ligands often involve hydrophobic contact points which provides the major binding energy.", [["Cell surface", "ANATOMY", 0, 12], ["Cell", "CELL", 0, 4], ["Cell surface receptor interactions", "TREATMENT", 0, 34]]], ["Hydrophobic residues surrounding these contribute to the specificity of binding (Clackson and Wells, 1995; Kwong et al., 1998; Kim et al., 2001) .", [["Hydrophobic residues", "PROBLEM", 0, 20]]], ["Thus in murine CEACAM1, the protruding Ile-41, which is surrounded by a number of surface exposed charged residues, e.g. Asp-42, Glu-44, Arg-47, Asp89, Glu-93 and Arg-97, might form such a binding area (Tan et al., 2002) .", [["surface", "ANATOMY", 82, 89], ["Ile-41", "CHEMICAL", 39, 45], ["Glu", "CHEMICAL", 129, 132], ["Glu-93 and Arg-97", "CHEMICAL", 152, 169], ["Ile-41", "CHEMICAL", 39, 45], ["Asp", "CHEMICAL", 121, 124], ["Glu", "CHEMICAL", 129, 132], ["Arg-47", "CHEMICAL", 137, 143], ["Asp89", "CHEMICAL", 145, 150], ["Glu", "CHEMICAL", 152, 155], ["Arg-97", "CHEMICAL", 163, 169], ["murine", "ORGANISM", 8, 14], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 15, 22], ["Asp-42", "SIMPLE_CHEMICAL", 121, 127], ["Glu-44", "SIMPLE_CHEMICAL", 129, 135], ["Arg-47", "SIMPLE_CHEMICAL", 137, 143], ["Asp89", "GENE_OR_GENE_PRODUCT", 145, 150], ["Glu-93", "SIMPLE_CHEMICAL", 152, 158], ["Arg-97", "AMINO_ACID", 163, 169], ["murine CEACAM1", "PROTEIN", 8, 22], ["murine", "SPECIES", 8, 14], ["Asp", "TEST", 121, 124], ["Glu", "TEST", 129, 132], ["Arg", "TEST", 137, 140], ["Asp89", "TEST", 145, 150], ["Glu", "TEST", 152, 155], ["Arg", "TEST", 163, 166], ["CEACAM1", "OBSERVATION_MODIFIER", 15, 22]]], ["Accordingly from current studies also, mutations introduced at position 91 in the human receptor support the requirement for a hydrophobic pocket at this site.", [["human", "ORGANISM", 82, 87], ["position 91", "PROTEIN", 63, 74], ["human receptor", "PROTEIN", 82, 96], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["current studies", "TEST", 17, 32], ["mutations", "PROBLEM", 39, 48], ["a hydrophobic pocket", "PROBLEM", 125, 145]]], ["In addition, an extended aliphatic chain is preferred as Ala disrupted binding of all bacteria and the polar Thr reduced binding of all Hi and several Nm strains.", [["Ala", "CHEMICAL", 57, 60], ["Ala", "CHEMICAL", 57, 60], ["Thr", "CHEMICAL", 109, 112], ["Ala", "AMINO_ACID", 57, 60], ["an extended aliphatic chain", "PROBLEM", 13, 40], ["all bacteria", "PROBLEM", 82, 94], ["Thr reduced binding", "PROBLEM", 109, 128], ["several Nm strains", "PROBLEM", 143, 161], ["aliphatic chain", "OBSERVATION", 25, 40], ["polar", "ANATOMY_MODIFIER", 103, 108], ["reduced", "OBSERVATION_MODIFIER", 113, 120], ["binding", "OBSERVATION_MODIFIER", 121, 128]]], ["This binding pocket is flanked by several polar residues (Fig. 1 ) whose contribution to bacterial ligand binding is apparent and variable (Virji et al., 1999; .", [["This binding pocket", "PROBLEM", 0, 19], ["bacterial ligand binding", "PROBLEM", 89, 113], ["pocket", "OBSERVATION_MODIFIER", 13, 19], ["several", "OBSERVATION_MODIFIER", 34, 41], ["polar residues", "OBSERVATION", 42, 56], ["bacterial ligand binding", "OBSERVATION", 89, 113]]], ["The importance of the Ile-91 and the surrounding residues on human CEACAM1 in bacterial binding is also supported by the observation that the mAb YTH71.3 directed against the N-domain also requires several residues in common with bacteria and blocks binding of all CEACAM1-binding bacteria we have investigated (Virji et al., 1999; Hill and Virji, 2003) .Molecular analysis of bacterial ligand-CEACAM1 interactions 339The murine N-domain strand arrangement derived form crystal structure depicts the CC\u2032 loop to assume a convoluted conformation.", [["Ile-91", "CHEMICAL", 22, 28], ["YTH71.3", "CHEMICAL", 146, 153], ["CC", "CHEMICAL", 500, 502], ["Ile-91", "CHEMICAL", 22, 28], ["Ile-91", "AMINO_ACID", 22, 28], ["human", "ORGANISM", 61, 66], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 67, 74], ["YTH71.3", "GENE_OR_GENE_PRODUCT", 146, 153], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 265, 272], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 394, 401], ["murine", "ORGANISM", 422, 428], ["Ile-91", "PROTEIN", 22, 28], ["human CEACAM1", "PROTEIN", 61, 74], ["mAb YTH71.3", "PROTEIN", 142, 153], ["N-domain", "PROTEIN", 175, 183], ["CEACAM1", "PROTEIN", 265, 272], ["bacterial ligand", "PROTEIN", 377, 393], ["CEACAM1", "PROTEIN", 394, 401], ["CC\u2032 loop", "PROTEIN", 500, 508], ["human", "SPECIES", 61, 66], ["murine", "SPECIES", 422, 428], ["human", "SPECIES", 61, 66], ["the surrounding residues", "PROBLEM", 33, 57], ["human CEACAM1", "TREATMENT", 61, 74], ["bacterial binding", "PROBLEM", 78, 95], ["the mAb", "TREATMENT", 138, 145], ["several residues", "PROBLEM", 198, 214], ["bacteria", "PROBLEM", 230, 238], ["blocks binding", "PROBLEM", 243, 257], ["all CEACAM1-binding bacteria", "PROBLEM", 261, 289], ["Molecular analysis", "TEST", 355, 373], ["bacterial ligand", "PROBLEM", 377, 393], ["The murine N-domain strand arrangement", "TREATMENT", 418, 456], ["the CC\u2032 loop", "TREATMENT", 496, 508], ["bacterial ligand", "OBSERVATION", 377, 393], ["convoluted conformation", "OBSERVATION", 521, 544]]], ["The previous model of human CEACAM1 contained a flat CC\u2032 loop like the Ig-folds on Fig. 10 .", [["CC", "CHEMICAL", 53, 55], ["human", "ORGANISM", 22, 27], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 28, 35], ["human CEACAM1", "PROTEIN", 22, 35], ["Ig", "PROTEIN", 71, 73], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["human CEACAM1", "TREATMENT", 22, 35], ["a flat CC\u2032 loop", "TREATMENT", 46, 61]]], ["Binding of bacterial ligands to CEACAM1-Fc constructs as determined in the current study.", [["CEACAM1-Fc", "GENE_OR_GENE_PRODUCT", 32, 42], ["CEACAM1", "PROTEIN", 32, 39], ["Fc constructs", "DNA", 40, 53], ["bacterial ligands", "PROBLEM", 11, 28], ["CEACAM1", "TEST", 32, 39], ["the current study", "TEST", 71, 88], ["bacterial ligands", "OBSERVATION", 11, 28]]], ["B and C. Diagrams showing CEACAM-binding meningococcal ligand structures.", [["CEACAM", "GENE_OR_GENE_PRODUCT", 26, 32], ["CEACAM", "PROTEIN", 26, 32], ["B and C. Diagrams", "TEST", 0, 17], ["CEACAM", "PROBLEM", 26, 32], ["binding meningococcal ligand structures", "PROBLEM", 33, 72], ["meningococcal ligand", "OBSERVATION", 41, 61]]], ["As only the Opa protein structure has been analysed in details so far with respect to CEACAM binding (de Jonge et al., 2003) , for clarity and ease of discussion, a 2D Opa protein structure (B) and relationship of the three variable domains of strain C751 Opa proteins are shown (C).", [["Opa", "GENE_OR_GENE_PRODUCT", 12, 15], ["CEACAM", "GENE_OR_GENE_PRODUCT", 86, 92], ["Opa", "GENE_OR_GENE_PRODUCT", 168, 171], ["C751 Opa", "GENE_OR_GENE_PRODUCT", 251, 259], ["Opa protein structure", "PROTEIN", 12, 33], ["CEACAM", "PROTEIN", 86, 92], ["Opa protein structure", "PROTEIN", 168, 189], ["B", "PROTEIN", 191, 192], ["variable domains", "PROTEIN", 224, 240], ["C751 Opa proteins", "PROTEIN", 251, 268], ["the Opa protein structure", "TEST", 8, 33], ["CEACAM binding", "PROBLEM", 86, 100], ["a 2D Opa protein structure", "TEST", 163, 189], ["Opa proteins", "TEST", 256, 268]]], ["SV, semivariable domains of strain C751 Opa-A, -B and -D are identical as are the hypervariable structures HV1 of OpaA and OpaB and the HV2 of OpaB and OpaD. which it was based.", [["SV", "ORGANISM", 0, 2], ["Opa-A, -B", "GENE_OR_GENE_PRODUCT", 40, 49], ["-D", "GENE_OR_GENE_PRODUCT", 54, 56], ["OpaA", "GENE_OR_GENE_PRODUCT", 114, 118], ["OpaB", "GENE_OR_GENE_PRODUCT", 123, 127], ["OpaB", "GENE_OR_GENE_PRODUCT", 143, 147], ["OpaD", "GENE_OR_GENE_PRODUCT", 152, 156], ["semivariable domains", "PROTEIN", 4, 24], ["Opa", "PROTEIN", 40, 43], ["A", "PROTEIN", 44, 45], ["B", "PROTEIN", 48, 49], ["D", "PROTEIN", 55, 56], ["OpaA", "PROTEIN", 114, 118], ["OpaB", "PROTEIN", 123, 127], ["HV2", "PROTEIN", 136, 139], ["OpaB", "PROTEIN", 143, 147], ["OpaD", "PROTEIN", 152, 156], ["SV", "TEST", 0, 2], ["strain", "TEST", 28, 34], ["Opa", "TEST", 40, 43], ["OpaA", "TEST", 114, 118], ["OpaB", "TEST", 123, 127]]], ["This resulted in Val-39 and Gly-41 being located at a distance from the binding focus Ile-91.", [["Gly-41", "CHEMICAL", 28, 34], ["Ile-91", "CHEMICAL", 86, 92], ["Val-39", "CHEMICAL", 17, 23], ["Gly-41", "CHEMICAL", 28, 34], ["Ile-91", "CHEMICAL", 86, 92], ["Val-39", "GENE_OR_GENE_PRODUCT", 17, 23], ["Gly-41", "GENE_OR_GENE_PRODUCT", 28, 34], ["Val", "TEST", 17, 20], ["Gly", "TEST", 28, 31]]], ["Both Val-39 and Gly-41 have been implicated in bacterial binding from alanine scanning and homologue scanning mutagenesis (Bos et al., 1999; Virji et al., 1999) .", [["Val-39 and Gly-41", "CHEMICAL", 5, 22], ["alanine", "CHEMICAL", 70, 77], ["Val-39 and Gly-41", "CHEMICAL", 5, 22], ["alanine", "CHEMICAL", 70, 77], ["Val-39", "GENE_OR_GENE_PRODUCT", 5, 11], ["Gly-41", "GENE_OR_GENE_PRODUCT", 16, 22], ["alanine", "AMINO_ACID", 70, 77], ["Both Val", "TEST", 0, 8], ["alanine scanning", "TEST", 70, 86]]], ["The remodelling shown here of CEACAM1 produces the convoluted structure of the CC\u2032 loop relocating Val-39 close to Ile-91.", [["CC\u2032 loop", "ANATOMY", 79, 87], ["CC", "CHEMICAL", 79, 81], ["Ile-91", "CHEMICAL", 115, 121], ["Val", "CHEMICAL", 99, 102], ["Ile", "CHEMICAL", 115, 118], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 30, 37], ["Ile-91", "AMINO_ACID", 115, 121], ["CEACAM1", "PROTEIN", 30, 37], ["Val-39", "PROTEIN", 99, 105], ["CEACAM1", "PROBLEM", 30, 37], ["Val", "TEST", 99, 102], ["CEACAM1", "OBSERVATION", 30, 37]]], ["Further, the aromatic ring of Tyr-34 suggested to be required to maintain the convoluted structure of the CC\u2032 loop (Tan et al., 2002) when substituted with Phe almost always supported bacterial binding.", [["Tyr-34", "CHEMICAL", 30, 36], ["CC", "CHEMICAL", 106, 108], ["Phe", "CHEMICAL", 156, 159], ["Tyr", "CHEMICAL", 30, 33], ["Phe", "CHEMICAL", 156, 159], ["Tyr-34", "SIMPLE_CHEMICAL", 30, 36], ["Phe", "AMINO_ACID", 156, 159], ["bacterial binding", "PROBLEM", 184, 201], ["bacterial binding", "OBSERVATION", 184, 201]]], ["Indeed, Y34F provides a better environment for most bacterial strains tested.", [["Y34F", "CHEMICAL", 8, 12], ["Y34F", "PROTEIN", 8, 12], ["most bacterial strains", "PROBLEM", 47, 69]]], ["On the other hand, Y34A frequently abrogated receptor recognition.", [["Y34A", "GENE_OR_GENE_PRODUCT", 19, 23], ["Y34A", "PROTEIN", 19, 23]]], ["However and surprisingly, Y34S is tolerated by a substantial number of bacterial ligands.", [["Y34S", "CHEMICAL", 26, 30], ["bacterial ligands", "PROBLEM", 71, 88], ["bacterial ligands", "OBSERVATION", 71, 88]]], ["Whether this is due to the flexible variable loop domains of the bacterial ligands which may produce an induced fit around the receptor needs consideration.", [["flexible variable loop domains", "PROTEIN", 27, 57], ["the flexible variable loop domains of the bacterial ligands", "PROBLEM", 23, 82], ["an induced fit", "PROBLEM", 101, 115], ["loop", "OBSERVATION", 45, 49], ["bacterial ligands", "OBSERVATION", 65, 82]]], ["Interestingly, Tyr-34 is conserved in the majority of the human CEACAMs with the exception of CEACAM4 which contains His at this site.", [["Tyr-34", "CHEMICAL", 15, 21], ["Tyr", "CHEMICAL", 15, 18], ["His", "CHEMICAL", 117, 120], ["Tyr-34", "GENE_OR_GENE_PRODUCT", 15, 21], ["human", "ORGANISM", 58, 63], ["CEACAMs", "CANCER", 64, 71], ["CEACAM4", "GENE_OR_GENE_PRODUCT", 94, 101], ["Tyr-34", "PROTEIN", 15, 21], ["CEACAM4", "PROTEIN", 94, 101], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["CEACAM4", "TREATMENT", 94, 101]]], ["However, the importance of Tyr-34 in human CEACAM1 maintaining the three dimensional structure requires human receptor crystallographic data.Molecular analysis of bacterial ligand-CEACAM1 interactions 339Substitutions Y34F and Q89N also produced interesting data from the point of view of pathogenesis.", [["Tyr-34", "CHEMICAL", 27, 33], ["Tyr", "CHEMICAL", 27, 30], ["Tyr-34", "GENE_OR_GENE_PRODUCT", 27, 33], ["human", "ORGANISM", 37, 42], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 43, 50], ["human", "ORGANISM", 104, 109], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 180, 187], ["Tyr-34", "PROTEIN", 27, 33], ["human CEACAM1", "PROTEIN", 37, 50], ["CEACAM1", "PROTEIN", 180, 187], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 104, 109], ["Tyr", "TEST", 27, 30], ["human CEACAM1", "TREATMENT", 37, 50], ["Molecular analysis", "TEST", 141, 159], ["bacterial ligand", "PROBLEM", 163, 179], ["pathogenesis", "PROBLEM", 289, 301], ["bacterial ligand", "OBSERVATION", 163, 179], ["pathogenesis", "OBSERVATION", 289, 301]]], ["Whilst Q89A and Q89N appear to affect some Opa proteins by reducing receptor recognition, suggesting its potential contribution in determining tissue tropism (Virji et al., 1999) , Q89N substitution occasionally caused dramatic increase in bacterial adhesion, especially of Hi isolates.", [["tissue", "ANATOMY", 143, 149], ["Q89N", "CHEMICAL", 181, 185], ["Q89A", "GENE_OR_GENE_PRODUCT", 7, 11], ["Q89N", "GENE_OR_GENE_PRODUCT", 16, 20], ["Opa", "GENE_OR_GENE_PRODUCT", 43, 46], ["tissue", "TISSUE", 143, 149], ["Q89N", "PROTEIN", 16, 20], ["Opa proteins", "PROTEIN", 43, 55], ["Q89N substitution", "TREATMENT", 181, 198], ["bacterial adhesion", "PROBLEM", 240, 258], ["Hi isolates", "PROBLEM", 274, 285], ["dramatic", "OBSERVATION_MODIFIER", 219, 227], ["increase", "OBSERVATION_MODIFIER", 228, 236], ["bacterial adhesion", "OBSERVATION", 240, 258]]], ["Y34F, as observed above, increased binding of strains within all species examined.", [["Y34F", "GENE_OR_GENE_PRODUCT", 0, 4], ["Y34F", "PROTEIN", 0, 4], ["increased binding of strains", "PROBLEM", 25, 53]]], ["As it is possible that multiple receptors presented on the target cells may overcome the reduced binding affinity of mutated receptors, we examined strain Rd binding to I91A and Q89A/N-substituted receptors expressed in transiently transfected COS cells.", [["cells", "ANATOMY", 66, 71], ["COS cells", "ANATOMY", 244, 253], ["N", "CHEMICAL", 183, 184], ["cells", "CELL", 66, 71], ["Rd", "GENE_OR_GENE_PRODUCT", 155, 157], ["I91A", "GENE_OR_GENE_PRODUCT", 169, 173], ["COS cells", "CELL", 244, 253], ["target cells", "CELL_TYPE", 59, 71], ["mutated receptors", "PROTEIN", 117, 134], ["I91A and Q89A/N-substituted receptors", "PROTEIN", 169, 206], ["COS cells", "CELL_LINE", 244, 253], ["multiple receptors", "PROBLEM", 23, 41], ["mutated receptors", "PROBLEM", 117, 134], ["I91A", "TEST", 169, 173], ["substituted receptors", "PROBLEM", 185, 206], ["transiently transfected COS cells", "PROBLEM", 220, 253], ["transfected COS cells", "OBSERVATION", 232, 253]]], ["Whilst the latter receptors were targeted on cells with low levels of receptor expression, only a proportion (c.", [["cells", "ANATOMY", 45, 50], ["cells", "CELL", 45, 50]]], ["50%) of cells with very high levels of I91A receptors had significant numbers of bacteria attached.", [["cells", "ANATOMY", 8, 13], ["cells", "CELL", 8, 13], ["I91A receptors", "GENE_OR_GENE_PRODUCT", 39, 53], ["I91A receptors", "PROTEIN", 39, 53], ["very high levels of I91A receptors", "PROBLEM", 19, 53], ["bacteria", "PROBLEM", 81, 89], ["bacteria", "OBSERVATION", 81, 89]]], ["Thus point mutations of CEACAMs can both decrease and increase bacterial load and additional factors that dictate bacterial binding include receptor levels on the target cells.Molecular analysis of bacterial ligand-CEACAM1 interactions 339The ligands of Neisseria (i.e. Opa proteins) and of Hi so far identified (i.e. P5 proteins) share similar beta-barrel structure with surface-exposed variable loops.", [["cells", "ANATOMY", 170, 175], ["surface", "ANATOMY", 372, 379], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 24, 31], ["cells", "CELL", 170, 175], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 215, 222], ["Opa", "GENE_OR_GENE_PRODUCT", 270, 273], ["P5", "GENE_OR_GENE_PRODUCT", 318, 320], ["CEACAMs", "PROTEIN", 24, 31], ["target cells", "CELL_TYPE", 163, 175], ["bacterial ligand", "PROTEIN", 198, 214], ["CEACAM1", "PROTEIN", 215, 222], ["Opa proteins", "PROTEIN", 270, 282], ["Hi", "PROTEIN", 291, 293], ["P5 proteins", "PROTEIN", 318, 329], ["beta-barrel structure", "PROTEIN", 345, 366], ["surface-exposed variable loops", "PROTEIN", 372, 402], ["point mutations of CEACAMs", "PROBLEM", 5, 31], ["increase bacterial load", "PROBLEM", 54, 77], ["bacterial binding", "PROBLEM", 114, 131], ["receptor levels", "TEST", 140, 155], ["Molecular analysis", "TEST", 176, 194], ["bacterial ligand", "PROBLEM", 198, 214], ["Neisseria", "PROBLEM", 254, 263], ["Opa proteins", "TEST", 270, 282], ["Hi", "PROBLEM", 291, 293], ["increase", "OBSERVATION_MODIFIER", 54, 62], ["bacterial load", "OBSERVATION", 63, 77], ["bacterial ligand", "OBSERVATION", 198, 214], ["Neisseria", "OBSERVATION", 254, 263], ["beta-barrel structure", "OBSERVATION", 345, 366], ["surface", "OBSERVATION_MODIFIER", 372, 379], ["variable loops", "OBSERVATION", 388, 402]]], ["The regions of P5 that may engage with the receptor have not been identified but those of Opa proteins were studied by mutagenesis of strain H44/76 (de Jonge et al., 2003) .", [["P5", "GENE_OR_GENE_PRODUCT", 15, 17], ["Opa", "GENE_OR_GENE_PRODUCT", 90, 93], ["P5", "DNA", 15, 17], ["Opa proteins", "PROTEIN", 90, 102], ["Opa proteins", "TEST", 90, 102]]], ["This strain is related to strain MC58, one of the strains used in the current study.", [["This strain", "PROBLEM", 0, 11], ["the strains", "PROBLEM", 46, 57], ["the current study", "TEST", 66, 83]]], ["The studies of de Jonge et al. implicated G \u00a5 (I/V/l) \u00a5 (S/E/Q) as the key motifs of HV2 regions (Fig. 9 ) of meningococcal Opa proteins in receptor targeting.", [["G \u00a5", "GENE_OR_GENE_PRODUCT", 42, 45], ["meningococcal Opa proteins", "GENE_OR_GENE_PRODUCT", 110, 136], ["HV2 regions", "DNA", 85, 96], ["meningococcal Opa proteins", "PROTEIN", 110, 136], ["The studies", "TEST", 0, 11], ["G \u00a5 (I/V/l) \u00a5 (S/E/Q", "TEST", 42, 62], ["meningococcal Opa proteins in receptor targeting", "TREATMENT", 110, 158]]], ["Together with this, an 99 ELK motif of the Opa HV1 region might be involved in the three dimensional presentation of the receptor-engaging residues of the bacterial ligand (de Jonge et al., 2003) .", [["Opa HV1", "GENE_OR_GENE_PRODUCT", 43, 50], ["99 ELK motif", "DNA", 23, 35], ["Opa HV1 region", "DNA", 43, 57], ["bacterial ligand", "ANATOMY", 155, 171]]], ["Within the strain C751, OpaB and OpaD proteins contain the motif GxLxS at positions 172-176 and 167-171, respectively, whereas Opa A contains a 168 PxIxN motif.", [["C751", "GENE_OR_GENE_PRODUCT", 18, 22], ["OpaB", "GENE_OR_GENE_PRODUCT", 24, 28], ["OpaD", "GENE_OR_GENE_PRODUCT", 33, 37], ["GxLxS", "GENE_OR_GENE_PRODUCT", 65, 70], ["Opa A", "GENE_OR_GENE_PRODUCT", 127, 132], ["strain C751, OpaB and OpaD proteins", "PROTEIN", 11, 46], ["GxLxS", "PROTEIN", 65, 70], ["Opa A", "PROTEIN", 127, 132], ["168 PxIxN motif", "DNA", 144, 159], ["the strain C751", "TEST", 7, 22], ["OpaB", "TEST", 24, 28], ["OpaD proteins", "TEST", 33, 46], ["the motif GxLxS", "TEST", 55, 70], ["a 168 PxIxN motif", "TREATMENT", 142, 159], ["motif GxLxS", "OBSERVATION", 59, 70]]], ["In the HV1 region, OpaA and B contain 99 DLK whereas OpaD contains EDK.", [["HV1 region", "ANATOMY", 7, 17], ["OpaA", "GENE_OR_GENE_PRODUCT", 19, 23], ["B", "GENE_OR_GENE_PRODUCT", 28, 29], ["DLK", "GENE_OR_GENE_PRODUCT", 41, 44], ["OpaD", "GENE_OR_GENE_PRODUCT", 53, 57], ["EDK", "GENE_OR_GENE_PRODUCT", 67, 70], ["HV1 region", "DNA", 7, 17], ["OpaA", "PROTEIN", 19, 23], ["B", "PROTEIN", 28, 29], ["DLK", "PROTEIN", 41, 44], ["OpaD", "PROTEIN", 53, 57], ["EDK", "PROTEIN", 67, 70], ["OpaA", "TEST", 19, 23], ["DLK", "PROBLEM", 41, 44], ["HV1", "ANATOMY", 7, 10], ["region", "ANATOMY_MODIFIER", 11, 17], ["99 DLK", "OBSERVATION", 38, 44]]], ["Studies in our laboratories are in progress to assess the precise variant C751 Opa and receptor residue pairs involved in mutual recognition.Molecular analysis of bacterial ligand-CEACAM1 interactions 339Polymorphisms that affect host susceptibility may be found at various sites in the genes encoding host receptors targeted by pathogens and may result in loss or gain of receptor-associated functions.", [["C751 Opa", "GENE_OR_GENE_PRODUCT", 74, 82], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 180, 187], ["C751 Opa", "PROTEIN", 74, 82], ["bacterial ligand", "PROTEIN", 163, 179], ["CEACAM1", "PROTEIN", 180, 187], ["host receptors", "PROTEIN", 302, 316], ["our laboratories", "TEST", 11, 27], ["Molecular analysis", "TEST", 141, 159], ["bacterial ligand", "PROBLEM", 163, 179], ["Polymorphisms", "PROBLEM", 204, 217], ["host susceptibility", "PROBLEM", 230, 249], ["bacterial ligand", "OBSERVATION", 163, 179]]], ["Some SNPs may lead to multiple and diverse downstream effects, e.g. altered transcriptional response and manifestation of disease (Sakuntabhai et al., 2005) .", [["Some SNPs", "PROBLEM", 0, 9], ["multiple and diverse downstream effects", "PROBLEM", 22, 61], ["altered transcriptional response", "PROBLEM", 68, 100], ["disease", "PROBLEM", 122, 129], ["multiple", "OBSERVATION_MODIFIER", 22, 30], ["diverse", "OBSERVATION_MODIFIER", 35, 42], ["downstream effects", "OBSERVATION", 43, 61], ["transcriptional response", "OBSERVATION", 76, 100]]], ["Extracellular domain polymorphisms may have a more direct effect via altered binding of pathogen ligands to their receptors.", [["Extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 13], ["Extracellular domain polymorphisms", "PROBLEM", 0, 34], ["altered binding of pathogen ligands", "PROBLEM", 69, 104]]], ["SNPs of the innate immune system especially those affecting pathogen associated pattern recognition receptors and cytokines have been studied extensively.", [["pattern recognition receptors", "GENE_OR_GENE_PRODUCT", 80, 109], ["pathogen associated pattern recognition receptors", "PROTEIN", 60, 109], ["cytokines", "PROTEIN", 114, 123], ["the innate immune system", "TREATMENT", 8, 32], ["cytokines", "TREATMENT", 114, 123]]], ["Changes such as Asp299Gly and Thr399Ile in the extracellular domains of LPS-binding Toll-like receptor 4 (TLR4) have been implicated in increased risk to bacterial infections (Schroder and Schumann, 2005) .", [["extracellular", "ANATOMY", 47, 60], ["LPS", "CHEMICAL", 72, 75], ["bacterial infections", "DISEASE", 154, 174], ["Asp", "CHEMICAL", 16, 19], ["Thr", "CHEMICAL", 30, 33], ["Asp299Gly", "GENE_OR_GENE_PRODUCT", 16, 25], ["Thr", "AMINO_ACID", 30, 33], ["399Ile", "AMINO_ACID", 33, 39], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 47, 60], ["LPS-binding Toll-like receptor 4", "GENE_OR_GENE_PRODUCT", 72, 104], ["TLR4", "GENE_OR_GENE_PRODUCT", 106, 110], ["Asp299Gly", "PROTEIN", 16, 25], ["Thr399Ile", "PROTEIN", 30, 39], ["extracellular domains", "PROTEIN", 47, 68], ["LPS-binding Toll-like receptor 4", "PROTEIN", 72, 104], ["TLR4", "PROTEIN", 106, 110], ["Asp", "TEST", 16, 19], ["LPS", "PROBLEM", 72, 75], ["bacterial infections", "PROBLEM", 154, 174], ["increased", "OBSERVATION_MODIFIER", 136, 145], ["bacterial", "OBSERVATION_MODIFIER", 154, 163], ["infections", "OBSERVATION", 164, 174]]], ["These SNPs have also been associated with severe respiratory syncytial virus (RSV) bronchiolitis in infants.", [["respiratory syncytial virus (RSV) bronchiolitis", "DISEASE", 49, 96], ["respiratory syncytial virus", "ORGANISM", 49, 76], ["RSV", "ORGANISM", 78, 81], ["infants", "ORGANISM", 100, 107], ["infants", "SPECIES", 100, 107], ["respiratory syncytial virus", "SPECIES", 49, 76], ["RSV", "SPECIES", 78, 81], ["severe respiratory syncytial virus (RSV) bronchiolitis in infants", "PROBLEM", 42, 107], ["associated with", "UNCERTAINTY", 26, 41], ["severe", "OBSERVATION_MODIFIER", 42, 48], ["respiratory syncytial virus", "OBSERVATION", 49, 76], ["bronchiolitis", "OBSERVATION", 83, 96]]], ["In this case, altered interaction of the viral fusion (F) protein, implicated as a ligand for TLR4, is regarded as the primary mechanism (Tal et al., 2004; Schroder and Schumann, 2005) .", [["viral fusion (F)", "GENE_OR_GENE_PRODUCT", 41, 57], ["TLR4", "GENE_OR_GENE_PRODUCT", 94, 98], ["viral fusion (F) protein", "PROTEIN", 41, 65], ["TLR4", "PROTEIN", 94, 98], ["the viral fusion", "PROBLEM", 37, 53], ["viral fusion", "OBSERVATION", 41, 53]]], ["However, these TLR4 SNPs could not be correlated with meningococcal disease (Read et al., 2001) .", [["meningococcal disease", "DISEASE", 54, 75], ["TLR4", "GENE_OR_GENE_PRODUCT", 15, 19], ["TLR4", "PROTEIN", 15, 19], ["these TLR4 SNPs", "TREATMENT", 9, 24], ["meningococcal disease", "PROBLEM", 54, 75]]], ["In contrast, rare SNPs were found more commonly in the TLR4 genes of patients with meningococcal disease (Smirnova et al., 2003) .", [["meningococcal disease", "DISEASE", 83, 104], ["TLR4", "GENE_OR_GENE_PRODUCT", 55, 59], ["patients", "ORGANISM", 69, 77], ["TLR4 genes", "DNA", 55, 65], ["patients", "SPECIES", 69, 77], ["rare SNPs", "PROBLEM", 13, 22], ["meningococcal disease", "PROBLEM", 83, 104], ["meningococcal disease", "OBSERVATION", 83, 104]]], ["This supports the notion that rare rather than common variants of TLR4 may be associated with infectious disease susceptibility.Molecular analysis of bacterial ligand-CEACAM1 interactions 339Studies presented here suggest some possible polymorphisms that can increase bacterial load.", [["infectious disease", "DISEASE", 94, 112], ["TLR4", "GENE_OR_GENE_PRODUCT", 66, 70], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 167, 174], ["TLR4", "PROTEIN", 66, 70], ["bacterial ligand", "PROTEIN", 150, 166], ["CEACAM1", "PROTEIN", 167, 174], ["common variants of TLR4", "PROBLEM", 47, 70], ["infectious disease susceptibility", "PROBLEM", 94, 127], ["Molecular analysis", "TEST", 128, 146], ["bacterial ligand", "PROBLEM", 150, 166], ["Studies", "TEST", 191, 198], ["polymorphisms", "PROBLEM", 236, 249], ["bacterial load", "PROBLEM", 268, 282], ["may be associated with", "UNCERTAINTY", 71, 93], ["infectious", "OBSERVATION", 94, 104], ["bacterial ligand", "OBSERVATION", 150, 166], ["suggest some possible", "UNCERTAINTY", 214, 235], ["bacterial load", "OBSERVATION", 268, 282]]], ["Several SNPs in CEACAMs have been identified and are listed in the NCBI SNP database and three have been identified in the N-domain of CEACAM1 including one at Gln-89.", [["SNP", "CHEMICAL", 72, 75], ["Gln-89", "CHEMICAL", 160, 166], ["Gln", "CHEMICAL", 160, 163], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 16, 23], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 135, 142], ["Gln-89", "GENE_OR_GENE_PRODUCT", 160, 166], ["CEACAMs", "DNA", 16, 23], ["NCBI SNP database", "DNA", 67, 84], ["N-domain", "PROTEIN", 123, 131], ["CEACAM1", "PROTEIN", 135, 142], ["Several SNPs in CEACAMs", "PROBLEM", 0, 23], ["CEACAM1", "TEST", 135, 142], ["Gln", "TEST", 160, 163]]], ["In this case, a Gln-89 to His substitution is observed.", [["Gln-89", "CHEMICAL", 16, 22], ["Gln-89", "CHEMICAL", 16, 22], ["His", "CHEMICAL", 26, 29], ["Gln-89", "SIMPLE_CHEMICAL", 16, 22], ["His", "AMINO_ACID", 26, 29], ["a Gln", "TEST", 14, 19], ["His substitution", "TREATMENT", 26, 42]]], ["Such a residue difference occurs within the members of CEACAM family.", [["CEACAM", "GENE_OR_GENE_PRODUCT", 55, 61], ["CEACAM family", "PROTEIN", 55, 68], ["a residue difference", "PROBLEM", 5, 25], ["residue difference", "OBSERVATION", 7, 25]]], ["For example, CEA contains H at position 89 (Fig. 2) .", [["H", "CHEMICAL", 26, 27], ["CEA", "GENE_OR_GENE_PRODUCT", 13, 16], ["CEA", "PROTEIN", 13, 16], ["CEA", "TEST", 13, 16], ["CEA", "OBSERVATION", 13, 16]]], ["This is the only major difference between CC1 and CEA that could affect bacterial binding (Fig. 2) .", [["CC1", "GENE_OR_GENE_PRODUCT", 42, 45], ["CEA", "GENE_OR_GENE_PRODUCT", 50, 53], ["CC1", "PROTEIN", 42, 45], ["CEA", "PROTEIN", 50, 53], ["bacterial binding", "PROBLEM", 72, 89], ["CEA", "ANATOMY", 50, 53], ["bacterial binding", "OBSERVATION", 72, 89]]], ["As such, the mutation Q89H in CC1 would be expected to produce CEA-like binding pattern and could affect tropism of the bacteria as observed for CEA (Virji et al., 1999; de Jonge et al., 2003) .", [["CC1", "GENE_OR_GENE_PRODUCT", 30, 33], ["CEA", "GENE_OR_GENE_PRODUCT", 63, 66], ["CEA", "GENE_OR_GENE_PRODUCT", 145, 148], ["Q89H", "DNA", 22, 26], ["CC1", "PROTEIN", 30, 33], ["CEA", "PROTEIN", 63, 66], ["CEA", "PROTEIN", 145, 148], ["CEA", "TEST", 63, 66], ["the bacteria", "PROBLEM", 116, 128], ["CEA", "TEST", 145, 148], ["CEA", "OBSERVATION", 63, 66]]], ["Further studies are required to assess whether other CEACAM polymorphisms, for example, substitutions such as Y34F and Q89N occur in human Molecular analysis of bacterial ligand-CEACAM1 interactions 341 populations and their frequencies in susceptible populations.", [["CEACAM", "GENE_OR_GENE_PRODUCT", 53, 59], ["Y34F", "GENE_OR_GENE_PRODUCT", 110, 114], ["human", "ORGANISM", 133, 138], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 178, 185], ["CEACAM polymorphisms", "DNA", 53, 73], ["bacterial ligand", "PROTEIN", 161, 177], ["CEACAM1", "PROTEIN", 178, 185], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["Further studies", "TEST", 0, 15], ["other CEACAM polymorphisms", "PROBLEM", 47, 73], ["substitutions", "PROBLEM", 88, 101], ["bacterial ligand", "PROBLEM", 161, 177], ["CEACAM1 interactions", "PROBLEM", 178, 198]]], ["SNP substitutions may also change the colonization profile of the nasopharynx, because in our competition studies we could demonstrate that increased binding afforded by Q89N to Hi-aeg isolate Ha3 increases the binding of Ha3 such that it out-competes Nm isolate C751OpaB in an in vitro competition assay for this receptor.", [["nasopharynx", "ANATOMY", 66, 77], ["SNP", "CHEMICAL", 0, 3], ["Ha3", "CHEMICAL", 193, 196], ["SNP", "CHEMICAL", 0, 3], ["nasopharynx", "ORGAN", 66, 77], ["Ha3", "GENE_OR_GENE_PRODUCT", 193, 196], ["Ha3", "GENE_OR_GENE_PRODUCT", 222, 225], ["Ha3", "PROTEIN", 222, 225], ["C751OpaB", "PROTEIN", 263, 271], ["SNP substitutions", "TREATMENT", 0, 17], ["our competition studies", "TEST", 90, 113], ["increased binding", "PROBLEM", 140, 157], ["nasopharynx", "ANATOMY", 66, 77]]], ["The situation with the native receptor was the reverse.", [["native receptor", "PROTEIN", 23, 38]]], ["As shown in Figs 8 and 9, additional factors that affect bacterial binding to cell-expressed receptor include receptor density.", [["cell", "ANATOMY", 78, 82], ["cell", "CELL", 78, 82], ["bacterial binding", "PROBLEM", 57, 74], ["receptor density", "OBSERVATION", 110, 126]]], ["Whilst certain residue substitutions, e.g. I91A, reduce functional affinity of bacterial interactions, high receptor densities increase such affinity.", [["certain residue substitutions", "PROBLEM", 7, 36], ["bacterial interactions", "PROBLEM", 79, 101], ["high receptor densities", "PROBLEM", 103, 126], ["residue substitutions", "OBSERVATION", 15, 36]]], ["In recent studies, the role of receptor density on enhancement of bacterial attachment and invasion have been evaluated in detail (Bradley et al., 2005; Rowe et al., 2006) .", [["recent studies", "TEST", 3, 17], ["bacterial attachment", "PROBLEM", 66, 86], ["invasion", "PROBLEM", 91, 99], ["receptor density", "OBSERVATION", 31, 47], ["bacterial attachment", "OBSERVATION", 66, 86], ["invasion", "OBSERVATION", 91, 99]]], ["It would be interesting to analyse bacterial invasion in cell lines expressing variant CEACAM1 carrying the above mutations by employing cell lines in which the receptor expression levels can be controlled, which are under development.Molecular analysis of bacterial ligand-CEACAM1 interactions 339Besides receptor polymorphisms, several other scenarios may lead to increased bacterial ligand binding to CEACAMs.", [["cell lines", "ANATOMY", 57, 67], ["cell lines", "ANATOMY", 137, 147], ["cell lines", "CELL", 57, 67], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 87, 94], ["cell lines", "CELL", 137, 147], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 274, 281], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 404, 411], ["cell lines", "CELL_LINE", 57, 67], ["CEACAM1", "PROTEIN", 87, 94], ["cell lines", "CELL_LINE", 137, 147], ["bacterial ligand", "PROTEIN", 257, 273], ["CEACAM1", "PROTEIN", 274, 281], ["CEACAMs", "PROTEIN", 404, 411], ["bacterial invasion", "PROBLEM", 35, 53], ["cell lines", "TREATMENT", 57, 67], ["the above mutations", "TREATMENT", 104, 123], ["employing cell lines", "TREATMENT", 127, 147], ["the receptor expression levels", "TEST", 157, 187], ["Molecular analysis", "TEST", 235, 253], ["bacterial ligand", "PROBLEM", 257, 273], ["receptor polymorphisms", "PROBLEM", 306, 328], ["several other scenarios", "PROBLEM", 330, 353], ["increased bacterial ligand binding", "PROBLEM", 366, 400], ["bacterial", "OBSERVATION_MODIFIER", 35, 44], ["invasion", "OBSERVATION", 45, 53], ["cell lines", "OBSERVATION", 57, 67], ["cell lines", "OBSERVATION", 137, 147], ["bacterial ligand", "OBSERVATION", 257, 273], ["receptor polymorphisms", "OBSERVATION", 306, 328], ["increased", "OBSERVATION_MODIFIER", 366, 375], ["bacterial ligand binding", "OBSERVATION", 376, 400]]], ["Both Nm and Hi CEACAM-binding ligands (Opa and P5) are known to undergo antigenic variation.", [["Hi CEACAM-binding ligands", "GENE_OR_GENE_PRODUCT", 12, 37], ["Opa", "GENE_OR_GENE_PRODUCT", 39, 42], ["P5", "GENE_OR_GENE_PRODUCT", 47, 49], ["CEACAM", "PROTEIN", 15, 21], ["Opa", "PROTEIN", 39, 42], ["P5", "PROTEIN", 47, 49], ["Hi CEACAM-binding ligands (Opa and P5", "TREATMENT", 12, 49], ["Nm", "OBSERVATION_MODIFIER", 5, 7], ["antigenic variation", "OBSERVATION", 72, 91]]], ["Thus, in any population, antigenic/structural variants are present and may be selected for during the course of host colonization and subsequent pathogenesis (Virji et al., 1996a; Duim et al., 1997; Meyers et al., 2003) .", [["antigenic/structural variants", "PROBLEM", 25, 54], ["host colonization", "TREATMENT", 112, 129], ["structural variants", "OBSERVATION", 35, 54]]], ["The receptor repertoire and subtypes may select bacteria capable of binding with high affinity.", [["bacteria", "PROBLEM", 48, 56], ["high affinity", "PROBLEM", 81, 94], ["high affinity", "OBSERVATION", 81, 94]]], ["As mentioned above, upregulation of receptor expression on target cells may also increase bacterial binding affinity.", [["cells", "ANATOMY", 66, 71], ["cells", "CELL", 66, 71], ["target cells", "CELL_TYPE", 59, 71], ["receptor expression on target cells", "TREATMENT", 36, 71], ["bacterial binding affinity", "PROBLEM", 90, 116], ["bacterial binding affinity", "OBSERVATION", 90, 116]]], ["In such cases, high affinity interactions result in cellular invasion, whereas lower affinity or load of bacteria may not proceed beyond surface adhesion (Tran Van Nhieu and Isberg, 1993; Bradley et al., 2005) .", [["cellular", "ANATOMY", 52, 60], ["surface", "ANATOMY", 137, 144], ["cellular", "CELL", 52, 60], ["high affinity interactions", "PROBLEM", 15, 41], ["cellular invasion", "PROBLEM", 52, 69], ["lower affinity", "PROBLEM", 79, 93], ["bacteria", "PROBLEM", 105, 113], ["high affinity", "OBSERVATION_MODIFIER", 15, 28], ["cellular invasion", "OBSERVATION", 52, 69]]], ["The expression of CEACAMs on normal epithelia of the respiratory tract has been reported, which would allow bacterial attachment and possible subsequent penetration into these tissues (Tsutsumi et al., 1990; Virji, 2001) .", [["epithelia", "ANATOMY", 36, 45], ["respiratory tract", "ANATOMY", 53, 70], ["tissues", "ANATOMY", 176, 183], ["CEACAMs", "GENE_OR_GENE_PRODUCT", 18, 25], ["normal epithelia", "TISSUE", 29, 45], ["respiratory tract", "ORGANISM_SUBDIVISION", 53, 70], ["tissues", "TISSUE", 176, 183], ["CEACAMs", "PROTEIN", 18, 25], ["CEACAMs", "PROBLEM", 18, 25], ["bacterial attachment", "PROBLEM", 108, 128], ["subsequent penetration into these tissues", "PROBLEM", 142, 183], ["CEACAMs", "OBSERVATION", 18, 25], ["normal", "OBSERVATION", 29, 35], ["epithelia", "ANATOMY_MODIFIER", 36, 45], ["respiratory tract", "ANATOMY", 53, 70]]], ["Following exposure to cytokines such as IFN-g or TNF-a, CEACAM expression by colonic carcinoma cells has been shown to increase (Fahlgren et al., 2003) .", [["colonic carcinoma cells", "ANATOMY", 77, 100], ["colonic carcinoma", "DISEASE", 77, 94], ["IFN-g", "GENE_OR_GENE_PRODUCT", 40, 45], ["TNF", "GENE_OR_GENE_PRODUCT", 49, 52], ["CEACAM", "GENE_OR_GENE_PRODUCT", 56, 62], ["colonic carcinoma cells", "CELL", 77, 100], ["cytokines", "PROTEIN", 22, 31], ["IFN", "PROTEIN", 40, 43], ["TNF", "PROTEIN", 49, 52], ["CEACAM", "PROTEIN", 56, 62], ["colonic carcinoma cells", "CELL_TYPE", 77, 100], ["cytokines", "TREATMENT", 22, 31], ["IFN", "TEST", 40, 43], ["TNF", "PROBLEM", 49, 52], ["a, CEACAM expression", "TREATMENT", 53, 73], ["colonic carcinoma cells", "PROBLEM", 77, 100], ["colonic", "ANATOMY", 77, 84], ["carcinoma", "OBSERVATION", 85, 94], ["increase", "OBSERVATION_MODIFIER", 119, 127]]], ["In addition, certain viral infections have also been shown to upregulate CEACAM1 expression in several epithelial cell lines (Avadhanula et al., 2006) .", [["epithelial cell lines", "ANATOMY", 103, 124], ["viral infections", "DISEASE", 21, 37], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 73, 80], ["epithelial cell lines", "CELL", 103, 124], ["CEACAM1", "PROTEIN", 73, 80], ["epithelial cell lines", "CELL_LINE", 103, 124], ["certain viral infections", "PROBLEM", 13, 37], ["CEACAM1 expression", "TREATMENT", 73, 91], ["several epithelial cell lines", "TREATMENT", 95, 124], ["viral infections", "OBSERVATION", 21, 37], ["CEACAM1 expression", "OBSERVATION", 73, 91], ["several", "OBSERVATION_MODIFIER", 95, 102], ["epithelial cell lines", "OBSERVATION", 103, 124]]], ["Increased cytokine levels following viral infection could lead to increased CEACAM expression and bacterial association with respiratory epithelia and subsequent invasion of deeper tissue by these organisms.", [["respiratory epithelia", "ANATOMY", 125, 146], ["tissue", "ANATOMY", 181, 187], ["viral infection", "DISEASE", 36, 51], ["CEACAM", "GENE_OR_GENE_PRODUCT", 76, 82], ["epithelia", "TISSUE", 137, 146], ["tissue", "TISSUE", 181, 187], ["cytokine", "PROTEIN", 10, 18], ["CEACAM", "PROTEIN", 76, 82], ["Increased cytokine levels", "PROBLEM", 0, 25], ["viral infection", "PROBLEM", 36, 51], ["increased CEACAM expression", "PROBLEM", 66, 93], ["respiratory epithelia", "PROBLEM", 125, 146], ["subsequent invasion of deeper tissue", "PROBLEM", 151, 187], ["these organisms", "PROBLEM", 191, 206], ["cytokine levels", "OBSERVATION", 10, 25], ["viral infection", "OBSERVATION", 36, 51], ["increased", "OBSERVATION_MODIFIER", 66, 75], ["CEACAM expression", "OBSERVATION", 76, 93], ["bacterial", "OBSERVATION_MODIFIER", 98, 107], ["respiratory epithelia", "OBSERVATION", 125, 146], ["invasion", "OBSERVATION_MODIFIER", 162, 170], ["deeper tissue", "OBSERVATION_MODIFIER", 174, 187]]], ["Such a situation may explain the epidemiological association of increased incidence of Nm and Hi infections following certain viral infections (Cartwright et al., 1991; Takala et al., 1993) .Molecular analysis of bacterial ligand-CEACAM1 interactions 339In summary, little is known about why certain people are more susceptible to infection by some of the frequent colonizers of the human nasopharynx.", [["nasopharynx", "ANATOMY", 389, 400], ["infections", "DISEASE", 97, 107], ["viral infections", "DISEASE", 126, 142], ["infection", "DISEASE", 331, 340], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 230, 237], ["people", "ORGANISM", 300, 306], ["human", "ORGANISM", 383, 388], ["nasopharynx", "ORGAN", 389, 400], ["CEACAM1", "PROTEIN", 230, 237], ["people", "SPECIES", 300, 306], ["human", "SPECIES", 383, 388], ["human", "SPECIES", 383, 388], ["Nm", "PROBLEM", 87, 89], ["Hi infections", "PROBLEM", 94, 107], ["certain viral infections", "PROBLEM", 118, 142], ["Molecular analysis", "TEST", 191, 209], ["bacterial ligand", "PROBLEM", 213, 229], ["infection", "PROBLEM", 331, 340], ["the frequent colonizers of the human nasopharynx", "PROBLEM", 352, 400], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["Nm", "OBSERVATION_MODIFIER", 87, 89], ["Hi", "ANATOMY", 94, 96], ["infections", "OBSERVATION", 97, 107], ["bacterial ligand", "OBSERVATION", 213, 229], ["infection", "OBSERVATION", 331, 340], ["frequent", "OBSERVATION_MODIFIER", 356, 364], ["colonizers", "OBSERVATION", 365, 375], ["human", "ANATOMY_MODIFIER", 383, 388], ["nasopharynx", "ANATOMY", 389, 400]]], ["Interestingly, opportunistic pathogens such as Nm and Hi as well as M. catarrhalis (not investigated here) target CEACAM1.", [["M. catarrhalis", "ORGANISM", 68, 82], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 114, 121], ["CEACAM1", "PROTEIN", 114, 121], ["M. catarrhalis", "SPECIES", 68, 82], ["M. catarrhalis", "SPECIES", 68, 82], ["opportunistic pathogens", "PROBLEM", 15, 38], ["Nm", "PROBLEM", 47, 49], ["Hi", "PROBLEM", 54, 56], ["M. catarrhalis", "PROBLEM", 68, 82], ["opportunistic", "OBSERVATION_MODIFIER", 15, 28], ["pathogens", "OBSERVATION", 29, 38], ["catarrhalis", "OBSERVATION", 71, 82]]], ["As specific substitutions such as Y > F and Q > N produce more favourable targets for distinct mucosal isolates, it is possible that occurrence of such receptor polymorphisms in the human population could lead to greater bacterial binding thus increasing the chances of cellular invasion.", [["mucosal", "ANATOMY", 95, 102], ["cellular", "ANATOMY", 270, 278], ["mucosal", "PATHOLOGICAL_FORMATION", 95, 102], ["human", "ORGANISM", 182, 187], ["cellular", "CELL", 270, 278], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 182, 187], ["specific substitutions", "PROBLEM", 3, 25], ["distinct mucosal isolates", "PROBLEM", 86, 111], ["such receptor polymorphisms", "PROBLEM", 147, 174], ["the human population", "PROBLEM", 178, 198], ["greater bacterial binding", "PROBLEM", 213, 238], ["cellular invasion", "PROBLEM", 270, 287], ["greater", "OBSERVATION_MODIFIER", 213, 220], ["bacterial binding", "OBSERVATION", 221, 238], ["cellular invasion", "OBSERVATION", 270, 287]]], ["Given the colonization rate of these organisms (generally > 10% of the population) and the frequency of invasive infection (up to 3:100 000 population), a combination of events may be required to increase host susceptibility.", [["infection", "DISEASE", 113, 122], ["these organisms", "PROBLEM", 31, 46], ["invasive infection", "PROBLEM", 104, 122], ["invasive", "OBSERVATION_MODIFIER", 104, 112], ["infection", "OBSERVATION", 113, 122]]], ["Inflammatory conditions that increase receptor density in populations carrying specific polymorphisms could provide the worst scenario.Molecular modelling of the CEACAM1 N-domainThe sequence of mature human CEACAM1 N-domain was aligned with the corresponding domain of murine CEACAM1, giving a gapless alignment for residues 1-109 with a residue identity of 42%.", [["CEACAM1", "GENE_OR_GENE_PRODUCT", 162, 169], ["human", "ORGANISM", 201, 206], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 207, 214], ["murine", "ORGANISM", 269, 275], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 276, 283], ["CEACAM1 N-domain", "PROTEIN", 162, 178], ["mature human CEACAM1 N-domain", "PROTEIN", 194, 223], ["murine CEACAM1", "PROTEIN", 269, 283], ["human", "SPECIES", 201, 206], ["murine", "SPECIES", 269, 275], ["human", "SPECIES", 201, 206], ["Inflammatory conditions", "PROBLEM", 0, 23], ["receptor density in populations carrying specific polymorphisms", "PROBLEM", 38, 101], ["murine CEACAM1", "TREATMENT", 269, 283], ["a residue identity", "TEST", 336, 354], ["increase", "OBSERVATION_MODIFIER", 29, 37], ["receptor density", "OBSERVATION_MODIFIER", 38, 54], ["murine CEACAM1", "OBSERVATION", 269, 283]]], ["The crystal structure co-ordinates of mouse CEACAM1 (residues 1-109) were taken from the structure file containing domains 1 and 2 (PDB code 1L6Z) and a homology model of human CEACAM1 N-domain was built using standard methods.", [["mouse", "ORGANISM", 38, 43], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 44, 51], ["human", "ORGANISM", 171, 176], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 177, 184], ["mouse CEACAM1", "PROTEIN", 38, 51], ["residues 1-109", "PROTEIN", 53, 67], ["domains 1 and 2", "PROTEIN", 115, 130], ["PDB code 1L6Z", "PROTEIN", 132, 145], ["human CEACAM1 N-domain", "PROTEIN", 171, 193], ["mouse", "SPECIES", 38, 43], ["human", "SPECIES", 171, 176], ["mouse", "SPECIES", 38, 43], ["human", "SPECIES", 171, 176], ["mouse CEACAM1", "TREATMENT", 38, 51], ["human CEACAM1 N", "TREATMENT", 171, 186], ["standard methods", "TREATMENT", 210, 226], ["crystal", "OBSERVATION_MODIFIER", 4, 11], ["mouse CEACAM1", "OBSERVATION", 38, 51]]], ["Final refinement of the model was performed by soaking it with a 5 \u00c5 thick layer of water and energy minimizing while constraining the backbone atoms to their original positions in the template structure.", [["water", "SIMPLE_CHEMICAL", 84, 89], ["a 5 \u00c5 thick layer of water", "TREATMENT", 63, 89], ["template structure", "OBSERVATION", 185, 203]]], ["The final round of minimization was for 2000 conjugate-gradient steps, constraining the backbone heavy atoms with a force constant of 0.5 kcal/\u00c5.", [["2000 conjugate-gradient steps", "TREATMENT", 40, 69]]], ["A stereochemical analysis of the structure was performed using Procheck and found to be of similar quality to the template crystal structure.Generation of NA1B-Fc constructs and proteinsProduction of mutants was carried out by site-directed mutagenesis of the pIG construct containing the DNA encoding the CEACAM1 NA1B domains described previously (Watt et al., 1994) .", [["NA1B-Fc", "GENE_OR_GENE_PRODUCT", 155, 162], ["pIG", "GENE_OR_GENE_PRODUCT", 260, 263], ["DNA", "CELLULAR_COMPONENT", 289, 292], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 306, 313], ["NA1B", "PROTEIN", 155, 159], ["Fc constructs", "DNA", 160, 173], ["pIG construct", "DNA", 260, 273], ["CEACAM1 NA1B domains", "PROTEIN", 306, 326], ["A stereochemical analysis", "TEST", 0, 25], ["Procheck", "TREATMENT", 63, 71], ["NA1B-Fc constructs", "TREATMENT", 155, 173], ["mutants", "PROBLEM", 200, 207], ["the pIG construct", "TREATMENT", 256, 273], ["the DNA", "TREATMENT", 285, 292], ["crystal structure", "OBSERVATION", 123, 140]]], ["The oligonucleotide primers used to create amino acid substitutions at positions 91, 34 and 89 of the N-domain are shown in Table 1 .", [["amino acid", "CHEMICAL", 43, 53], ["amino acid", "CHEMICAL", 43, 53], ["amino acid", "AMINO_ACID", 43, 53], ["N-domain", "PROTEIN", 102, 110], ["The oligonucleotide primers", "TREATMENT", 0, 27], ["amino acid substitutions", "TREATMENT", 43, 67]]], ["Some primer sequences have been published previously (Watt et al., 1994) .", [["primer sequences", "DNA", 5, 21], ["Some primer sequences", "TEST", 0, 21]]], ["For introducing mutations, CEACAM1 was amplified by polymerase chain reaction from the pIG-NA1B construct using either the common forward primer and a reverse primer containing the desired mutation, or a complementary forward primer containing the mutation and a common reverse primer.", [["CEACAM1", "GENE_OR_GENE_PRODUCT", 27, 34], ["pIG-NA1B", "GENE_OR_GENE_PRODUCT", 87, 95], ["CEACAM1", "PROTEIN", 27, 34], ["pIG-NA1B construct", "DNA", 87, 105], ["common forward primer", "DNA", 123, 144], ["reverse primer", "DNA", 151, 165], ["complementary forward primer", "DNA", 204, 232], ["common reverse primer", "DNA", 263, 284], ["introducing mutations", "PROBLEM", 4, 25], ["CEACAM1", "TEST", 27, 34], ["polymerase chain reaction", "PROBLEM", 52, 77], ["the pIG-NA1B construct", "TREATMENT", 83, 105], ["the common forward primer", "PROBLEM", 119, 144], ["a reverse primer", "PROBLEM", 149, 165], ["the desired mutation", "PROBLEM", 177, 197], ["a complementary forward primer", "PROBLEM", 202, 232], ["the mutation", "PROBLEM", 244, 256]]], ["CEACAM1 with the appropriate mutation was amplified using the common forward and common reverse primers.", [["CEACAM1", "GENE_OR_GENE_PRODUCT", 0, 7], ["CEACAM1", "PROTEIN", 0, 7], ["common forward and common reverse primers", "DNA", 62, 103], ["CEACAM1", "TREATMENT", 0, 7], ["the appropriate mutation", "PROBLEM", 13, 37], ["common", "ANATOMY", 81, 87], ["reverse primers", "OBSERVATION", 88, 103]]], ["The gene was then cloned into pIG using the restriction sites HindIII and EcoRI.Generation of NA1B-Fc constructs and proteinsChimeric soluble receptor proteins containing the appropriate amino acid substitutions were prepared as previously described by transient transfection of COS cells (Teixeira et al., 1994; Virji et al., 1999) .", [["COS cells", "ANATOMY", 279, 288], ["amino acid", "CHEMICAL", 187, 197], ["amino acid", "CHEMICAL", 187, 197], ["pIG", "GENE_OR_GENE_PRODUCT", 30, 33], ["HindIII", "GENE_OR_GENE_PRODUCT", 62, 69], ["EcoRI", "GENE_OR_GENE_PRODUCT", 74, 79], ["NA1B-Fc", "GENE_OR_GENE_PRODUCT", 94, 101], ["amino acid", "AMINO_ACID", 187, 197], ["COS cells", "CELL", 279, 288], ["pIG", "DNA", 30, 33], ["restriction sites HindIII", "DNA", 44, 69], ["EcoRI", "DNA", 74, 79], ["NA1B", "PROTEIN", 94, 98], ["Fc constructs", "DNA", 99, 112], ["Chimeric soluble receptor proteins", "PROTEIN", 125, 159], ["COS cells", "CELL_LINE", 279, 288], ["the restriction sites HindIII", "TREATMENT", 40, 69], ["NA1B-Fc constructs", "TREATMENT", 94, 112], ["proteinsChimeric soluble receptor proteins", "TREATMENT", 117, 159], ["the appropriate amino acid substitutions", "PROBLEM", 171, 211], ["Fc constructs", "OBSERVATION", 99, 112], ["acid substitutions", "OBSERVATION", 193, 211]]], ["The CEACAM1-Q89A-Fc used in overlay experiments was kindly donated by Dr S. Watt (Virji et al., 1999; Watt et al., 2001) .Bacterial strains and cell linesThe strains used in this study have been described previously (Virji et al., 1999; .", [["strains", "ANATOMY", 132, 139], ["cell lines", "ANATOMY", 144, 154], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 4, 11], ["Q89A-Fc", "GENE_OR_GENE_PRODUCT", 12, 19], ["cell lines", "CELL", 144, 154], ["CEACAM1", "PROTEIN", 4, 11], ["Q89A", "PROTEIN", 12, 16], ["Fc", "PROTEIN", 17, 19], ["cell lines", "CELL_LINE", 144, 154], ["The CEACAM1", "TEST", 0, 11], ["Bacterial strains", "PROBLEM", 122, 139], ["cell lines", "TREATMENT", 144, 154], ["The strains", "PROBLEM", 154, 165], ["this study", "TEST", 174, 184], ["strains", "OBSERVATION", 132, 139], ["cell lines", "OBSERVATION", 144, 154]]], ["Nm strain C751 (serogroup A) variants used were C751OpaA, C751OpaB and C751OpaD.", [["Nm strain C751", "ORGANISM", 0, 14], ["serogroup A)", "GENE_OR_GENE_PRODUCT", 16, 28], ["C751OpaA", "PROTEIN", 48, 56], ["C751OpaB", "PROTEIN", 58, 66], ["C751OpaD", "PROTEIN", 71, 79], ["Nm strain", "TEST", 0, 9]]], ["The strain MC58 (serogroup B) variant used expressed an Opa previously designated OpaX, which is encoded by the opaB locus.", [["MC58 (serogroup B", "ORGANISM", 11, 28], ["Opa", "GENE_OR_GENE_PRODUCT", 56, 59], ["OpaX", "GENE_OR_GENE_PRODUCT", 82, 86], ["opaB", "GENE_OR_GENE_PRODUCT", 112, 116], ["Opa", "PROTEIN", 56, 59], ["OpaX", "PROTEIN", 82, 86], ["opaB locus", "DNA", 112, 122], ["The strain MC58", "TEST", 0, 15]]], ["Opa -C751 isolate, which has been shown not to bind to CHO-CC1 (Virji, 1999) and RdCC-, a derivative of THi Rd, known not to bind to CHO-CC1 (M. Virji, unpublished) were used as controls.", [["Opa -C751", "CHEMICAL", 0, 9], ["RdCC", "CHEMICAL", 81, 85], ["Opa", "GENE_OR_GENE_PRODUCT", 0, 3], ["RdCC", "SIMPLE_CHEMICAL", 81, 85], ["THi Rd", "ORGANISM", 104, 110], ["Opa", "PROTEIN", 0, 3], ["THi Rd", "PROTEIN", 104, 110], ["CC1", "PROTEIN", 137, 140], ["Opa", "TEST", 0, 3]]], ["THi strain Rd is an acapsulate serotype d isolate, Eagan is serotype b isolate and A950002 is a NTHi strain.", [["Rd", "GENE_OR_GENE_PRODUCT", 11, 13], ["THi strain", "PROBLEM", 0, 10], ["an acapsulate serotype d isolate", "PROBLEM", 17, 49], ["serotype b isolate", "PROBLEM", 60, 78], ["a NTHi strain", "PROBLEM", 94, 107]]], ["Hi-aeg strains Ha3, Ha30 and F2087 are all conjunctiva isolates.", [["conjunctiva", "ANATOMY", 43, 54], ["Ha3", "GENE_OR_GENE_PRODUCT", 15, 18], ["Ha30", "GENE_OR_GENE_PRODUCT", 20, 24], ["F2087", "GENE_OR_GENE_PRODUCT", 29, 34], ["conjunctiva", "ORGAN", 43, 54], ["Ha30", "TEST", 20, 24], ["conjunctiva isolates", "OBSERVATION", 43, 63]]], ["Nm was grown on brainheart infusion (BHI) agar supplemented with 10% heated horse blood (HBHI).", [["blood", "ANATOMY", 82, 87], ["brainheart", "SIMPLE_CHEMICAL", 16, 26], ["horse", "ORGANISM", 76, 81], ["blood", "ORGANISM_SUBSTANCE", 82, 87], ["horse", "SPECIES", 76, 81], ["brainheart infusion", "TREATMENT", 16, 35]]], ["Hi strains were grown on HBHI agar further supplemented with Levinthal base (10 mg ml -1 each of NAD and haemin).", [["NAD", "CHEMICAL", 97, 100], ["NAD", "CHEMICAL", 97, 100], ["haemin", "CHEMICAL", 105, 111], ["NAD", "SIMPLE_CHEMICAL", 97, 100], ["haemin", "SIMPLE_CHEMICAL", 105, 111], ["Hi strains", "PROBLEM", 0, 10], ["HBHI agar", "TREATMENT", 25, 34], ["Levinthal base", "TREATMENT", 61, 75]]], ["All strains were cultured at 37\u00b0C in 5% CO2.Bacterial strains and cell linesCOS-1 cells (African green monkey kidney cells) used for transient transfection were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 2-10% heat-inactivated Foetal Calf Serum (FCS, Gibco\u2122), 2 mM glutamine, 50 mg ml -1 penicillin and 50 mg ml -1 streptomycin in a humidified atmosphere of 5% CO2 at 37\u00b0C.ImmunoblottingAntibody binding to CEACAM1 constructs.", [["strains", "ANATOMY", 54, 61], ["cell linesCOS-1 cells", "ANATOMY", 66, 87], ["kidney cells", "ANATOMY", 110, 122], ["CO2", "CHEMICAL", 40, 43], ["glutamine", "CHEMICAL", 287, 296], ["penicillin", "CHEMICAL", 310, 320], ["streptomycin", "CHEMICAL", 337, 349], ["CO2", "CHEMICAL", 383, 386], ["CO2", "CHEMICAL", 40, 43], ["glutamine", "CHEMICAL", 287, 296], ["penicillin", "CHEMICAL", 310, 320], ["streptomycin", "CHEMICAL", 337, 349], ["CO2", "CHEMICAL", 383, 386], ["CO2", "SIMPLE_CHEMICAL", 40, 43], ["cell linesCOS-1 cells", "CELL", 66, 87], ["African green monkey kidney cells", "CELL", 89, 122], ["Foetal", "ORGANISM", 249, 255], ["Calf", "ORGANISM", 256, 260], ["Serum", "ORGANISM_SUBSTANCE", 261, 266], ["FCS", "ORGANISM_SUBSTANCE", 268, 271], ["Gibco\u2122", "SIMPLE_CHEMICAL", 273, 279], ["glutamine", "AMINO_ACID", 287, 296], ["penicillin", "SIMPLE_CHEMICAL", 310, 320], ["streptomycin", "SIMPLE_CHEMICAL", 337, 349], ["CO2", "SIMPLE_CHEMICAL", 383, 386], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 429, 436], ["cell linesCOS-1 cells", "CELL_LINE", 66, 87], ["African green monkey kidney cells", "CELL_TYPE", 89, 122], ["CEACAM1 constructs", "DNA", 429, 447], ["green monkey", "SPECIES", 97, 109], ["African green monkey", "SPECIES", 89, 109], ["All strains", "PROBLEM", 0, 11], ["Bacterial strains", "PROBLEM", 44, 61], ["cell linesCOS", "TEST", 66, 79], ["African green monkey kidney cells", "TREATMENT", 89, 122], ["transient transfection", "PROBLEM", 133, 155], ["Dulbecco", "TEST", 173, 181], ["Foetal Calf Serum", "TEST", 249, 266], ["FCS", "TEST", 268, 271], ["Gibco\u2122", "TEST", 273, 279], ["2 mM glutamine", "TREATMENT", 282, 296], ["penicillin", "TREATMENT", 310, 320], ["streptomycin", "TREATMENT", 337, 349], ["a humidified atmosphere", "TREATMENT", 353, 376], ["ImmunoblottingAntibody binding to CEACAM1 constructs", "PROBLEM", 395, 447], ["strains", "OBSERVATION", 54, 61], ["cell linesCOS", "OBSERVATION", 66, 79], ["Foetal Calf", "ANATOMY", 249, 260], ["CEACAM1 constructs", "OBSERVATION", 429, 447]]], ["NA1B-Fc proteins were dotted at 0.2 mg ml -1 on to nitrocellulose and non-specific binding sites blocked using 3% (w/v) BSA in Dulbecco's PBS containing 0.05% Tween-20 (PBST) for 1 h at room temperature.", [["BSA", "CHEMICAL", 120, 123], ["Tween-20", "CHEMICAL", 159, 167], ["nitrocellulose", "CHEMICAL", 51, 65], ["Tween-20", "CHEMICAL", 159, 167], ["NA1B-Fc", "GENE_OR_GENE_PRODUCT", 0, 7], ["/v) BSA", "SIMPLE_CHEMICAL", 116, 123], ["Tween-20", "SIMPLE_CHEMICAL", 159, 167], ["NA1B", "PROTEIN", 0, 4], ["Fc proteins", "PROTEIN", 5, 16], ["NA1B", "TEST", 0, 4], ["Fc proteins", "TEST", 5, 16], ["nitrocellulose", "TREATMENT", 51, 65], ["non-specific binding sites", "PROBLEM", 70, 96], ["BSA", "TEST", 120, 123], ["Dulbecco's PBS", "TREATMENT", 127, 141]]], ["Receptor was detected using the following antibodies, rabbit polyclonal AO115, rat monoclonal YTH71.3 both directed against the N-domain and mouse monoclonal Kat4c which recognizes the A and B domains (Jones et al., 1995) .", [["rabbit", "ORGANISM", 54, 60], ["AO115", "GENE_OR_GENE_PRODUCT", 72, 77], ["rat", "ORGANISM", 79, 82], ["YTH71.3", "GENE_OR_GENE_PRODUCT", 94, 101], ["mouse", "ORGANISM", 141, 146], ["Kat4c", "GENE_OR_GENE_PRODUCT", 158, 163], ["rabbit polyclonal AO115", "PROTEIN", 54, 77], ["rat monoclonal YTH71.3", "PROTEIN", 79, 101], ["N-domain", "PROTEIN", 128, 136], ["mouse monoclonal Kat4c", "PROTEIN", 141, 163], ["A and B domains", "PROTEIN", 185, 200], ["rabbit", "SPECIES", 54, 60], ["rat", "SPECIES", 79, 82], ["mouse", "SPECIES", 141, 146], ["rabbit", "SPECIES", 54, 60], ["rat", "SPECIES", 79, 82], ["mouse", "SPECIES", 141, 146], ["the following antibodies", "TEST", 28, 52], ["rabbit polyclonal AO115", "TEST", 54, 77], ["rat monoclonal YTH71.3", "TEST", 79, 101], ["the N-domain", "TREATMENT", 124, 136], ["mouse monoclonal Kat4c", "TREATMENT", 141, 163]]], ["Bound antibody was subsequently detected using an appropriate secondary antibody conjugated to alkaline phosphatase and developed using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate.ImmunoblottingBacterial interactions with receptor constructs.", [["nitroblue tetrazolium", "CHEMICAL", 136, 157], ["5-bromo-4-chloro-3-indolylphosphate", "CHEMICAL", 162, 197], ["nitroblue tetrazolium", "CHEMICAL", 136, 157], ["5-bromo-4-chloro-3-indolylphosphate", "CHEMICAL", 162, 197], ["nitroblue tetrazolium", "SIMPLE_CHEMICAL", 136, 157], ["5-bromo-4-chloro-3-indolylphosphate", "SIMPLE_CHEMICAL", 162, 197], ["Bound antibody", "PROTEIN", 0, 14], ["secondary antibody", "PROTEIN", 62, 80], ["alkaline phosphatase", "PROTEIN", 95, 115], ["Bound antibody", "TEST", 0, 14], ["an appropriate secondary antibody", "TEST", 47, 80], ["alkaline phosphatase", "TEST", 95, 115], ["nitroblue tetrazolium", "TREATMENT", 136, 157], ["bromo", "TREATMENT", 164, 169], ["chloro", "TREATMENT", 172, 178], ["indolylphosphate", "TREATMENT", 181, 197], ["ImmunoblottingBacterial interactions with receptor constructs", "PROBLEM", 198, 259]]], ["Bacterial lysates (c.", [["lysates", "ANATOMY", 10, 17], ["Bacterial lysates", "ORGANISM_SUBSTANCE", 0, 17], ["Bacterial lysates (c.", "PROBLEM", 0, 21], ["lysates", "OBSERVATION", 10, 17]]], ["2 \u00a5 10 7 bacteria) were applied to nitrocellulose strips, air-dried and non-specific binding sites blocked using 3% BSA in PBST for 1 h at room temperature.", [["BSA", "CHEMICAL", 116, 119], ["nitrocellulose", "CHEMICAL", 35, 49], ["BSA", "SIMPLE_CHEMICAL", 116, 119], ["nitrocellulose strips", "TREATMENT", 35, 56], ["non-specific binding sites", "PROBLEM", 72, 98], ["3% BSA in PBST", "TREATMENT", 113, 127]]], ["Strips were overlaid with either native or mutated soluble NA1B-Fc diluted in 1% BSA in PBST at required concentrations for 1 h at room temperature.", [["BSA", "CHEMICAL", 81, 84], ["NA1B-Fc", "GENE_OR_GENE_PRODUCT", 59, 66], ["BSA", "SIMPLE_CHEMICAL", 81, 84], ["NA1B", "PROTEIN", 59, 63], ["Fc", "PROTEIN", 64, 66], ["Strips", "TREATMENT", 0, 6]]], ["In most experiments, excess (1-3 mg ml -1 ) of the receptor was used.", [["the receptor", "TREATMENT", 47, 59]]], ["In competition studies, a range of concentrations (0.008-0.5 mg ml -1 ) was employed.", [["competition studies", "TEST", 3, 22], ["a range of concentrations", "TREATMENT", 24, 49]]], ["Following washing to remove unbound NA1B-Fc, receptor binding was detected using anti-human-Fc alkaline phosphatase conjugate and substrates as described above.", [["NA1B-Fc", "GENE_OR_GENE_PRODUCT", 36, 43], ["NA1B", "PROTEIN", 36, 40], ["Fc", "PROTEIN", 41, 43], ["anti-human-Fc alkaline phosphatase conjugate", "PROTEIN", 81, 125], ["unbound NA1B", "TEST", 28, 40], ["anti-human-Fc alkaline phosphatase conjugate", "TREATMENT", 81, 125]]], ["For quantification, densitometric analyses of the developed immunoblots were carried out using NIH Scion Image software.", [["quantification", "TEST", 4, 18], ["densitometric analyses", "TEST", 20, 42], ["the developed immunoblots", "PROBLEM", 46, 71]]], ["In most cases, multiple estimations were carried out and means and SE of each determination have been reported.Site directed mutagenesis in the N-domain of CEACAM1-4L and transient transfection of COS cellsSite directed mutagenesis of CEACAM1-4L receptor gene was performed using the QuickChange\u00ae Site Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions.", [["COS cells", "ANATOMY", 197, 206], ["CEACAM1-4L", "GENE_OR_GENE_PRODUCT", 156, 166], ["COS cells", "CELL", 197, 206], ["CEACAM1-4L receptor", "GENE_OR_GENE_PRODUCT", 235, 254], ["N-domain", "PROTEIN", 144, 152], ["CEACAM1", "PROTEIN", 156, 163], ["4L", "PROTEIN", 164, 166], ["COS cells", "CELL_LINE", 197, 206], ["CEACAM1-4L receptor gene", "DNA", 235, 259], ["multiple estimations", "TEST", 15, 35], ["Site directed mutagenesis", "PROBLEM", 111, 136], ["CEACAM1", "TEST", 156, 163], ["transient transfection of COS cells", "TREATMENT", 171, 206], ["CEACAM1", "TEST", 235, 242], ["4L receptor gene", "TREATMENT", 243, 259], ["the QuickChange\u00ae Site", "TREATMENT", 280, 301], ["CEACAM1", "OBSERVATION", 156, 163], ["COS cells", "OBSERVATION", 197, 206]]], ["Primers (Table 1) were used to introduce the desired mutations into the pRc/CMV-CEACAM1-4L construct (kindly provided by Professor Wolfgang Zimmermann).", [["pRc", "GENE_OR_GENE_PRODUCT", 72, 75], ["CMV", "ORGANISM", 76, 79], ["CEACAM1-4L", "GENE_OR_GENE_PRODUCT", 80, 90], ["pRc/CMV-CEACAM1-4L construct", "DNA", 72, 100], ["the desired mutations", "TREATMENT", 41, 62], ["the pRc/CMV", "TREATMENT", 68, 79]]], ["Following sequencing to ensure the desired substitution had been obtained, the pRc/CMV-CEACAM1-4L construct was transiently transfected into COS-1 cells for functional analysis using DEAE dextran method described previously (Teixeira et al., 1994; Virji et al., 1996a) .", [["COS-1 cells", "ANATOMY", 141, 152], ["dextran", "CHEMICAL", 188, 195], ["pRc", "GENE_OR_GENE_PRODUCT", 79, 82], ["CMV", "ORGANISM", 83, 86], ["CEACAM1-4L", "GENE_OR_GENE_PRODUCT", 87, 97], ["COS-1 cells", "CELL", 141, 152], ["dextran", "SIMPLE_CHEMICAL", 188, 195], ["pRc/CMV-CEACAM1-4L construct", "DNA", 79, 107], ["COS-1 cells", "CELL_LINE", 141, 152], ["the pRc/CMV", "TEST", 75, 86], ["CEACAM1", "TEST", 87, 94], ["4L construct", "TREATMENT", 95, 107], ["functional analysis", "TEST", 157, 176], ["DEAE dextran method", "TREATMENT", 183, 202]]]], "8195508e6a8c844e0c8863cec82020b0d27ee263": [["IntroductionThe coronavirus disease 2019 pandemic originated in December 2019 in the city of Wuhan, China, spreading across the globe and causing millions of cases and hundreds of thousands of deaths within a few months [1, 2] .", [["coronavirus disease", "DISEASE", 16, 35], ["deaths", "DISEASE", 193, 199], ["coronavirus", "ORGANISM", 16, 27], ["The coronavirus disease", "PROBLEM", 12, 35], ["pandemic", "PROBLEM", 41, 49], ["coronavirus disease", "OBSERVATION", 16, 35], ["globe", "ANATOMY", 128, 133]]], ["As the world braces for likely further pandemic waves in late 2020, disease surveillance is crucial in order to monitor the situation and guide public health action.", [["the world braces", "TREATMENT", 3, 19], ["further pandemic waves", "PROBLEM", 31, 53], ["disease surveillance", "TEST", 68, 88]]], ["An essential component of COVID- 19 surveillance is estimation of the time-varying effective reproduction number Rt, defined as the average number of secondary cases at time t produced by an infected individual over his/her infectious period.", [["COVID", "TEST", 26, 31], ["essential", "OBSERVATION_MODIFIER", 3, 12], ["component", "OBSERVATION_MODIFIER", 13, 22], ["infected", "OBSERVATION", 191, 199], ["infectious", "OBSERVATION", 224, 234]]], ["Rt reflects the real-world transmissibility of a pathogen, and is affected by the mobility patterns, social mixing, control measures, population immunity and other factors that are prevalent at each point in time.", [["a pathogen", "PROBLEM", 47, 57], ["social mixing, control measures", "TREATMENT", 101, 132], ["pathogen", "OBSERVATION", 49, 57], ["mobility", "OBSERVATION", 82, 90]]], ["Rt>1Introductionindicates exponential growth, Rt=1 indicates sustained transmission and Rt<1 suggests exponential decay of an epidemic.IntroductionVarious methods to estimate Rt have been described in the literature [3] [4] [5] ; we present an improvement that addresses the inherent limitations of surveillance data, such as incompleteness and reporting delays, allowing for almost real-time estimation of epidemic trends.", [["an epidemic", "PROBLEM", 123, 134], ["IntroductionVarious methods", "TREATMENT", 135, 162], ["surveillance data", "TEST", 299, 316], ["growth", "OBSERVATION_MODIFIER", 38, 44], ["epidemic", "OBSERVATION", 126, 134]]], ["We apply our method in the case of the COVID-19 pandemic in Greece, and examine how transmissibility of the SARS-CoV-2 virus has varied over time and in relation to control measures, population mobility and ambient temperature.Estimation of the effective reproduction number RtOur way of estimating Rt extends the methods by Cori et al [3] , implemented in a Bayesian framework.", [["SARS", "DISEASE", 108, 112], ["SARS-CoV-2 virus", "ORGANISM", 108, 124], ["CoV-2 virus", "SPECIES", 113, 124], ["SARS-CoV-2 virus", "SPECIES", 108, 124], ["the SARS", "PROBLEM", 104, 112], ["CoV-2 virus", "PROBLEM", 113, 124], ["ambient temperature", "TEST", 207, 226]]], ["In brief, Rt is estimated as the ratio of new locally-acquired infections at time t, to the sum of already infected individuals (local or imported) weighted by an infectivity function ws that is approximated by the serial interval distribution [3, 6] .", [["infections", "DISEASE", 63, 73], ["acquired infections", "PROBLEM", 54, 73], ["already infected individuals", "PROBLEM", 99, 127], ["an infectivity function", "TEST", 160, 183], ["new", "OBSERVATION_MODIFIER", 42, 45], ["locally", "OBSERVATION_MODIFIER", 46, 53], ["infections", "OBSERVATION", 63, 73], ["infected", "OBSERVATION", 107, 115]]], ["We parametrically model the serial interval with a Gamma distribution, with userprovided mean and standard deviation (SD); a range can be specified for both parameters, from which values are randomly drawn, to include additional uncertainty in the serial interval estimates.", [["standard deviation (SD)", "PROBLEM", 98, 121], ["Gamma distribution", "OBSERVATION", 51, 69]]], ["As in the original method, in order to reduce noise in the Rt estimates a rolling time window can be specified over which transmission is assumed constant; this is often set at 7 days.Estimation of the effective reproduction number RtAs dates of symptom onset are often partially missing in real-world surveillance data, we use the subset of observed durations between symptom onset and case ascertainment, assumed to also follow a Gamma distribution, to perform Bayesian imputation of any unknown symptom onset dates.", [["noise", "PROBLEM", 46, 51], ["a rolling time window", "TREATMENT", 72, 93], ["symptom", "PROBLEM", 246, 253], ["effective", "OBSERVATION_MODIFIER", 202, 211]]], ["This includes asymptomatic cases, for whom we impute an onset date assuming similar duration between infection and case detection as symptomatic cases.", [["infection", "DISEASE", 101, 110], ["infection", "PROBLEM", 101, 110], ["symptomatic cases", "PROBLEM", 133, 150]]], ["In similar fashion, we use a Gamma distribution for the incubation time (again with user-provided mean and SD) to impute infection times for all cases.", [["infection", "DISEASE", 121, 130], ["infection", "PROBLEM", 121, 130], ["infection", "OBSERVATION", 121, 130]]], ["Whereas using symptom onset dates results in exact but time-lagging estimates of Rt [3] , using infection times produces time-accurate estimates, which are necessary in order to assess the effectiveness of control measures and other factors that potentially affect transmission. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintEstimation of the effective reproduction number RtThe copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.", [["infection", "DISEASE", 96, 105], ["infection", "PROBLEM", 96, 105], ["control measures", "TREATMENT", 206, 222], ["med", "ANATOMY", 317, 320]]], ["19.20198028 doi: medRxiv preprint Bayesian imputation of infection times incorporates the appropriate uncertainty in the underlying epidemic curve of infections, reflecting the full range of curves that are compatible with the observed data.", [["infection", "DISEASE", 57, 66], ["infections", "DISEASE", 150, 160], ["medRxiv", "TREATMENT", 17, 24], ["infection", "PROBLEM", 57, 66], ["infections", "PROBLEM", 150, 160], ["infection", "OBSERVATION", 57, 66], ["infections", "OBSERVATION", 150, 160]]], ["At the same time this smoothens out both the epidemic curve and the resulting Rt estimates, making it harder to detect abrupt changes in transmissibility and their possible relation to control measures [7] .", [["abrupt changes in transmissibility", "PROBLEM", 119, 153]]], ["Although a degree of smoothing is desirable, if this is deemed excessive, a shorter rolling time window can be used.Estimation of the effective reproduction number RtDelays in case diagnosis and reporting (case ascertainment) will result in right-truncation, i.e. artificially low infection counts for later days in the time series, biasing recent Rt estimates downwards.", [["infection", "DISEASE", 281, 290], ["a shorter rolling time window", "TREATMENT", 74, 103], ["right-truncation", "PROBLEM", 241, 257], ["artificially low infection counts", "PROBLEM", 264, 297], ["degree", "OBSERVATION_MODIFIER", 11, 17], ["smoothing", "OBSERVATION", 21, 30], ["effective", "OBSERVATION_MODIFIER", 134, 143], ["right", "ANATOMY_MODIFIER", 241, 246], ["low", "OBSERVATION_MODIFIER", 277, 280], ["infection", "OBSERVATION", 281, 290]]], ["Our approach was to divide the later counts by the cumulative probability of ascertainment, as given by the distribution of the duration between infection and ascertainment.", [["infection", "DISEASE", 145, 154], ["infection", "PROBLEM", 145, 154], ["infection", "OBSERVATION", 145, 154]]], ["This simple method has the advantage of not requiring additional historical or other data, compared to more elaborate methods.", [["other data", "TEST", 79, 89]]], ["As an alternative we used a \"data augmentation\" approach, whereby future cases were added in the dataset based on the reporting rate of the previous week.", [["a \"data augmentation\" approach", "TREATMENT", 26, 56]]], ["A comparison of the two approaches is included in the online supplement (Supplementary Figure 1 ).Estimation of the effective reproduction number RtThe overall model is run using Markov Chain Monte Carlo (MCMC) in JAGS [10] .", [["Markov Chain Monte Carlo (MCMC)", "TREATMENT", 179, 210], ["effective", "OBSERVATION_MODIFIER", 116, 125]]], ["In addition, the dates of ascertainment and the mean and SD of the incubation period can be specified for optimal inference.Data sources and analysisWe applied our method for estimating Rt on national-level COVID-19 surveillance data collected in Greece by the National Public Health Organization (NPHO) from 26 February (when the first case was identified) to 3 August 2020.", [["ascertainment", "TEST", 26, 39], ["surveillance data", "TEST", 216, 233]]], ["All cases were laboratory-confirmed with RT-PCR testing, and were considered imported if they had arrived in Greece in the last 3 days before a swab was obtained.", [["RT-PCR testing", "TEST", 41, 55], ["a swab", "TEST", 142, 148]]], ["A 7-day rolling time window was used for Rt estimation.", [["A 7-day rolling time window", "TREATMENT", 0, 27], ["Rt estimation", "TEST", 41, 54]]], ["Sensitivity analyses were undertaken with shorter time windows, as well as with the subsets of hospitalized cases and severe cases (defined as hospitalized in intensive care or dead).", [["Sensitivity analyses", "TEST", 0, 20], ["severe cases", "PROBLEM", 118, 130]]], ["Dates when major control measures were implemented (or relaxed) were overlaid on the resulting time series of Rt estimates, in order to assess their effects on COVID-19Data sources and analysistransmissibility.Data sources and analysisIn addition, we sought to examine the association between population mobility, ambient temperature and Rt during the study period.", [["Rt estimates", "TEST", 110, 122], ["COVID", "TEST", 160, 165], ["ambient temperature", "TREATMENT", 314, 333], ["the study", "TEST", 348, 357]]], ["CC-BY 4.0 International license It is made available under a perpetuity.Data sources and analysisis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintData sources and analysisThe copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.19.20198028 doi: medRxiv preprint relative mobility measure (compared to the baseline period of 3 January to 6 February 2020).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["analysis", "TEST", 246, 254], ["medRxiv", "TREATMENT", 375, 382], ["med", "ANATOMY", 135, 138], ["mobility", "OBSERVATION_MODIFIER", 401, 409]]], ["As a sensitivity analysis we omitted \"parks\" from the mobility measure, as it comprises mostly outdoors activities.", [["a sensitivity analysis", "TEST", 3, 25]]], ["Then, given the 7-day rolling window, we fitted a linear regression of the logRt estimates on the 7-day moving averages of mobility and temperature.", [["the 7-day rolling window", "TREATMENT", 12, 36]]], ["To incorporate the uncertainty of the dependent variable (Rt), we ran the regressions separately on each Rt series obtained in each MCMC iteration and combined the regression coefficients using Rubin's rules [17] .", [["the dependent variable (Rt)", "PROBLEM", 34, 61], ["each Rt series", "TEST", 100, 114], ["the regression coefficients", "PROBLEM", 160, 187], ["Rubin's rules", "TEST", 194, 207], ["dependent", "OBSERVATION_MODIFIER", 38, 47], ["variable", "OBSERVATION_MODIFIER", 48, 56]]], ["Alternative specifications of this regression were explored as sensitivity analyses.", [["this regression", "PROBLEM", 30, 45], ["sensitivity analyses", "TEST", 63, 83]]], ["All analyses were undertaken in the R software environment, version 4.0.2 [18] .ResultsUntil 3 August 2020 a total of 4,737 COVID-19 cases had been reported in Greece.", [["All analyses", "TEST", 0, 12], ["COVID", "TEST", 124, 129]]], ["Of those, 280 cases were from two large clusters neither linked to nor representative of the general population (a large cruiseferry arriving in Greece from abroad, and a migrant hosting facility); these were excluded, leaving 4,459 cases for the Rt estimation.", [["the Rt estimation", "TEST", 243, 260], ["large", "OBSERVATION_MODIFIER", 34, 39], ["clusters", "OBSERVATION", 40, 48], ["large", "OBSERVATION_MODIFIER", 115, 120]]], ["Table 1 presents the age distribution of these cases and their breakdown by location of transmission and severity; approximately one quarter were imported, one third were hospitalized, and 8% were severe cases, i.e. were hospitalized in intensive care or died.", [["breakdown", "OBSERVATION_MODIFIER", 63, 72]]], ["Imported cases were on average younger than local cases, while hospitalized and severe cases were older than non-hospitalized (p<0.001, Table 1 March the food service industry and shopping centres were closed, and on 23 March all non-essential movement was restricted (i.e. a lockdown was implemented).", [["severe cases", "PROBLEM", 80, 92]]], ["And on 1 July international airport connections were restored with most countries, effectively allowing the Greek tourism sector to operate.ResultsAlthough the first peak in daily cases occurred at the time of the lockdown, infections appear to peak much earlier, specifically at the time of school closure.", [["infections", "DISEASE", 224, 234], ["infections", "PROBLEM", 224, 234], ["school closure", "TREATMENT", 292, 306], ["infections", "OBSERVATION", 224, 234]]], ["Similarly, a second peak on late August corresponds to an increase of infections since early July, coincidental with an influx of imported cases (Figure 1 ). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintResultsThe copyright holder for this this version posted September 22, 2020. . https://doi.org/10.1101/2020.09.19.20198028 doi: medRxiv preprint late May was followed by an Rt consistently below 1 until early July, when the border opening and influx of imported cases was subsequently followed by a rise in local COVID-19 cases and Rt (Figures 1 and 2 ).ResultsOur delay adjustment method performed relatively well, but consistently underestimated the Rt for the latest 7-10 days in the time series (Figure 2 and Supplementary Figure 1) ; we therefore omitted the last week of estimates from our regression model (after 27 July).", [["infections", "DISEASE", 70, 80], ["a second peak", "PROBLEM", 11, 24], ["infections", "PROBLEM", 70, 80], ["medRxiv", "TREATMENT", 418, 425], ["local COVID", "TEST", 597, 608], ["Rt (Figures", "TEST", 622, 633], ["adjustment method", "TEST", 661, 678], ["second", "OBSERVATION_MODIFIER", 13, 19], ["peak", "OBSERVATION_MODIFIER", 20, 24], ["increase", "OBSERVATION_MODIFIER", 58, 66], ["infections", "OBSERVATION", 70, 80], ["med", "ANATOMY", 196, 199]]], ["A significant association was found between Rt and both mobility and temperature; each 10% of increase in relative mobility increased Rt by 8.1% (95% CrI 6.1-10.2%), whereas each unit celsius of increase in the 7-day temperature average decreased Rt by 4.6% (95% CrI 5.4-13.7%).", [["Rt", "TEST", 134, 136], ["CrI", "TEST", 150, 153], ["Rt", "TEST", 247, 249], ["CrI", "TEST", 263, 266], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["increase", "OBSERVATION_MODIFIER", 195, 203]]], ["The adjusted R-squared of the model was 54.3%, indicating a fairly good fit to the data, and had the lowest AIC of all alternative models explored as sensitivity analyses (Supplementary Table 2 ).ResultsIn sensitivity analyses using hospitalized and severe cases, the Rt time series was very similar to the one obtained using all cases, albeit with much reduced precision given the lower numbers of cases (Supplementary Figure 2 ).DiscussionMonitoring the transmissibility of the SARS-CoV-2 virus during the COVID-19 pandemic is crucial in order to assess the effectiveness of control measures and guide public health policy.", [["SARS", "DISEASE", 480, 484], ["SARS-CoV-2 virus", "ORGANISM", 480, 496], ["COVID-19", "ORGANISM", 508, 516], ["CoV-2 virus", "SPECIES", 485, 496], ["SARS-CoV-2 virus", "SPECIES", 480, 496], ["the model", "TEST", 26, 35], ["sensitivity analyses", "TEST", 150, 170], ["severe cases", "PROBLEM", 250, 262], ["the Rt time series", "TEST", 264, 282], ["the SARS", "PROBLEM", 476, 484], ["CoV", "TEST", 485, 488], ["the COVID", "TEST", 504, 513], ["control measures", "TREATMENT", 577, 593]]], ["Rt is a useful and easily understandable metric for this purpose, but its reliable estimation presents considerable challenges [7] , especially given the inherent limitations of surveillance data [19] .", [["surveillance data", "TEST", 178, 195]]], ["Our method to estimate Rt does not require structural assumptions other than the serial interval distribution, and introduces several improvements that make it appropriate for use in a surveillance context.", [["structural assumptions", "TREATMENT", 43, 65], ["the serial interval distribution", "PROBLEM", 77, 109], ["distribution", "OBSERVATION_MODIFIER", 97, 109]]], ["It works with minimal or incomplete data, it largely adjusts for reporting delays, and can produce time-accurate estimates using an external estimate of the incubation period; the latter is essential for correctly assessing the effectiveness of control measures, as any intervention to reduce infection rates will only be reflected in case reporting rates after a substantial period of time.", [["infection", "DISEASE", 293, 302], ["control measures", "TREATMENT", 245, 261], ["any intervention", "TREATMENT", 266, 282], ["infection rates", "PROBLEM", 293, 308]]], ["Our method is also very easy to use through our \"bayEStim\" package for the R software environment.DiscussionOn the other hand, there are certain limitations with our approach.", [["our \"bayEStim\" package", "TREATMENT", 44, 66]]], ["Imprecision can be high especially with low case counts, as our model incorporates all sources of uncertainty in Rt, serial interval, incubation period, missing symptom onset dates and delay distribution.", [["low case counts", "PROBLEM", 40, 55], ["missing symptom onset dates", "PROBLEM", 153, 180], ["delay distribution", "PROBLEM", 185, 203], ["high", "OBSERVATION_MODIFIER", 19, 23]]], ["Bayesian imputation of infection times also introduces smoothing, which is both appropriate and to an extent desirable, but can also blur abrupt changes in Rt [7] .", [["infection", "DISEASE", 23, 32], ["Bayesian imputation of infection", "PROBLEM", 0, 32], ["infection", "OBSERVATION", 23, 32]]], ["Substantial changes in testing or ascertainment rates over time can bias the results, as can the presence of few large clusters compared to overall cases; down-weighting of cluster-related cases, for example according to their percentage positive compared to overall cases, may be a possible solution and has been implemented in \"bayEStim\".", [["Substantial changes in testing", "PROBLEM", 0, 30], ["ascertainment rates", "TEST", 34, 53], ["few large clusters", "PROBLEM", 109, 127], ["few", "OBSERVATION_MODIFIER", 109, 112], ["large", "OBSERVATION_MODIFIER", 113, 118], ["clusters", "OBSERVATION", 119, 127]]], ["Ideally our method should be applied to hospitalized or severe case series, which can be less subject to underascertainment or non-random testing, although in our case Rt estimates were not appreciably different. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintDiscussionThe copyright holder for this this version posted September 22, 2020. . relationship between population mobility and viral transmissibility, indicating that social distancing and staying home can be very effective in bringing the Rt of COVID-19 below 1 [20] .", [["severe case series", "PROBLEM", 56, 74], ["non-random testing", "TEST", 127, 145], ["Rt estimates", "TEST", 168, 180], ["viral transmissibility", "PROBLEM", 472, 494], ["COVID", "TEST", 591, 596], ["not", "UNCERTAINTY", 186, 189], ["appreciably", "OBSERVATION_MODIFIER", 190, 201], ["different", "OBSERVATION_MODIFIER", 202, 211], ["med", "ANATOMY", 251, 254], ["viral transmissibility", "OBSERVATION", 472, 494]]], ["Indeed both mobility and Rt started falling rapidly just as the first control measures were introduced, indicating that the multiple control measures introduced, combined with good public compliance, resulted in effective social distancing earlier than the full lockdown of 23 March.", [["the multiple control measures", "TREATMENT", 120, 149], ["both", "OBSERVATION_MODIFIER", 7, 11], ["mobility", "OBSERVATION", 12, 20]]], ["This was likely crucial, as the virus did not get enough time to spread widely among the population.", [["the virus", "PROBLEM", 28, 37], ["likely", "UNCERTAINTY", 9, 15], ["crucial", "OBSERVATION_MODIFIER", 16, 23]]], ["Counterintuitively, the lockdown appears to not have substantially contributed to a further reduction in COVID-19 transmissibility, as Rt had already fallen significantly below 1 at least a week earlier and remained stable thereafter.", [["a further reduction", "TREATMENT", 82, 101], ["COVID", "TEST", 105, 110], ["stable", "OBSERVATION_MODIFIER", 216, 222]]], ["It is possible that without the lockdown the decrease in mobility and Rt might not have been sustained, but this purely hypothetical.DiscussionAs social distancing measures were relaxed, Rt in Greece remained largely below 1 until early July.", [["the lockdown the decrease in mobility", "PROBLEM", 28, 65], ["decrease", "OBSERVATION_MODIFIER", 45, 53]]], ["Then a large influx of tourists (with 1.3 million arrivals during all of July [21] , in a population of around 10.5 million), with hundreds of imported COVID-19 cases (Figure 1) , was followed by a steep increase in locallyacquired cases and Rt climbing back to 1.", [["a steep increase in locallyacquired cases", "PROBLEM", 196, 237], ["large", "OBSERVATION_MODIFIER", 7, 12], ["influx", "OBSERVATION_MODIFIER", 13, 19]]], ["This coincided with a continued increase in mobility beyond baseline levels ( Figure 2 ).", [["a continued increase in mobility", "PROBLEM", 20, 52], ["increase", "OBSERVATION_MODIFIER", 32, 40], ["mobility", "OBSERVATION_MODIFIER", 44, 52]]], ["It should be emphasized that the arrival of imported cases from abroad does not in itself raise Rt, as transmissibility depends entirely on local conditions of social mixing and mobility.DiscussionHowever, summer in Greece is defined by people, Greek and foreign, going on vacation in large numbers and in proximity to each other, especially in tourist hotspots; moreover, an estimated 850,000 local jobs are directly or indirectly linked to the tourism industry [22] .", [["people", "ORGANISM", 237, 243], ["people", "SPECIES", 237, 243], ["foreign", "OBSERVATION", 255, 262]]], ["This situation creates the general conditions for sustained spread of the virus among the population, through increased mobility and crowding.", [["the virus", "PROBLEM", 70, 79], ["increased mobility", "PROBLEM", 110, 128], ["crowding", "PROBLEM", 133, 141], ["increased", "OBSERVATION_MODIFIER", 110, 119], ["mobility", "OBSERVATION_MODIFIER", 120, 128], ["crowding", "OBSERVATION_MODIFIER", 133, 141]]], ["It is the combination of increased case importations and increased transmissibility that results in more COVID-19 cases identified during the summer, a phenomenon which is expected to abate in September as the tourist season winds down.", [["increased case importations", "PROBLEM", 25, 52], ["increased transmissibility", "PROBLEM", 57, 83], ["COVID", "TEST", 105, 110], ["increased", "OBSERVATION_MODIFIER", 25, 34]]], ["In the meantime, is is important to push Rt back below 1 as much as possible, with targeted social distancing measures and widespread use of other protective measures like masks and hand hygiene.DiscussionFinally, we found a relationship between ambient temperature and COVID-19 transmissibility; in fact the 18.3 degrees celsius difference between the lowest and highest temperature in our data corresponds to a 58.1% change in Rt (95% CrI 35.7-72.7%), which appears quite significant.", [["hand", "ANATOMY", 182, 186], ["hand", "ORGANISM_SUBDIVISION", 182, 186], ["social distancing measures", "TREATMENT", 92, 118], ["other protective measures", "TREATMENT", 141, 166], ["ambient temperature", "TEST", 246, 265], ["Rt", "TEST", 429, 431], ["CrI", "TEST", 437, 440], ["18.3 degrees", "OBSERVATION_MODIFIER", 309, 321], ["appears quite", "UNCERTAINTY", 460, 473], ["significant", "OBSERVATION_MODIFIER", 474, 485]]], ["This may be attributed to the effects of heat on the virus itself, but is likely more down to behavioural patterns in the population, with more social interaction happening outdoors as the weather gets warmer and vice versa.", [["heat on the virus itself", "PROBLEM", 41, 65], ["may be attributed to", "UNCERTAINTY", 5, 25]]], ["This effect however does not appear sufficient to counterbalance the increased mobility associated with the summer season in Greece, which is unsurprising considering the lack of population immunity to SARS-CoV-2 [23] .", [["SARS", "DISEASE", 202, 206], ["SARS-CoV-2", "ORGANISM", 202, 212], ["SARS-CoV", "SPECIES", 202, 210], ["the increased mobility", "PROBLEM", 65, 87], ["CoV", "TEST", 207, 210], ["increased", "OBSERVATION_MODIFIER", 69, 78], ["mobility", "OBSERVATION", 79, 87]]], ["Moreover, with the higher transmissibility anticipated during the winter, a substantially higher degree of social distancing will likely be required to keep Rt below 1 and the pandemic under control.DiscussionIn conclusion, we present an improved method and software for estimating Rt that is tailored to the realities of a disease surveillance context, and can be a valuable component of the surveillance activities during the current COVID-19 pandemic.", [["the current COVID", "TEST", 424, 441], ["pandemic", "PROBLEM", 445, 453], ["pandemic", "OBSERVATION", 176, 184], ["disease", "OBSERVATION", 324, 331]]], ["Applying our method to the Greek case demonstrates the important conclusions that can be drawn, and that can guide the further management of the pandemic. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintDiscussionThe copyright holder for this this version posted September 22, 2020. .Conflict of Interest statementST and VS serve on the Expert Advisory Group for COVID-19 of the Hellenic Ministry of Health, which is an unpaid position.", [["the further management", "TREATMENT", 115, 137], ["the pandemic", "PROBLEM", 141, 153], ["COVID", "TEST", 447, 452], ["med", "ANATOMY", 193, 196]]], ["TL and DP declare no competing interests.Conflict of Interest statement.", [["DP", "ANATOMY", 7, 9]]], ["CC-BY 4.0 International license It is made available under a perpetuity.Conflict of Interest statementis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintConflict of Interest statementThe copyright holder for this this version posted September 22, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintConflict of Interest statementThe copyright holder for this this version posted September 22, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintConflict of Interest statementThe copyright holder for this this version posted September 22, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["med", "ANATOMY", 140, 143], ["med", "ANATOMY", 374, 377], ["med", "ANATOMY", 606, 609]]]]}